Document:

EX-10.17

 Exhibit 10.17 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 Triple asterisks denote omissions. 
 COLLABORATION AGREEMENT

 This Collaboration Agreement (“Agreement”), effective as of June 30, 2010 (the “Effective
Date”), is entered into by and between MacroGenics, Inc., a Delaware corporation with a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”), and Green Cross Corp., a Korean company with a place of
business at 303 Bojeong-Dong, Giheung-Gu, Yongin, 446-770, Korea (“Green Cross”). MacroGenics and Green Cross may be referred to herein individually as a “Party” or collectively as the “Parties.”

 Recitals: 
 A. MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of patients with cancer, inflammatory and infectious diseases. 

B. Green Cross conducts research and development with respect to, and sells, pharmaceutical products. 

C. Green Cross and MacroGenics desire to enter into collaboration for the development of MacroGenics’ anti-HER2 Antibody known as
MGAH22, and if approved for commercialization, the commercialization of a Product in South Korea, all upon the terms and conditions set forth in this Agreement. 
 D. MacroGenics desires to grant to Green Cross, and Green Cross desires to receive, an exclusive license for all Indications for all pharmaceutical forms of MGAH22 for South Korea, upon the terms and
conditions set forth in this Agreement. 
 In consideration of the foregoing premises and the mutual covenants herein contained,
the Parties hereby agree as follows: 
 Agreement: 
 1. DEFINITIONS. Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set
forth below: 
 1.1 “Affiliate” means with respect to any Party, any person or entity controlling, controlled
by or under common control with such Party. For purposes of this Section 1.1, “control” means (a) in the case of a corporate entity, direct or indirect 

 
ownership of at least fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such corporate entity and (b) in the case of an entity
that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.

 1.2 “Allocable Overhead” means costs incurred by each Party that are attributable to that Party’s
*** reasonably allocated to the Party’s departments or functions, or used to support activities under the Collaboration based on space occupied or headcount or other activity-based methods consistently applied by each Party. The
Allocable Overhead shall not include any costs attributable to *** 
 1.3 “Antibody” means a molecule
comprising or containing: (a) one or more immunoglobulin variable domains; (b) fragments, variants, modifications or derivatives of such immunoglobulin variable domains; and (c) the nucleic acid consisting of a sequence of nucleotides
encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a) or (b). The term “Antibody” shall include any monospecific antibodies; less than full-length antibody forms such as Fv, Fab, and F(ab’);
single-chain antibodies; and an antibody bound to a drug, label or other moiety and any antibody that is conjugated or fused to any other composition, including for example, a toxin, radionucleotide, small molecule, polypeptide or polypeptide
fragment. The term Antibody also includes, without limitation to its source or method of manufacture, any human, humanized, primatized, chimeric or other antibody. 
 1.4 “Applicable Laws and Regulations” means all international, national, federal, state, regional, provincial and local government laws, rules, and regulations that apply to either Party
or to the conduct of the Collaboration under this Agreement including without limitation cGMP, GCP, GBPS, and the laws, rules and regulations of the ICH, that may be in effect, as applicable and amended from time to time. 

1.5 “Arbitral Tribunal” has the meaning set forth in Section 17.7(a). 

1.6 “BLA” means (a) a Biologics License Application or New Drug Application (“NDA”) filed with the
FDA for marketing approval of a Product or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings outside the Territory with applicable Regulatory Authorities,
for approval to commercially market and sell a Product, or (b) similar filings in the Territory with applicable Regulatory Authorities, including the KFDA, for approval to commercially market and sell a Product. The term BLA shall exclude
pricing and reimbursement approvals. 
 1.7 “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 2 

 1.8 “Calendar Year” means the respective periods of twelve (12) months
commencing on January 1 and ending on December 31. 
 1.9 “cGMP” means current good manufacturing
practices and general biologics products standards as promulgated under the FDCA or Applicable Law and Regulations in the Territory, as applicable. 
 1.10 “Change in Control” means the occurrence of any of the following: 
 (a) Either Party to this Agreement enters into a merger, consolidation, stock sale or sale or transfer of all or substantially all of its assets, or other similar transaction or series of transactions
with another Person unless, following such transaction or transactions, (i) the individuals and entities who were the beneficial owners of the outstanding voting securities of the subject Party immediately prior to such transaction beneficially
own, directly or indirectly, at least fifty percent (50%) of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or similar governing persons of the corporation or other
entity resulting from such transaction (“Successor”) in substantially the same proportions as their ownership immediately prior to such transaction of such outstanding voting securities, (ii) at least fifty percent
(50%) of the members of the Board of Directors or similar governing body of the Successor were members of the Board of Directors of the subject Party at the time of the execution of the initial agreement, or the action of the Board of Directors
of the subject Party, providing for such transaction; (iii) the subject Party retains title ownership after the transaction or transactions to properties and assets (x) representing more than fifty percent (50%) of such Person’s
consolidated total assets or (y) from which more than fifty percent (50%) of such Person’s consolidated operating income for its most recent fiscal was derived, and (iv) the subject Party is the surviving entity in such
transaction or transactions; 
 (b) any transaction or series of related transactions in which any Person or group of Persons
acquires beneficial ownership of securities of the subject Party representing more than fifty percent (50%) of the combined voting power of the then outstanding securities of the subject Party. 

1.11 “Clinical Data” means all data generated or arising from the conduct of a clinical trial or other Development
efforts under this Agreement. 
 1.12 “Clinical Material(s)” means MGAH22 and Product formulated in accordance
with the specifications as adopted by the JSC and United States and Korean laws, rules and regulations (a) for preclinical activities, and (b) for administration to subjects in clinical trials. 

1.13 “CMC” means Chemistry Manufacturing and Controls. 

1.14 “Collaboration” means the program established under this Agreement, which includes collaborative development
of Products. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 3 

 1.15 “Commencement” means the first dosing of a human subject with the
applicable Product in the applicable human clinical trial. 
 1.16 “Commercial Supply Costs” shall mean the
costs paid by Green Cross to MacroGenics for the commercial supply of Product pursuant to Section 6.2(d), provided that Commercial Supply Costs for a Product shall not be deemed incurred by Green Cross for purposes of this Agreement until the
Calendar Quarter in which such Product is sold by Green Cross or any of its Related Parties. 
 1.17
“Commercialization” or “Commercialize” means activities taken before and after obtaining Regulatory Approval relating specifically to the pre-launch, launch, promotion, marketing, sales force recruitment, sale and
distribution of a pharmaceutical product and post-launch medical activities, including without limitation: (a) distribution for commercial sale; (b) strategic marketing, sales force Detailing, advertising, and market and product support;
(c) medical education and liaison and any Phase IV Clinical Trials, to the extent permitted by this Agreement; (d) all customer support and product distribution, invoicing and sales activities; and (e) all post-approval
regulatory activities, including those necessary to maintain Regulatory Approvals. 
 1.18 “Commercially Reasonable
Efforts” means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar
objective of such Party under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be similar to those efforts and resources commonly used by a
Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved
labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved. 

1.19 “Competing Product” means any Antibody that binds to the protein termed “HER2/Neu”, other than a Product.

 1.20 “Completion” or “Completed” for a clinical trial means the later of the following
dates: (a) the date on which all patients have completed protocol-defined study drug administration, and (b) *** 
 1.21 “Confidential Information” means any and all non-public scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information and data, in
any tangible or intangible form, including all Know-how subject to Section 12. 
 1.22
“Control,” “Controls” or “Controlled by” means (except as used in Section 1.1), with respect to any item of or right under Patents or Know-how, the
ability 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 4 

 
of a Party (whether through ownership or license, other than pursuant to this Agreement) to grant access to, or a license or sublicense of, such item or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense. 

1.23 “CRO” means a clinical research organization. 

1.24 “CTA” means a Clinical Trial Application or its equivalent used to obtain approval to conduct human clinical
investigations filed with or submitted to the KFDA in order to establish the clinical safety and/or efficacy of one or more investigational products in conformance with the requirements of the KFDA. 

1.25 “Data Exclusivity Period” means the period during which the FDA or KFDA (or, in countries other than the United
States or South Korea, an equivalent regulatory agency) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that is contained in such BLA, and that is not published or publicly available outside of such
BLA. 
 1.26 “Details” or “Detailing” means face-to-face sales presentations made to
physicians, nurses, pharmacists, and other individuals who provide healthcare services to patients, in their capacity as such. 

1.27 “Develop” or “Development” or “Developing” means research, discovery, process
development, manufacturing for preclinical and clinical uses, and preclinical and clinical drug or biological development activities, including, without limitation, test method development and stability testing, toxicology, formulation, quality
assurance/quality control development, statistical analysis, preclinical and clinical studies and regulatory affairs, approval and registration, in each case, of MGAH22 or a Product for therapy of human diseases. 

1.28 “Development Costs” means all costs incurred in connection with any Development activities. 

1.29 “FDA” means the United States Food and Drug Administration, or any successor agency thereto. 

1.30 “FDCA” means the Federal Food, Drug and Cosmetic Act, as amended. 

1.31 “Field” means all oncology therapies; provided, however, that in the case of any Products covered by a Patent or
other intellectual property right licensed in one or more Upstream Licenses, “Field” shall be limited to the minimum extent necessary to comply with the terms of such Upstream License for so long as such limitation is necessary to avoid
breach of the Upstream License. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 5 

 1.32 “Filing of a BLA” means the acceptance by a Regulatory Authority of
such BLA for filing. 
 1.33 “First Commercial Sale” means, with respect to any Product, the first sale
to a Third Party for end use or consumption of such Product in the Territory after Regulatory Approval has been granted by the Regulatory Agency for the Product in the Territory. 

1.34 “Fully Burdened Manufacturing Cost” or “FBMC” means one hundred percent (100%) of
MacroGenics’ actual manufacturing cost of goods produced, as determined for each stage of the manufacturing process, in accordance with GAAP, including product quality assurance/control costs, failed lots, plus applicable Allocable Overhead.
Such Fully Burdened Manufacturing Cost shall include, without limitation: (i) *** 
 1.35 “GAAP”
means U.S. Generally Accepted Accounting Principles as the same may be in effect from time to time. 
 1.36
“GBPS” means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable to the Collaboration. 
 1.37 cGMP” or “current Good Manufacturing Practices” means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the “PHS
Act”), and in regulations at 21 C.F.R. Parts 210, 211 and 600, as in effect at the time when any clinical trial regarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are
interpreted and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards. 

1.38 “GCP” or “Good Clinical Practices” means current Good Clinical Practices as set forth in the
Applicable Laws and Regulations, such as FDCA and the PHS Act and regulations set forth at 21 C.F.R. Part 312, as well as (but not limited to) the requirements set forth in Directive 2001/20/EC of the European Parliament and of the Council of
4 April 2001 and Commission Directive 2005/28/EC of 8 April 2005, to the extent applicable to a clinical trial regarding any Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority (e.g., FDA and
Member States of the European Union), and as interpreted under prevailing industry standards, including standards of medical ethics, applicable guidance documents issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed
consent requirements set forth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to Institutional Review Boards set forth in 21 C.F.R. Part 56 and the equivalent legal
requirements in other applicable jurisdictions, all as the same may be amended from time to time. 
 1.39 “GLP”
or “Good Laboratory Practices” means the recognized rules governing the conduct of non-clinical safety studies and ensuring the quality, integrity and reliability of study data as set forth in Applicable Laws and Regulations, such
as 21 C.F.R. Part 58. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 6 

 1.40 “Green Cross Indemnitees” has the meaning set forth in
Section 14.2. 
 1.41 “Green Cross Licensed Know-how” means all Know-how (excluding any Patent) Controlled by Green Cross as of the Effective Date or at any time during the Term that is: (a) related to MGAH22 and (b) necessary for MacroGenics to exercise the rights
licensed to it under this Agreement or perform its obligations under this Agreement. “Green Cross Licensed Know-how” shall also include Green Cross’ interest in any Know-how deemed jointly owned pursuant to Section 15.1(c). 
 1.42 “Green Cross
Licensed Patents” means any and all Patents Controlled by Green Cross at any time during the Term that: (a) are related to any data, result or invention conceived or reduced to practice in the course of conducting the Collaboration
solely by Green Cross specifically in relation to MGAH22 and (b) Green Cross’ interest in any Patent deemed jointly owned pursuant to Section 15.1(c). 
 1.43 “Health Insurance Portability and Accountability Act” or “HIPAA” means the act enacted by the U.S. Congress in 1996 and took effect in 2003 that strictly dictates
the parameters that identifiable private health information (PHI) can be shared outside of the research environment, as amended. 
 1.44 *** 
 1.45 “ICH” means the International Conference
on Harmonisation. 
 1.46 “IND” means an Investigational New Drug application, or similar application or
submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

1.47 “Indemnifying Party” means the Party that is obligated to indemnify the Indemnitee under Section 14. 

1.48 “Indemnitee” means either the Green Cross Indemnitee or the MacroGenics Indemnitee, as applicable. 

1.49 “Independent Ethics Committee” or “IEC” means an independent body (a review board or a committee,
institutional, regional, national, or supranational), constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial and to
provide public assurance of that protection, by, among other things, reviewing and approving / providing favorable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in
obtaining and documenting informed consent of the trial subjects. The legal status, 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 7 

 
composition, function, operations and regulatory requirements pertaining to IEC may differ among countries, but should allow the Independent Ethics Committee to act in agreement with GCP as
described in this guideline. 
 1.50 “Indication” means a separate and distinct disease, disorder or medical
condition in humans or non-human animals which a product is intended to treat, prevent, diagnose, monitor or ameliorate and which, for a Product, is intended to be reflected in the labeling for such Product as an approved Indication, and which, for
an approved Product, is reflected in the labeling for such Product. 
 1.51 “Informed Assent Form” or
“IAF” means an agreement to participate by subjects who are not able to give consent, either because they are minors or because they are legally incompetent. 
 1.52 “Informed Consent Form” or “ICF” means a document that outlines a patient’s rights during participation in a clinical trial. It also discusses the potential
risks and benefits associated with participation, including all available data on previous studies. The ICF must be signed by the patient or authorized caregiver before entrance is granted into a study. 

1.53 “Initial Public Offering” means the first completed offering of capital stock of MacroGenics registered under the
Securities Act of 1933, as amended. 
 1.54 “Investigational Review Board” or “IRB” means in
accordance with 45 C.F.R. 46, Protection of Human Subjects (Revised November 13, 2001) and 21 C.F.R. 45, Subpart C, IRB Functions and Operations, (as amended June 18, 1991 and other applicable regulations), an independent body comprising
medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the subjects involved in a clinical trial. It may also be referred to as an IEC in accordance with ICH E6,
Section 1.27. 
 1.55 “Jointly Owned IP” has the meaning set forth in Section 15.1(c). 

1.56 “Jointly Owned Patents” has the meaning set forth in Section 15.2(b)(i). 

1.57 “Joint Development Committee” or “JDC” has the meaning set forth in Section 2.2. 

1.58 “Joint Steering Committee” or “JSC” has the meaning set forth in Section 2.1. 

1.59 “KFDA” means Korean Food and Drug Administration, or any successor agency thereto. 

1.60 “Know-how” means (a) any proprietary scientific or technical
information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 8 

 
formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical,
biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data and (b) any proprietary biological, chemical
or physical materials. 
 1.61 “Licensing Transaction” has the meaning set forth in Section 12.3(d)(ii)(C).

 1.62 “Losses” has the meaning set forth in Section 14.1. 

1.63 “MacroGenics Indemnitee” has the meaning set forth in Section 14.1. 

1.64 “MacroGenics Licensed Know-how” means the
Know-how (excluding any Patents) that is Controlled by MacroGenics as of the Effective Date or at any time during the Term, that is: (a) related to MGAH22 and (b) necessary for Green Cross to
exercise the rights licensed to it pursuant to this Agreement or to perform its obligations under this Agreement. 
 1.65
“MacroGenics Licensed Patents” means the Patents Controlled by MacroGenics as of the Effective Date or at any time during the Term that: (a) claim the composition of matter of MGAH22 or a Product, (b) would be infringed
but for the license granted hereunder by making, having made, selling, using, offering for sale or importing MGAH22 or any Product, or (c) are otherwise necessary for Green Cross to exercise the rights licensed to it under this Agreement, or to
perform its obligations under this Agreement, as listed in Exhibit A attached hereto. “MacroGenics Licensed Patents” shall include MacroGenics’ interest in any Patents deemed jointly owned pursuant to Section 15.1(c). 

1.66 “MacroGenics Licensed Technology” means the MacroGenics Licensed Patents and the MacroGenics Licensed Know-how. 
 1.67 “MacroGenics Licensed Trademarks” means any and all
Trademarks Controlled by MacroGenics as of the Effective Date or at any time during the Term, that are registered for or apply to a Product, as listed on Exhibit B. 
 1.68 “MGAH22” means the therapeutic Antibody which binds to the HER2/Neu receptor described in IND # 107768. 
 1.69 “Net Sales” means the gross amount invoiced for Products (or, as the case may be, a Competing Product) sold by Green Cross or its Related Parties in the Territory initially and
directly to Third Parties which are not Related Parties after deducting, if not previously deducted, from the amount invoiced, the following, in each case to the extent included in the gross invoice price: 

(a) reasonable trade, quantity and cash discounts and rebates (including, but not limited to, wholesaler inventory management fees),
chargebacks, and retroactive price reductions or allowances actually allowed or granted from the billed amount; 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 9 

 (b) credits or allowances actually granted upon claims, rejections or returns of such sales
of Products, including recalls and amounts credited or repaid because of retroactive price reductions specifically identifiable to the Product; 
 (c) taxes imposed on the production, sale, import, delivery or use of the Product (including, without limitation, sales, use, excise or value added taxes but excluding income taxes), duties or other
governmental charges (including, without limitation, charges for product testing required for importation) levied on or measured by the billing amount when included in billing, as adjusted for rebates and refunds; and 

(d) costs incurred for importing (including, but not limited to, transportation, freight and insurance, and warehousing in the
Territory). 
 Such amounts shall be determined from the books and records of Green Cross or its Related Party, maintained in
accordance with International Financial Reporting Standards (IFRS) or such similar accounting principles, consistently applied. Green Cross further agrees, in determining such amounts, it will use Green Cross’ then-current standard procedures
and methodology, including Green Cross’ then-current standard exchange rate methodology for the translation of foreign currency sales into U.S. Dollars or, in the case of Sublicensees, such similar methodology, consistently applied. 

1.70 “Patent(s)” means (a) all patents and patent applications in any country or supranational jurisdiction and
(b) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the like, of any such patents or
patent applications. 
 1.71 “Patent Prosecution” means the responsibility for (a) preparing, filing,
prosecuting, and pursuing registration of, applications (of all types) for any Patent (b) for maintaining any Patent, and (c) for managing any interference or opposition proceeding relating to the foregoing. 

1.72 “Permitted Subcontractors” has the meaning set forth in Section 3.5. 

1.73 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency
of a government. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 10 

 1.74 “Phase I Clinical Development Plan” means the plan set forth on
Exhibit C. 
 1.75 “Phase I Clinical Trial” means a human clinical trial of a Product in patients in any
country that would satisfy the requirements of Applicable Laws and Regulations for such country, such as 21 C.F.R. § 312.21(a), relating to human clinical trials conducted in the United States. 

1.76 “Phase II Clinical Development Plan” means the plan set forth on Exhibit D, as amended pursuant to Section 4.

 1.77 “Phase II Clinical Trial” means a human clinical trial conducted in patients with a Product in
accordance with GCP and intended to demonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit and/or daily dosage regimen required, or that would otherwise satisfy the
requirements of Applicable Laws and Regulations of the country in which such human clinical trial is conducted, such as 21 C.F.R. § 312.21(b), relating to human clinical trials conducted in the United States, or any successor regulation
thereto or foreign equivalents. 
 1.78 “Phase III Clinical Trial” means a human clinical trial in any
country that is conducted in accordance with GCPs and the results of which are intended to be used as a pivotal study to establish both safety and efficacy of a Product as a basis for a BLA submitted to the FDA, KFDA or the appropriate Regulatory
Authority of such other country, or that would otherwise satisfy the requirements of 21 C.F.R. § 312.21(c), or any successor regulation thereto or foreign equivalents. 

1.79 “Phase IV Clinical Trial” means a human clinical trial conducted after the Regulatory Approval of a Product,
which trial is conducted (a) voluntarily to enhance scientific knowledge of such Product (e.g., for expansion of product labeling or dose optimization); or (b) conducted due to a request or requirement of a Regulatory Authority.

 1.80 “Personal Information Protection and Electronic Documents Act” or “PIPEDA” or
“PIPED Act” means the Canadian law relating to data privacy. 
 1.81 “Product” means a product
that incorporates a pharmaceutical form of MGAH22 as an active ingredient. 
 1.82 “Product Brand” has the
meaning set forth in Section 5.2. 
 1.83 “Regulatory Approval” means all approvals from the relevant
Regulatory Authority to market and sell a Product in any country (including all applicable pricing and reimbursement approvals), including a BLA. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 11 

 1.84 “Regulatory Authority” means any applicable government regulatory
authority involved in granting approvals for the conduct of clinical trials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Product, including in the United States the FDA and in South Korea the KFDA, and any successor
governmental authority having substantially the same function. 
 1.85 “Related Party” means, with respect to a
Party, its Affiliates and Sublicensees. 
 1.86 “Requesting Party” has the meaning set forth in Section 9.2.

 1.87 “Royalty Term” means, with respect to sales of a Product in the Territory, the time period beginning on
the First Commercial Sale of such Product in the Territory and expiring on the latest of the following dates: 
 (a) the twelfth (12th) anniversary of the date of First Commercial Sale of the Product in the Territory; 
 (b) the expiration in the Territory of the last-to-expire MacroGenics Licensed Patent having a Valid Claim covering the use or sale of the Product in the Territory; or 

(c) the expiration of any Data Exclusivity Period for the Product in the Territory. 

1.88 “Securities Act” has the meaning set forth in Section 8.2(b). 

1.89 “Site Regulatory Package” or “SRP” means a set of investigational site specific regulatory
documents requiring review and approval by the JDC. The SRP typically consists of the following documents: Form FDA 1572, principal investigator curriculum vitae, signed protocol signature page, site-specific ICF/IAF (back-translated into English if
the local language is other than English), privacy requirements (e.g., HIPAA, PIPEDA), IRB/IEC membership, and country-specific requirements. 
 1.90 “Sublicensee” means a Third Party that is granted a sublicense under the licenses granted to a Party under this Agreement, as permitted under this Agreement. 

1.91 “Successor” has the meaning set forth in Section 1.10. 

1.92 “Term” has the meaning set forth in Section 16.1. 

1.93 “Territory” means South Korea. 
 1.94 “Third Party” means an entity other than (a) Green Cross and its Affiliates, and (b) MacroGenics and its Affiliates. 

1.95 “Third Party Royalties” means royalties (other than Upstream Royalties) paid by Green Cross to a Third Party to
acquire any Third Party rights which would be infringed by the Development, manufacturing, importation, or Commercialization of any Product in the Territory. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 12 

 1.96 “Total Evaluable Patients” means, on a worldwide basis, those patients
who have completed protocol-defined procedures and can be assessed for the primary endpoint of the trial. 
 1.97
“Trademark(s)” means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications throughout the world. 

1.98 “Trademark Prosecution” means the responsibility for (a) preparing, filing, and seeking registration of,
trademark applications (of all types) for any Trademark, (b) for maintaining any Trademark, and (c) for managing any interference or opposition proceeding relating to the foregoing. 

1.99 “United States” or “US” means the United States of America and its territories and possessions,
including without limitation the Commonwealth of Puerto Rico and the U.S. Virgin Islands. 
 1.100 “Upstream
Agreements” means the license agreements with MacroGenics’ Third Party licensors listed in Exhibit E or otherwise identified in writing by MacroGenics to Green Cross as such. 

1.101 “Upstream Licensors” means MacroGenics’ Third Party licensors under the Upstream Agreements. 

1.102 “Upstream Royalties” has the meaning set forth in Section 8.6. 

1.103 “Valid Claim” means a claim of: (a) an issued and unexpired Patent included within the MacroGenics
Licensed Patents in a country which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and has not
been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b) *** 
 2.
GOVERNANCE 
 2.1 Joint Steering Committee 

(a) Membership. The Parties hereby establish a Joint Steering Committee, or JSC, to coordinate and oversee activities on which the
Parties collaborate under this Agreement. The Parties agree that participation in the JSC and any subcommittee of the JSC is a right, rather than an obligation of each Party under this Agreement. The JSC shall consist of three
(3) representatives from each Party. MacroGenics shall designate one (1) of its representatives as the initial chairperson of the JSC. Thereafter, the role of chairperson will alternate between MacroGenics and Green Cross representatives
on a yearly basis. Each Party may replace its appointed JSC representatives at any time upon reasonable written notice to the other Party. The initial 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 13 

 
representatives and chair of the JSC are set forth in Exhibit F attached hereto. The chair shall have the responsibility to call meetings, circulate meeting agendas at least ten (10) days
prior to each regular JSC meeting, draft minutes for each JSC meeting and circulate such minutes for both Parties’ written approval. The chair shall have no other authority or special voting power. 

(b) Responsibilities. The responsibilities of the JSC shall be: 

(i) to provide a vehicle by which the Parties may share information regarding the overall strategy for the Collaboration;

 (ii) to approve changes to the Phase I Clinical Development Plan and Phase II Clinical Development Plan;

 (iii) to facilitate the exchange of information between the Parties with respect to the activities hereunder
and to establish procedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect the Collaboration; 

(iv) to establish an overall regulatory strategy for Products in the Territory that is compatible with and complements the
worldwide regulatory strategy being implemented by MacroGenics for the Products and to allocate the responsibility for regulatory activities between the Parties; 

(v) to oversee the activities of subcommittees created under this Agreement, and to seek to resolve any issues that such
subcommittees cannot resolve; 
 (vi) to perform such other functions as appropriate to further the purposes of
this Agreement, as determined by the Parties; and 
 (vii) to establish such subcommittees in addition to the
JDC, as are agreed upon in writing by the Parties. 
 (viii) to discuss any additional studies, including a Phase
III Clinical Trial, in which Green Cross may desire to participate; 
 (c) Decision-Making. The JSC shall make decisions
unanimously, with each Party’s representatives collectively having one (1) vote and at least one (1) representative from each Party present. 
 (d) Disputes. In the event the JSC cannot reach an agreement regarding any matter within the JSC’s authority for a period of ***, then the dispute shall be promptly submitted to the
***. If the dispute remains unresolved for *** after submission to such persons, then the ***; provided, however, that the *** shall have the ***; and provided further that the foregoing shall not be deemed to
limit or otherwise alter any obligation of Green Cross or MacroGenics under this Agreement. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 14 

 (e) JSC Meetings. JSC meetings shall be held semi-annually, or on any other schedule
agreed by the Parties. With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as nonvoting observers (provided such non-voting observers have confidentiality obligations to
such Party that are at least as stringent as those set forth in this Agreement). A JSC meeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2) of the minimum number of meetings
shall be held in person. Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings.
The Parties will alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JSC meetings. 
 (f) Duration of JSC. The JSC shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the JSC or (b) termination of this Agreement. 

(g) Limitations. The JSC shall have no authority other than that expressly set forth in this Section 2.1 and, specifically,
shall have no authority (a) to amend or interpret this Agreement, or (b) to determine whether or not a breach of this Agreement has occurred. 
 2.2 Joint Development Committee 
 (a) Membership. Within
thirty (30) days after the Effective Date, the Parties shall establish a Joint Development Committee, or JDC, as a subcommittee of the JSC, to coordinate the Development of Products as set forth in Section 2.2(b). The JDC shall consist of
three (3) representatives from each Party. Each Party may replace its appointed JDC representatives at any time upon reasonable written notice to the other Party. The Parties shall alternate in designating a representative on the JDC as the
chair of the JDC on an annual basis, with MacroGenics designating the first chair. The chair shall have the responsibility to call meetings, circulate meeting agendas at least ten (10) days prior to each regular JDC meeting, draft minutes for
each JDC meeting and circulate such minutes for both Parties’ written approval. The chair shall have no other special authority or voting power. 
 (b) Responsibilities. The responsibilities of the JDC shall be: 
 (i) to share and discuss the Parties’ performance under the Phase I Clinical Development Plan and Phase II Clinical Development Plan, on a quarterly basis; 

(ii) to share and discuss the data generated by or on behalf of the Parties in the course of performance towards the goals
set forth in the Phase I Clinical Development Plan and Phase II Clinical Development Plan; 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 15 

 (iii) to coordinate Development strategies, allocate resources and set
timelines, in each case to facilitate the activities under the Phase I Clinical Development Plan and Phase II Clinical Development Plan; 
 (iv) to review and approve proposed clinical trial sites; 
 (v) to
facilitate the exchange of information between the Parties with respect to the activities under the Phase I Clinical Development Plan and Phase II Clinical Development Plan; and 

(vi) to perform such other functions as appropriate to further the purposes of this Agreement, as determined by the
Parties. 
 (c) Decision Making. The JDC shall make decisions unanimously, with each Party’s representatives
collectively having one (1) vote and at least one (1) representative from each Party present. 
 (d) Disputes.
In the event the JDC cannot reach an agreement regarding any matter within the JDC’s authority for a period of ***, then at the option of either Party the matter shall be referred to the JSC for resolution pursuant to Section 2.1(c)
and 2.1(d) above. 
 (e) JDC Meetings. JDC meetings shall be held quarterly, or on any other schedule agreed by the
Parties. With the consent of the representatives of each Party serving on the JDC, other representatives of each Party may attend meetings as nonvoting observers (provided such non-voting observers have confidentiality obligations to such Party that
are at least as stringent as those set forth in this Agreement). A JDC meeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2) of the minimum number of meetings shall be held in
person. Meetings of the JDC shall be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses for participating in the JDC meetings. The Parties
will alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JDC meetings. 
 (f) Duration of JDC. The JDC shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the JDC or (b) termination of this Agreement. 

(g) Limitations. The JDC shall have no authority other than that expressly set forth in this Section 2.2 and, specifically,
shall have no authority (a) to amend or interpret this Agreement, or (b) to determine whether or not a breach of this Agreement has occurred. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 16 

 3. DEVELOPMENT 

3.1 Overview. The Parties shall use Commercially Reasonable Efforts to Develop Products in the Territory in accordance with the
Phase I Clinical Development Plan and Phase II Clinical Development Plan, as set forth below, with the goal of achieving regulatory approval for the marketing of Products. 
 (a) MacroGenics Responsibilities. MacroGenics shall perform those activities for which it is identified as the responsible party in the Phase I Clinical Development Plan (unless such responsibility
is transferred to Green Cross or a Third Party by MacroGenics), including, without limitation, ***, as appropriate, ***. 
 (b) Green Cross Responsibilities 
 (i) Green Cross shall
perform those activities for which it is identified as the responsible party in the Phase I Clinical Development Plan (and such other activities for which responsibility is transferred to Green Cross), and shall conduct all activities described in
the Phase II Clinical Development Plan. Without limiting the foregoing, in the Territory: 
 (ii) Green Cross
shall (A) support clinical trial site and CRO-related activities ***, (B) ***; (C) support clinical trial site and CRO-related activities for the ***, under a CTA filed by Green Cross in the Territory, and
(D) support other additional Development activities responsive to unique regulatory or commercial requirements in Territory; and 
 (iii) Green Cross’ responsibilities shall include the submission of all CTAs; interaction with the KFDA; ***; provided, however, that with respect to the provision of data, information and
materials, such obligation to assist shall require Green Cross to use Commercially Reasonable Efforts, and shall not require Green Cross to generate any data not within its possession. 

(c) Joint and Additional Responsibilities. For activities specified in the Phase I Clinical Development Plan for which both
Parties are identified as the responsible Party, the Parties’ respective obligations shall be as determined by the JSC. If it is determined that the performance of activities not identified in the Phase I Development Plan are required for
Completion of the Phase I Clinical Trial, then the responsibility for such activities shall be determined by the JSC. 

3.2 Development Plans 
 (a) Clinical Development Plans. The JDC shall review the progress of the conduct of the Phase I Clinical Development Plan and Phase II Clinical Development Plan at each meeting of the JDC.

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 17 

 (b) Review of the Clinical Development Plans. On no less than an annual basis, the
JDC shall review the Phase I Clinical Development Plan and Phase II Clinical Development Plan, as appropriate, and recommend any amendment, and any changes to such plans shall be subject to the approval by the JDC and, subsequently, by the JSC.

 3.3 Conduct of Development 
 (a) General Obligation. Each Party shall use Commercially Reasonable Efforts to conduct the Development activities for which it is responsible, as described in the Phase I Clinical Development Plan
and Phase II Clinical Development Plan, in compliance with: (a) the terms and conditions of this Agreement; (b) the Phase I Clinical Development Plan and Phase II Clinical Development Plan, as updated from time to time; (c) all
applicable GLP, GCP and applicable cGMP requirements, including, without limitation those specified by the ICH; and (d) all Applicable Laws and Regulations. 
 (b) Green Cross Diligence. Without limiting Section 3.3(a): 

(i) Green Cross shall ***; provided, however, that if all necessary documents required for Regulatory Approval of
such Commencement in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of Green Cross’ acts or omissions, then such period shall be equitably extended to account for such delay for a
period mutually agreed upon in writing by the Parties; 
 (ii) Green Cross shall ***; and 

(iii) Green Cross shall use ***; provided, however, that if all necessary documents required for Regulatory
Approval of such Completion or filing in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of Green Cross’ acts or omissions, then such period shall be equitably extended to account
for such delay for a period mutually agreed upon in writing by the Parties. 
 (c) Green Cross Rights. Green Cross shall
have the option to participate in any additional studies, including a Phase III Clinical Trial, with respect MGAH22 to the extent that such studies are required by a Regulatory Authority in the Territory. 

3.4 Development Costs 
 (a) Phase I Clinical Development Plan. Green Cross shall be responsible for all Development Costs incurred by Green Cross in connection with the conduct of the Phase I Clinical Development
Plan, including, without limitation, Third Party costs for CRO-related activities for the Phase I Clinical Trial in the Territory. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 18 

 
MacroGenics shall be responsible for all Development Costs incurred by MacroGenics in connection with the conduct of the Phase I Clinical Development Plan, including without limitation, Third
Party costs for CRO-related activities for the Phase I Clinical Trial outside of the Territory, except as follows: 
 (i) Clinical Materials. MacroGenics shall be responsible for the cost of the supply of all Clinical Materials for the initial Phase I Clinical Trial; 

(ii) Labor Costs. Each Party shall be responsible for its direct labor costs (e.g., salaries, wages, employee
benefits, overtime costs, and shirt premiums) for the conduct of its obligations under the Phase I Clinical Development Plan; 
 (iii) *** MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross
in US Dollars not later than sixty (60) days following the receipt of the applicable invoice. 
 (iv)
Data Management Costs. Each Calendar Quarter, Green Cross shall reimburse MacroGenics for *** of the costs incurred by MacroGenics in connection with the management of Clinical Data from the Phase I Clinical Trials during such Calendar
Quarter. MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than *** following the receipt
of the applicable invoice. 
 (v) Insurance Costs. Each Calendar Quarter, Green Cross shall reimburse
MacroGenics for all costs incurred by MacroGenics in connection with all insurance policies required for the conduct of the Phase I Clinical Trials in the Territory during such Calendar Quarter. MacroGenics will invoice Green Cross at the end of the
applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than *** following the receipt of the applicable invoice. MacroGenics shall include Green
Cross as a named insured on each such policy acquired by MacroGenics. 
 (vi) Limitation on Reimbursement of
***. Notwithstanding anything to contrary set forth in Section 3.4(a)(iv) or 3.4(a)(v), in no event shall Green Cross be obligated to reimburse MacroGenics for any costs in connection with the *** 

(b) Phase II Clinical Development Plan. Green Cross shall be responsible for all Development Costs incurred in the Territory by
either Party under the Phase II Clinical Development Plan, except for the cost of the supply of Clinical Materials, which shall be the responsibility of MacroGenics. 
 3.5 Subcontractors. MacroGenics shall have the right to engage Third Party contractors to perform any portion of its obligations under this Agreement (provided that 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 19 

 
MacroGenics shall use Commercially Reasonable Efforts to require such Third Party contractors to cooperate with Green Cross, so as to permit Green Cross to comply with any of its development or
commercial diligence obligations, and its reporting and payment obligations under any of the Upstream Agreements insofar as they relate to MGAH22 or any Product), and Green Cross shall have the right to engage a CRO in the Territory to support the
conduct of the Phase I Clinical Trial *** (each such subcontractor, a “Permitted Subcontractor”). Any such Permitted Subcontractor used in the provision of services shall be required to agree in writing to be bound by
terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this Agreement.
Either Party’s use of Permitted Subcontractors shall not relieve such Party of any of its obligations pursuant to this Agreement. 
 3.6 Clinical Trial Data. Except to the extent prohibited by any Applicable Law or Regulation, each Party shall provide all Clinical Data to the other on a schedule reasonably requested by the
other. 
 3.7 Information and Cooperation. In addition to the obligations under Section 3.6, each Party shall use
Commercially Reasonable Efforts to keep the other Party informed of its research, Development and Commercialization (including promotional) activities hereunder, and shall provide to the other Party, as appropriate, regular summary updates. If
reasonably necessary for a Party to perform its work under this Agreement or to exercise its rights under this Agreement, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier
provided, and the other Party shall promptly provide the requesting Party with information and data as is reasonably available and reasonably related to the work under this Agreement. Neither Party is required to generate additional data or prepare
additional reports to comply with the foregoing obligation. All such reports, information and data provided shall be subject to Section 12.1. Prior to commencing the manufacture of Products or conduct of studies for the Product outside of the
scope of this Agreement in the Territory, MacroGenics shall notify Green Cross of any such activity and consult with Green Cross with respect thereto; provided, however, that MacroGenics shall not undertake any such activity if and to the extent
such activity would have a material adverse affect on Green Cross. 
 4. ADJUSTMENT OF PHASE II
CLINICAL DEVELOPMENT PLAN. If the Parties agree to add additional patients or Indications to the Phase II Clinical Development Plan, or replace the Indication specified therein as of
the Effective Date with a new Indication, then the Parties shall negotiate in good faith to agree upon the terms applicable to such expansion or change. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 20 

 5. COMMERCIALIZATION 

5.1 Overview. Green Cross shall have full responsibility and authority for all aspects of the Commercialization of Products in the
Territory at its sole expense, including, without limitation, developing and executing a plan for commercial launch, obtaining all required approvals from Regulatory Authorities for Commercialization (including, without limitation, reimbursement
activities), marketing and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related functions. Green Cross shall use Commercially
Reasonable Efforts to Commercialize the Products. Green Cross shall update MacroGenics regarding its Commercialization activities at regular meetings of the JSC as contemplated by Section 2.1.(e). As between Green Cross and MacroGenics,
***. Green Cross shall bear all of the costs and expenses incurred in connection with all such Commercialization activities in the Territory. Green Cross shall timely notify MacroGenics as to the occurrence of the First Commercial Sale in the
Territory. 
 5.2 Product Labeling; Promotional Materials. Green Cross shall Commercialize the Products in the Territory
under the worldwide brand specified by MacroGenics (“Product Brand”), except to the extent such branding is not permitted by any applicable Regulatory Authority, or deemed culturally inappropriate, in the Territory, in which case
MacroGenics shall specify an alternate Product Brand. Except for the depiction of trademarks, logos and other symbols that are intended to identify MacroGenics’ as a company or the manufacturer or owner of a Product, Green Cross shall be
responsible for designing and supplying the printable artworks of product labeling in electronic version and promotional materials for the Products for the Territory. Green Cross shall be responsible for how and the manner in which Products shall be
presented and described in the Territory to the medical community in any promotional materials for a Product intended to be disseminated in the Territory, and the placement of the name and logos of Green Cross therein, in each case as permitted by
applicable law and consistent with the Product Brand and labeling for the Products approved by the applicable Regulatory Authority. 
 5.3 Sales and Distribution 
 (a) Orders and Sales. Green Cross shall
be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and inventory and receivables for the Products throughout the Territory. Green Cross shall have the right and sole responsibility for
establishing and modifying the terms and conditions with respect to the sale of the Products in the Territory, including any terms and conditions relating to or affecting the price at which the Products shall be sold, discounts available to any
Third Party payers (including, without limitation, managed care providers, indemnity plans, unions, self insured entities, and government payer, insurance or contracting programs), any discount attributable to payments on receivables, distribution
of the Products, and credits, price adjustments, or other discounts and allowances to be granted or refused; provided, however, that Green Cross shall act in good faith when doing the foregoing. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 21 

 (b) Pricing. Green Cross shall have the sole right to determine all pricing of the
Products in the Territory. Notwithstanding anything in this Agreement express or implied to the contrary, MacroGenics shall not have any right to direct, control, or approve Green Cross’ pricing of Products for the Territory. The provision to
MacroGenics of any pricing data is for informational purposes only. Green Cross shall be responsible for preparing and implementing the reimbursement strategy for the Products in the Territory. However, except to the extent prohibited by Applicable
Laws and Regulations, MacroGenics shall use Commercially Reasonable Efforts to provide all the necessary data so that Green Cross can file for the medical reimbursement price in the Territory; provided, however, that MacroGenics shall not be
obligated to generate any data not within its possession. 
 5.4 Compliance. Each Party shall comply with the terms of
this Agreement and all Applicable Laws and Regulations relating to activities performed or to be performed by such Party (or its Affiliates, contractor(s) or Sublicensee(s)) under or in relation to the Commercialization of the Products pursuant to
this Agreement. 
 5.5 Commercialization Diligence 

(a) Prior to Submission of First BLA. For each Product under Development, prior to the submission of the first BLA to the first
Regulatory Authority in the Territory, Green Cross shall submit to the JSC a written summary plan for the Commercialization for each such Product under Development. Thereafter, Green Cross shall regularly report on its Commercialization activities
at meetings of the JSC or, if formed, the Joint Commercialization Committee. Such reports shall cover subject matter at a level of detail similar to that which Green Cross affords to its senior executives with respect to similar Green Cross
products. All such plans and information shall be presented for discussion purposes, and Green Cross agrees to consider in good faith any comments or suggestions MacroGenics may make with respect to Commercialization of Products. 

(b) Launch. Green Cross shall launch each Product in the Territory ***, provided that MacroGenics has supplied Product
ordered by Green Cross in accordance with Section 6.2(c) for such launch within a reasonable period prior to the planned launch date. 
 (c) Following Regulatory Approval. Green Cross shall use Commercially Reasonable Efforts to Commercialize each Product in the Territory after obtaining Regulatory Approval for such Product.

 5.6 Upstream Agreements. Green Cross agrees to provide to MacroGenics such information as it reasonably
requires, or otherwise cooperate with MacroGenics, so as to permit MacroGenics to comply with any of its development or commercial diligence obligations, and reporting and payment obligations under any of the Upstream Agreements insofar as they
relate to MGAH22 or any Product. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 22 

 6. MANUFACTURE AND SUPPLY 

6.1 Clinical Supply of Products. MacroGenics shall be responsible for the manufacture of all Product required for the clinical
trials described in the Phase I Clinical Development Plan, Phase II Clinical Development Plan and, if any, additional development plans, including any plan for a Phase III Clinical Trial, agreed upon in writing by the Parties for additional studies
under this Agreement, either by itself or through one or more Third Parties, including all costs of such manufacture, as set forth in Section 3.4. 
 6.2 Commercial Supply of Products 
 (a) Responsibility. MacroGenics
shall be responsible for the manufacture of all commercial supplies of Product required by Green Cross for the Commercialization of Products in the Territory, in accordance with this Section 6.2, except as the Parties may otherwise agree
pursuant to Section 6.4. 
 (b) Forecasts. For so long as MacroGenics is providing Product, Green Cross, through the
JDC, shall furnish to MacroGenics *** forecast of probable quarterly orders for supplies of Product, to be updated quarterly based on Green Cross’ good faith estimate of its need for Product. 

(c) Orders. Green Cross agrees to buy, and MacroGenics agrees to sell, such quantities of Product as may be set forth on purchase
orders placed by Green Cross in accordance with the provisions of this Section 6.2. The Parties shall mutually agree upon an appropriate purchase agreement. Any purchase orders for Product will reference this Agreement and will be consistent
with the terms contained herein. Each purchase order shall set forth a delivery date for the quantities of Product ordered, which date will in no event be less than *** from the date of the purchase order. MacroGenics will use Commercially
Reasonable Efforts to deliver each order on or before the applicable deliver date. If a purchase order cannot be fulfilled or delivered as requested by Green Cross, then MacroGenics shall immediately inform Green Cross of such fact. If MacroGenics
is unable to manufacture sufficient quantities of Products to deliver to Green Cross hereunder, then MacroGenics shall allocate any shortages among its customers, including, without limitation, Green Cross, on a pro-rata basis based on the
comparative order volumes of all customers at the time of such shortage. MacroGenics shall use Commercially Reasonable Efforts to promptly resume production of Commercial Supply. 

(d) Price; Payment. The price of Product ordered by Green Cross under this Section 6.2 will be equal to *** of
MacroGenics’ Fully Burdened Manufacturing Costs for such material. All payments due hereunder to MacroGenics shall be paid to MacroGenics in US Dollars not later than *** following the receipt of the applicable invoice. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 23 

 6.3 Delivery. Unless otherwise agreed by the parties in writing, all shipments will
be shipped F.O.B. MacroGenics’ or its contract manufacturer’s facility. 
 6.4 Technology Transfer. If Green
Cross requests, the Parties shall enter into good faith discussions regarding the possibility of a transfer to Green Cross of technology that is sufficient to enable Green Cross to manufacture commercial supplies of Product in accordance with the
Applicable Laws and Regulations of the Territory, provided that nothing herein shall be deemed to obligate MacroGenics to enter into any agreement to transfer to Green Cross any such technology. 

6.5 Manufacturing Specifications. All Clinical Materials and commercial supplies of Product shall be manufactured in accordance
with the specifications determined by MacroGenics and all Applicable Laws and Regulations. 
 6.6 Change of Manufacturing
Process. MacroGenics shall reasonably inform Green Cross of developments in matters of process development and manufacturing of Products, and shall consult with Green Cross with respect to the development and manufacturing processes of Products
adopted by MacroGenics to the extent necessary to obtain Regulatory Approval(s) of the same in the Territory. Green Cross shall promptly notify MacroGenics of any information that will impact approvability of Products in the Territory. 

7. REGULATORY 
 7.1 Overview. The JSC shall establish an overall regulatory strategy for obtaining Regulatory Approval of the Product in the Territory, and shall allocate regulatory responsibilities between the
Parties in a manner consistent with the provisions contained herein. Green Cross shall participate in regulatory matters as determined by the JSC, including CMC and other manufacturing-related matters, nonclinical matters, and clinical matters. In
addition, Green Cross will have access to adverse event and other safety related data. 
 7.2 Regulatory Filings for Phase I
Clinical Trial. MacroGenics shall hold the INDs in the Territory and be responsible for the filing of the INDs and all additional regulatory documents for the initial Phase I Clinical Trial with Regulatory Authorities in the Territory (such as
INDs, and IND amendments), including, without limitation, all associated submissions (e.g., safety reports, protocol submissions, CMC updates), for responding to inquiries and correspondences from the Regulatory Authorities, and the submission of
all required reports for the Phase I Clinical Trial until the Completion of the Phase I Clinical Trial. MacroGenics shall continue to hold INDs filed as of the Effective Date. MacroGenics will transfer its responsibilities for preparing the Korean
IND and IND amendments to Green Cross, but Green Cross shall provide ***, Green 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 24 

 
Cross may submit such filing, submission or response to the KFDA at the same time as Green Cross submits the same to MacroGenics; provided that Green Cross uses Commercially Reasonable Efforts to
obtain additional time. MacroGenics will transfer its responsibilities for interacting with the KFDA to Green Cross, but Green Cross shall attempt to include MacroGenics on any face-to-face meetings or teleconferences, if deemed necessary by Green
Cross, and shall not commit to making any revisions to the Phase I Clinical Trial unless for an immediate safety issues, without prior agreement with MacroGenics. Green Cross shall allow MacroGenics to review any written correspondence to the KFDA
before it is sent to the KFDA. 
 7.3 Regulatory Filings Following Phase I Clinical Trial. Except as set forth in
Section 7.2, Green Cross shall be responsible for the filing of all regulatory documents for MGAH22 and all Products with Regulatory Authorities in the Territory (such as INDs, NDAs and amended INDs and NDAs), including without limitation all
associated submissions (e.g., safety alerts, protocol submissions), for responding to inquiries and correspondence from the Regulatory Authorities responsible for regulatory matters in the Territory, and the monitoring of all clinical experiences
and submission of all required reports throughout clinical Development and Commercialization, in each case in compliance with all laws and regulations. MacroGenics shall be responsible for providing to Green Cross any revisions to the
investigator’s brochure and CMC information required for KFDA submissions. Green Cross may request MacroGenics to participate in meetings with the KFDA if it is foreseeable that there may be discussions about the Product beyond the scope of
Green Cross’ development of the Product in the Territory (e.g., CMC matters, data from clinical trials MacroGenics conducted). Each Party shall provide information to the other Party as necessary and reasonably consult with the other Party
regarding any filings, and regarding significant or material notices, actions or requests from or by Regulatory Authorities. Each Party shall, at the other Party’s request, review and comment on filings, submissions, and responses to Regulatory
Authorities related to any Product. Green Cross shall hold and maintain all Regulatory Approvals for the Commercialization of the Product in the Territory, as set forth in Section 10.1(c). 

7.4 Records of Correspondence with KFDA. Following each communication (whether by phone or in person) with the KFDA regarding
matters arising under this Agreement, Green Cross shall prepare a record of such meeting in accordance with its standard business practices (e.g., written minutes) and provide to MacroGenics a copy of such record. 

7.5 Safety Data Exchange Agreement. The Parties shall conduct in good faith and agree upon a safety data exchange agreement, the
agreement setting forth the safety information required to be shared by each Party and the schedule for the sharing of such safety information and other appropriate procedures and matters, as detailed in Exhibit G. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 25 

 8. PAYMENTS 

8.1 Upfront Payment. Within thirty (30) days after the Effective Date, Green Cross shall pay to MacroGenics One Million
Dollars ($1,000,000), which shall be non-refundable and non-creditable against any other payments due under this Agreement. 

8.2 Purchase of MacroGenics Stock Upon Initial Public Offering 

(a) If during the first three (3) years of the Term there is an Initial Public Offering which raises a ***, and if the
underwriter(s) in such Initial Public Offering permit it, Green Cross is obligated to purchase a number of shares of the same class of capital stock, simultaneously with the closing(s) of, and at the same purchase price as the shares sold in, the
Initial Public Offering that is equal to the number of shares that could be purchased for ***. 
 (b) Green Cross
acknowledges that any securities purchased in accordance with Section 8.2(a) shall not be registered under the Securities Act of 1933, as amended (“Securities Act”), and may not be sold, assigned, pledged, hypothecated,
encumbered or an any other manner transferred or disposed of in the absence of an effective registration statement or an exemption from registration under the Securities Act. In connection with any Initial Public Offering, Green Cross agrees to
enter into a lock-up agreement with the underwriter(s) if the managing underwriter(s) demands or requests such an agreement; provided, however, that such provisions will not be less favorable to Green Cross than the provisions of any lock-up
agreements entered into by the managing underwriter(s) with other holders of securities issued by MacroGenics. 
 8.3
Clinical Development Milestone Payments. Green Cross shall pay to MacroGenics the milestone payments listed below, which shall be non-refundable, and non-creditable (unless otherwise stipulated under this Agreement). Any such milestone
payments are subject to any credits, offsets and waivers specified by this Agreement. 
 (a) For the Commencement of the first
Phase II Clinical Trial: ***; provided, however, that this milestone payment shall not be payable to MacroGenics if *** 
 (b) For the Commencement of the first Phase III Clinical Trial: ***; provided, however, that this milestone payment shall not be payable to MacroGenics *** If all necessary documents
required for Regulatory Approval of Completion of the Phase II Clinical Trial by Green Cross, if any, are not received within a reasonable period prior to the agreed upon projected Completion date, other than as a result of Green Cross’ acts or
omissions, then such *** period shall be equitably extended to account for such delay for a period mutually agreed upon in writing by the Parties. 
 (c) Approval of BLA for first Indication for a Product by KFDA in the Territory: *** 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 26 

 8.4 Commercial Milestone Payments. Green Cross shall pay to MacroGenics the Net Sales
milestone payments set forth below, which shall be due and payable within *** after the end of the first Calendar Year during which such milestone is triggered. 
 (a) First occurrence of aggregate Net Sales for a period of *** of all Products in the Territory *** ***. 
 (b) First occurrence of aggregate Net Sales for a period of *** of all Products in the Territory exceeding *** 
 8.5 Product Royalties. 
 (a) Green Cross shall pay to MacroGenics a royalty
at the rate determined in accordance with the royalty chart included in Exhibit H attached hereto on Net Sales of Products for the Royalty Term. 
 (b) Green Cross shall pay to MacroGenics a royalty of *** on Net Sales of Competing Products for the Royalty Term. 
 8.6 Upstream License Royalties. In addition to the other royalty payments set forth in this Section 8, Green Cross shall reimburse MacroGenics for royalty payments payable by MacroGenics as a
result of the Collaboration pursuant to: (a) the Upstream Agreements identified on Exhibit E as of the Effective Date and (b) any additional Upstream Agreements identified by MacroGenics after the Effective Date that include a license to
any patent(s) that has any claim(s) that would otherwise prevent MacroGenics from fulfilling its obligations under this Agreement or from supplying MGAH22 or any Product in the Territory (the “Upstream Royalties”). Green Cross’
obligation under this Section 8.6 with respect to the payment of Upstream Royalties under an Upstream Agreement shall terminate upon termination of MacroGenics’ obligation to pay royalties under the terms of such Upstream Agreement.

 8.7 Third Party Agreements. Green Cross (or its Affiliate or Sublicensee) shall be responsible, at its sole expense
and discretion, for obtaining any agreements with Third Parties (other than the Upstream Agreements) for any Third Party rights which would be infringed by the Development, manufacturing, importation, or Commercialization of any Product in the
Territory. 
 8.8 Payment of Milestones. All milestone payments shall be due and payable within *** after the
event for which the payment is due. 
 8.9 Reports; Payments 

(a) Net Sales Quarterly Reports. During the Term, following the First Commercial Sale of a Product in the Territory, Green Cross
shall furnish to MacroGenics: 
 (i) a quarterly written report for the Calendar Quarter showing the Net Sales of
all Products (and Competing Products) subject to royalty payments sold by Green Cross and its Related Parties in the Territory during the reporting period and the royalties payable under this Agreement; and 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 27 

 (ii) a quarterly report for the Calendar Quarter showing Green Cross’
Commercial Supply Costs, Third Party Royalties and Upstream Royalties for such Calendar Quarter, with such detail as shall reasonably allow MacroGenics to determine the basis for such quarterly costs. 

(b) Submission and Payment Schedule 

(i) Reports. Reports under this Section 8.9 shall be due on the ninetieth (90th) day following the close of each Calendar Quarter. 

(ii) Royalties. Royalties shown to have accrued by each report shall, unless otherwise specified under this
Agreement, be due and payable on the date such report is due. 
 8.10 Payment Exchange Rate. All payments to be made by
Green Cross to MacroGenics under this Agreement shall be made in United States dollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by MacroGenics. For invoices that Green Cross
shall forward to MacroGenics, Green Cross shall use an exchange rate equal to the Telegraphic Transfer (T/T) selling rate as published by Korean Exchange Bank as of the close of business on the last business day of the preceding month. 

8.11 Tax Withholding. If laws, rules or regulations require Green Cross to withhold income taxes or other taxes imposed upon
payments set forth in this Section 8, Green Cross shall make such withholding payments as required and subtract such withholding payments from the payments set forth in this Section 8. Green Cross shall submit original receipts or other
appropriate proof of payment of the withholding taxes to MacroGenics within a reasonable period of time to allow MacroGenics to document such tax withholdings for purposes of claiming foreign tax credits and similar benefits, and shall cooperate
with reasonable requests of MacroGenics (without acting to the detriment of Green Cross) related to MacroGenics obtaining such credits and benefits. 
 9. Record Keeping and Inspections and Audits 
 9.1 Records

 (a) Collaboration Activities. Each Party shall maintain appropriate records of: (i) all significant research,
Development, manufacturing and Commercialization events and activities conducted by it or on its behalf related to a Product, and all costs in connection therewith, as applicable; and (ii) all significant information generated by it or on its
behalf in connection with research and development 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 28 

 
of MGAH22 and Products under this Agreement, in each case in accordance with such Party’s usual documentation and record retention practices. Such records shall be in sufficient detail to
properly reflect, in good scientific manner, all significant work done and results of studies and trials undertaken, and further shall be at a level of detail appropriate for patent and regulatory purposes. 

(b) Green Cross Royalties. Green Cross shall keep complete and accurate records in sufficient detail to enable the royalties
payable under Section 8 and its Commercial Supply Costs, Third Party Royalties and Upstream Royalties to be determined. 

(c) MacroGenics’ Royalties. MacroGenics shall keep complete and accurate records of royalty payments due under the Upstream
Agreements in sufficient detail to enable the Upstream Royalties payable by Green Cross under Section 8.6 to be determined. At the request of Green Cross, MacroGenics shall make such records available to Green Cross. 

(d) MacroGenics’ FBMC. MacroGenics shall keep complete and accurate records with such detail as shall reasonably allow Green
Cross to determine the basis for such FBMC. At the request of Green Cross, MacroGenics shall make such records available to Green Cross. 
 9.2 Audit Rights. Upon the written request of a Party (“Requesting Party”) with reasonable advance notice and not more than once in each Calendar Year, the other Party shall permit
an independent certified public accounting firm of nationally recognized standing selected by Requesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal business hours to such of the records as
may be reasonably necessary to verify the accuracy of the reports under Section 8 for any Calendar Year ending not more than thirty-six (36) months prior to the date of such request. The accounting firm shall disclose to the Requesting
Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with this audit right. This right to audit shall remain in effect
throughout the life of this Agreement and for a period of three (3) years after the termination of this Agreement. 
 9.3
Discrepancies. If such accounting firm identifies a discrepancy, the other Party shall pay Requesting Party the amount of the discrepancy within thirty (30) days of the date Requesting Party delivers to the other Party such accounting
firm’s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by Requesting Party unless the underpayment by the other Party exceeded five percent (5%) of the amount
owed for such Calendar Year, in which case the other Party shall pay to Requesting Party the reasonable fees charged by such accounting firm. 
 9.4 Confidentiality. Each Party shall treat all information of the other Party subject to review under this Section 9 in accordance with the confidentiality and non-use

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 29 

 
provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party and any applicable Related Parties, obligating it or
them to retain all such information in confidence pursuant to such confidentiality agreement. 
 10.
LICENSES 
 10.1 License to Green Cross 

(a) License. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Green Cross an exclusive,
royalty-bearing (i) license, with the right to grant sublicenses (subject to Section 10.1(b)), under the MacroGenics Licensed Technology and the MacroGenics Licensed Trademarks; and (ii) to the extent needed under this
Section 10.1(a), sublicense under the MacroGenics Licensed Technology licensed pursuant to the Upstream Agreements, in the case of each of (i) and (ii), to conduct the Phase I Clinical Development Plan and Phase II Clinical Development
Plan, and to distribute, sell, offer for sale and import Products in the Field in the Territory during the Term. 
 (b)
Sublicensees. Green Cross may grant sublicensees solely for purposes of performing its Development obligations under this Agreement. In no event shall Green Cross grant any sublicense to any of the rights granted to it pursuant to
Section 10.1(a) for any other purpose without MacroGenics’ prior written consent. Each sublicense granted by Green Cross shall be consistent with this Agreement and subordinate thereto, and Green Cross shall remain responsible to
MacroGenics for the compliance of each such Sublicensee with the financial and other obligations due under this Agreement. Green Cross shall provide a copy of each such sublicense to MacroGenics so that MacroGenics can confirm Green Cross’
compliance with the foregoing. Each sublicense granted by Green Cross under this Agreement shall permit the conversion of such sublicense to a direct license with MacroGenics at MacroGenics’ sole option in the event this Agreement is terminated
and, upon such conversion, MacroGenics shall be responsible for all former obligations of Green Cross under such sublicense. Green Cross shall use Commercially Reasonable Efforts to include in each such sublicense a requirement obligating such
sublicensees to cooperate with MacroGenics. 
 (c) Regulatory Approvals. Green Cross shall hold and maintain all
Regulatory Approvals for the Commercialization of the Product in the Territory. 
 (d) MacroGenics Retained Rights.
MacroGenics shall retain the following: (i) the right to conduct its obligations under the Phase I Clinical Development Plan and Phase II Clinical Development Plan in the Territory, including, without limitation, data management, monitoring,
regulatory compliance and support and shipping requirements and all other requirements in connection with this Agreement; (ii) the right to manufacture or have manufactured MGAH22 and Products for uses pursuant to this Agreement as provided in
Section 6 in the Territory; and (iii) all rights not otherwise granted to Green Cross inside and outside the Territory. 
 (e) Opportunity ***. In the event that during the period between the ***, MacroGenics wishes to ***, MacroGenics shall provide Green Cross *** 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 30 

 10.2 Upstream Agreements. Certain MacroGenics Licensed
Know-how and MacroGenics Licensed Patents sublicensed under Section 10.1(a) above and identified on Exhibit A are licensed (or sublicensed, in some instances) to MacroGenics by certain Third Parties
pursuant to the Upstream Agreements. Green Cross acknowledges and agrees that its sublicense to and any warranties and/or representations made by MacroGenics under this Agreement regarding such MacroGenics Licensed Technology granted under
Section 10.1(a) are at all times subject to the applicable terms of the Upstream Agreements, current copies of which, for those in effect as of the Effective Date, have been provided to Green Cross as of the Effective Date, including
restrictions on the type and nature of the antibodies licensed as Products thereunder, diligence requirements, and termination provisions thereof, and that MacroGenics is in no way licensing or purporting to license or sublicense to Green Cross
rights under the Upstream Agreements that if sublicensed to Green Cross would be a violation of any Upstream Agreement. Green Cross covenants not to take or fail to take any action that violates the terms of such Upstream Agreements applicable to
Sublicensees, or that would cause MacroGenics to be in breach of any of the terms of the Upstream Agreements. 
 10.3 License
to MacroGenics. Green Cross hereby grants to MacroGenics a royalty-free, worldwide license during the Term, with the right to grant sublicenses, under the Green Cross Licensed Patents and Green Cross Know-how that is incorporated into any
Product, and all other intellectual property Controlled by Green Cross that is specifically related to MGAH22 to the extent needed by MacroGenics to research, identify, develop, make, have made, use, sell, offer for sale and import Products,
including, without limitation, as contemplated by Section 10.1(c) above, in all cases without any obligation to obtain Green Cross’ prior consent. The license granted pursuant to this Section 10.3 shall be non-exclusive in the
Territory and exclusive in the rest of the world outside the Territory. After the Term, the Parties shall discuss in good faith whether future licenses are necessary for MacroGenics to continue to use Green Cross Licensed Patents or Green Cross
Licensed Know-how, and determine reasonable terms and conditions for such license at MacroGenics’ request. 
 10.4
Clinical Data Licenses. Subject to the terms and conditions of this Agreement, Green Cross hereby grants to MacroGenics a non-exclusive, royalty-free, perpetual license, with the right to grant and authorize the grant of sublicenses, to use
all Clinical Data and any data generated by Green Cross or any of its representatives or independent contractors pursuant to its performing its responsibilities under this Agreement for the research, Development, manufacture Commercialization and
sales of MGAH22 and Products by MacroGenics outside the Territory and for MacroGenics to exercise its rights and fulfill its obligations under this Agreement. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Green
Cross a non-exclusive, 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 31 

 
royalty-free, license, with the right to grant sublicenses, during the Term to use all Clinical Data and other data generated by MacroGenics pursuant to its performing its responsibilities under
this Agreement for Green Cross to fulfill its obligations under this Agreement. 
 10.5 Negative Covenant. Each Party
covenants that, except to the extent Third Parties generally are lawfully permitted to do so, it will not use or practice any of the other Party’s intellectual property rights licensed to it under this Section 10 except for the purposes
expressly permitted in the applicable license grant. 
 10.6 No Implied Licenses. Except as explicitly set forth in this
Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party. 

10.7 Diversion 
 (a) Green Cross hereby covenants and agrees that it will not, either directly or indirectly, promote, market, distribute, import, sell or have sold Products, including via the Internet or mail order, to
any Third Party, address or Internet Protocol address outside of the Territory. 
 (b) If any of Green Cross’ Products are
diverted for use outside the Territory, the following shall apply: (i) if such Products were diverted by an identifiable customer, distributor, employee, consultant or agent of Green Cross then, upon the request of MacroGenics, Green Cross
shall not sell such Products to, or allow the sale of such Products by, any such customer, distributor, employee, consultant or agent for the remaining Term and shall use Commercially Reasonable Efforts to buy back all such Products from such
customer, distributor, employee, consultant or agent within *** of such request from MacroGenics; or (ii) Green Cross shall use Commercially Reasonable Efforts to investigate the location of such diverted Products and buy it back; but, if and
to the extent that, Green Cross elects not to, or is unable to, buy back the applicable diverted Products, then MacroGenics may, in its sole discretion, buy back the applicable diverted Products, and Green Cross shall reimburse MacroGenics for all
reasonable costs incurred by MacroGenics in connection with the buy-back or lost sales of any such diverted Products. 
 11.
EXCLUSIVITY. During the Term, Green Cross shall not (either by itself, or with or through a Related Party or Third Party) Develop or Commercialize any (i) Product outside of the scope of this Agreement or
(ii) Competing Product. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 32 

 12. CONFIDENTIALITY; PUBLICATION 

12.1 Nondisclosure Obligation 
 (a) Definition and Restrictions. All Confidential Information disclosed by one Party to the other Party at any time, including, without limitation, before the Effective Date or after the expiration
or termination of this Agreement, shall be maintained in confidence by the receiving Party and shall not be disclosed by the receiving Party to any Third Party or used by the receiving Party for any purpose except as set forth herein without the
prior written consent of the disclosing Party, *** The following shall not be deemed Confidential Information for purposes of the restrictions set forth in this Section 12.3(a): 

(i) Information that is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the
disclosing Party, as documented by the receiving Party’s business records; 
 (ii) Information that is or
becomes part of the public domain through no fault of the receiving Party; 
 (iii) Information that is
subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party; and 

(iv) Information that is developed by the receiving Party independently of Confidential Information received from the
disclosing Party, as documented by the receiving Party’s business records. 
 (b) Combinations. Any combination of
features or disclosures shall not be deemed to fall within the exclusions set forth in Section 12.1(a) merely because individual features are published or available to the general public or in the rightful possession of the receiving Party
unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party. 
 (c) Exceptions. Notwithstanding the restrictions set forth in Section 12.1(a), the receiving Party may disclose Confidential Information of the other Party to: 

(i) governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct
clinical trials or to market Products, but such disclosure may be only to the extent reasonably necessary to obtain Patents or authorizations; or 
 (ii) as the receiving Party deems necessary to be disclosed, to its Affiliates, agents, consultants, or other Third Parties for the Development or 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 33 

 
Commercialization of Product(s), or in connection with a licensing transaction related to such Product(s) or loan, financing or investment or acquisition, merger, consolidation or similar
transaction (or for such entities to determine their interest in performing such activities) or in order to perform its obligations under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to
whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement; provided that the term of confidentiality and non-use applicable to such Third Parties shall be
no less than *** from the date of disclosure to them. 
 (d) Disclosure Required by Judicial or Administrative
Process. If a Party is required by judicial or administrative process to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section 12.1, such Party shall promptly inform the other
Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise
subject to the confidentiality and non-use provisions of this Section 12.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including without limitation obtaining an
order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. 
 (e) Obligations
Upon Termination. Upon the termination or expiration of this Agreement, or upon the earlier request of either Party, the receiving Party shall return to the disclosing Party, all of the disclosing Party’s Confidential Information, including
all copies thereof, provided that the receiving Party may retain one copy for archival purposes. 
 12.2 Publication

 (a) Publication of Results. Green Cross and MacroGenics each acknowledge the other Party’s interest in publishing
the results of its activities under the Collaboration in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent
protection and in protecting business interests and trade secret information. Consequently, the JSC shall establish procedures for review of publications related to the Collaboration, ensuring that, except for disclosures permitted pursuant to
Section 12.1, either Party and its employees wishing to make a publication related to work performed under this Agreement shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least
*** prior to submission for publication or for presentation. 
 (b) Review of Publications and Presentations

 (i) The reviewing Party shall have the right (a) to propose modifications to the publication or
presentation for patent reasons, trade secret reasons, 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 34 

 
or for purposes of removing the Confidential Information of the reviewing Party, or (b) to request a reasonable delay in publication or submission for presentation in order to protect trade
secret or patentable information. 
 (ii) If the reviewing Party requests the removal of the reviewing
Party’s Confidential Information or a delay, the publishing Party shall remove such Confidential Information and delay submission for publication or submission for presentation for a period of *** to enable patent applications protecting
each Party’s rights in such Confidential Information to be filed in accordance with Section 15 below. 

(iii) Upon expiration of such *** and satisfaction of any other conditions imposed by the JSC, the publishing Party
shall be free to proceed with the publication or submission for presentation. 
 (iv) Upon request of the Party
seeking publication, the reviewing Party shall consider expediting the time frames set forth in this Section 12.2. 
 (v) If the reviewing Party requests modifications to the publication or submission for presentation, the publishing Party shall edit such publication to prevent disclosure of the Confidential Information
of the reviewing Party or trade secret or proprietary business information prior to submission for publication or for presentation. 
 12.3 Publicity; Use of Names 
 (a) Press Releases. The Parties shall
issue a mutually acceptable press release announcing the execution of this Agreement. A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder upon prior written approval of the other Party, such
approval not to be unreasonably withheld or delayed; provided, however, that no approval of the other Party shall be required if a subsequent press release or SEC filing solely discloses the information that (1) a milestone under this Agreement
has been achieved and/or any payments associated therewith have been received; (2) the filing and/or approval of a BLA generally has occurred (provided, however, that specific dates of filing shall not be disclosed); (3) initiation of any
Phase II Clinical Trial or later clinical trial; and (4) commercial launch of a Product or any information that has previously been approved and disclosed as permitted by this Section 12.3(a). In the case of items (1)-(4) of the
preceding sentence, the disclosing Party shall provide the other Party a copy of such proposed disclosures at least *** prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in
light of any reporting obligations of such disclosing Party under applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United States Securities and Exchange Commission or any other
governmental agency. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 35 

 (b) No Other Use of Company Names. Except as otherwise provided in this
Section 12.3(b), neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission
of the other Party. 
 (c) Approved Press Releases. In addition and notwithstanding anything to the contrary herein,
(a) if the relevant text of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republished in such proposed press release provided that the Party
issuing such press release provides notice to the other Party of such press release at least four (4) business days prior to the issuance of such press release, where practicable, and (b) if the relevant text of a proposed public
announcement such as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior approved presentation
materials, Q&A script or the like) then such text may be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party. 

(d) Existence of Agreement 
 (i) No Disclosure. Neither Party shall disclose the existence or terms of this Agreement pursuant to a press release or otherwise except as provided in this Section 12.3(d). 

(ii) Permitted Disclosures 
 (A) Notwithstanding the terms of this Section 12, either Party shall be permitted to disclose the existence and terms of this Agreement and the conduct of the Collaboration under this Agreement, to
the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United States Securities and Exchange
Commission or any other governmental agency. The disclosing Party shall take reasonable and lawful actions to avoid and/or minimize the degree of such disclosure. 
 (B) Either Party may also disclose the existence and terms of this Agreement to its attorneys and advisors, and to potential acquirors, in connection with a potential acquisition or other change of
control transaction and to existing and potential investors or lenders of such Party, as a part of their due diligence investigations, or to potential licensees or to permitted assignees in each case under an agreement to keep the terms of this
Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 36 

 (C) MacroGenics may also disclose the existence and terms of this Agreement pursuant to
transactions related to the Commercialization or Development of MGAH22 or any Product (“Licensing Transactions”), in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and
non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction, provided that prior to the disclosure of the terms of this Agreement in
connection with any Licensing Transaction, MacroGenics shall redact in any written summary or copy of this Agreement, all financial terms of this Agreement, in a manner substantially consistent with a form provided to Green Cross by MacroGenics on
or before the Effective Date. The transactions described in Section 12.3(d)(ii)(B) shall not be deemed Licensing Transactions for purposes of this Section 12.3(d)(ii)(C). 
 13. REPRESENTATIONS AND WARRANTIES 
 13.1 Representations and Warranties of MacroGenics. MacroGenics represents and warrants to Green Cross that, as of the Effective Date: 

(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, and to grant the licenses
contemplated under Section 10, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach or constitute a default under any contractual obligation or court or
administrative order by which MacroGenics is bound; 
 (b) all necessary consents, approvals and authorizations of all
government authorities and other persons required to be obtained by MacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained; 

(c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the MacroGenics Licensed Technology and
MacroGenics Licensed Trademarks, and has the right to grant to Green Cross the licenses that it purports to grant hereunder and has not granted any Third Party rights that would interfere or be inconsistent with Green Cross’ rights hereunder;

 (d) to its knowledge, except for those licensed or sublicensed under the Upstream Agreements, the MacroGenics Licensed
Patents and MacroGenics Licensed Know-how are not subject to any existing royalty or other payment obligations to any Third Party; and 
 (e) as of the Effective Date, to its knowledge, the issued Patents in the MacroGenics Licensed Patents are valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other
proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 37 

 
any of the MacroGenics Licensed Patents or that alleges the use of the MacroGenics Licensed Patents or the MacroGenics Licensed Know-how or the
development, manufacture commercialization and use of the Products would infringe or misappropriate the intellectual property or intellectual property rights of any Third Party (and it has not received any notice alleging such an infringement or
misappropriation). In the event that MacroGenics becomes aware of any such action or proceeding, it shall immediately notify Green Cross in writing. 
 13.2 Representations and Warranties of Green Cross. Green Cross represents and warrants to MacroGenics that as of the Effective Date: 

(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, to grant the licenses granted
hereunder, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which
Green Cross is bound; 
 (b) all necessary consents, approvals and authorizations of all government authorities and other
persons required to be obtained by Green Cross as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained. 
 (c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the Green Cross Licensed Patents and Green Cross Licensed
Know-how, and has the right to grant to MacroGenics the licenses that it purports to grant hereunder and has not granted any Third Party rights that would interfere or be inconsistent with MacroGenics’
rights hereunder; 
 (d) to its knowledge, the Green Cross Licensed Patents and Green Cross Licensed Know-how are not subject to any existing royalty or other payment obligations to any Third Party; and 
 (e) as of the Effective Date, to its knowledge, the issued Patents in the Green Cross Licensed Patents are valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other
proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of any of the Green Cross Licensed Patents or that alleges the use of the Green Cross Licensed Patents or the Green
Cross Licensed Know-how or the development, manufacture commercialization and use of the Products would infringe or misappropriate the intellectual property or intellectual property rights of any Third Party
(and it has not received any notice alleging such an infringement or misappropriation). In the event that Green Cross becomes aware of any such action or proceeding, it shall immediately notify MacroGenics in writing. 

13.3 Upstream Agreements. MacroGenics represents, warrants and covenants to Green Cross that: 

(a) Exhibit E lists all of the Upstream Agreements in existence as of the Effective Date. True and correct copies of the existing
Upstream Agreements have previously been provided to Green Cross by MacroGenics, and copies of any additional Upstream Agreement entered following the Effective Date will be provided to Green Cross by MacroGenics. Notwithstanding the foregoing,
prior to entering into additional Upstream Agreements, MacroGenics shall inform Green Cross to allow Green Cross to review the same. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 38 

 (b) The Upstream Agreements identified on Exhibit E are, to MacroGenics’ knowledge, in
full force and effect as of the Effective Date, and MacroGenics is not aware of any that it has committed any material breach of any of the provisions of any of such Upstream Agreements, nor does there exist any condition that, to the knowledge of
MacroGenics, with passage of time or sending of notice would constitute a material breach by MacroGenics of any of the provisions of such Upstream Agreements, nor is MacroGenics aware of any material breach of such Upstream Agreements by any other
party thereto. 
 (c) To the extent required to grant the licenses in this Agreement, MacroGenics has the right under the
Upstream Agreements listed on Exhibit E to enter into this Agreement and grant the licenses contemplated hereby. 
 (d)
MacroGenics will fulfill all of its material obligations under the Upstream Agreements and otherwise comply with the terms thereof. MacroGenics shall furnish to Green Cross copies of all notices received by MacroGenics relating to alleged breaches
or defaults by MacroGenics of its obligations under the Upstream Agreements within five (5) business days of MacroGenics receipt thereof. 
 (e) To the extent MacroGenics is permitted or required under the terms of the Upstream Agreements to participate in the prosecution, maintenance, or enforcement or defense of any Patent or other
intellectual property right sublicensed to Green Cross under this Agreement, MacroGenics shall do so after consultation with Green Cross and, as and to the extent permitted by the Upstream Agreements, Green Cross shall have the same rights with
respect thereto as set forth in Section 15 hereof. 
 13.4 No Other Representations or Warranties. EXCEPT AS
EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF
THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 39 

 14. INDEMNIFICATION 

14.1 By Green Cross. Green Cross agrees to indemnify and hold harmless MacroGenics, its Affiliates, and their directors, officers,
employees and agents (individually and collectively, the “MacroGenics Indemnitee(s)”) from and against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) incurred in connection with
any claims, demands, actions or other proceedings by any Third Party (individually and collectively, “Losses”) first arising after the Effective Date to the extent arising from (a) activities performed by Green Cross or any of
its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use, Commercialization or sale of MGAH22 or Products or any other exercise of their rights or performance of their obligations hereunder, (b) the
use by Green Cross or any of its Related Parties or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed Know-how except as permitted in this Agreement, (c) the negligence,
illegal conduct or willful misconduct of Green Cross, or (d) Green Cross’ material breach of this Agreement, except to the extent such Losses arise out of any of MacroGenics Indemnitee’s negligence, illegal conduct or willful
misconduct, or breach of this Agreement. 
 14.2 By MacroGenics. MacroGenics agrees to indemnify and hold harmless Green
Cross, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the “Green Cross Indemnitee(s)”) from and against all Losses to the extent arising from (a) activities performed by
MacroGenics or any of its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use, Commercialization or sale of Products, (b) any latent or hidden defect in a Product that is not caused by any act or
omission of Green Cross, (c) the use by Green Cross or any of its Related Parties or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed Know-how or any intellectual
property rights under Upstream Agreements as permitted under this Agreement, (d) the negligence, illegal conduct or willful misconduct of MacroGenics, or (e) MacroGenics’ material breach of this Agreement, except to the extent such
Losses arise out of any of Green Cross Indemnitee’s negligence, illegal conduct or willful misconduct, or breach of this Agreement. 
 14.3 Defense. If any such claims or actions are made, the Indemnitee shall be defended at the Indemnifying Party’s sole expense by counsel selected by the Indemnifying Party and reasonably
acceptable to the Indemnitee, provided that the Indemnitee may, at its own expense, also be represented by counsel of its own choosing. The Indemnifying Party shall have the sole right to control the defense of any such claim or action, subject to
the terms of this Section 14. 
 14.4 Settlement. The Indemnifying Party may settle any such claim, demand, action
or other proceeding or otherwise consent to an adverse judgment (a) with prior written notice to the Indemnitee but without the consent of the Indemnitee where the only liability to the Indemnitee is the payment of money and the Indemnifying
Party makes such payment, or (b) in all other cases, only with the prior written consent of the Indemnitee, such consent not to be unreasonably withheld. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 40 

 14.5 Notice. The Indemnitee shall notify the Indemnifying Party promptly of any
claim, demand, action or other proceeding under Section 14.1 or Section 14.2 and shall reasonably cooperate with all reasonable requests of the Indemnifying Party with respect thereto. 

14.6 Permission by Indemnifying Party. The Indemnitee may not settle any such claim, demand, action or other proceeding or
otherwise consent to an adverse judgment in any such action or other proceeding or make any admission as to liability or fault without the express written permission of the Indemnifying Party. Provided, however, that such permission shall not be
required if such settlement does not involve (a) any admission of legal wrongdoing by the other Party’s Indemnitee(s), or (b) the imposition of any equitable relief against the other Party’s Indemnitee(s). 

14.7 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 14.7 IS INTENDED TO OR SHALL LIMIT OR
RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 14, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12. 
 15. INVENTIONS; PATENT PROVISIONS 
 15.1 Ownership of Intellectual Property 
 (a) Ownership of MacroGenics
IP. As between MacroGenics and Green Cross, MacroGenics shall remain the sole and exclusive owner of all MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and MacroGenics Licensed Know-how that
exist as of the Effective Date. 
 (b) Ownership of Green Cross IP. As between Green Cross and MacroGenics, Green Cross
shall remain the sole and exclusive owner of all Green Cross Licensed know-how that exists as of the Effective Date. 
 (c) Ownership of Jointly Owned IP. MacroGenics shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Collaboration
solely by MacroGenics or its consultants or subcontractors, together with all intellectual property rights therein. Green Cross shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of
conducting the Collaboration solely by Green Cross or its 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 41 

 
consultants or subcontractors, together with all intellectual property rights therein. MacroGenics and Green Cross shall jointly own all data, results and inventions, whether patentable or not,
conceived or reduced to practice by MacroGenics and Green Cross jointly (“Jointly Owned IP”), together with all intellectual property rights therein, with each Party owning an undivided half interest and the right to exploit without
the duty of accounting or seeking consent from the other Party to the extent to be permitted under Applicable Laws and Regulations. 
 15.2 Patent and Trademark Filing, Prosecution and Maintenance 
 (a)
Overall Strategy. The JSC shall establish an overall strategy for the filing, prosecution and maintenance of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Green Cross Licensed Patents in the Territory. 

(b) Prosecution 
 (i) The responsibility for Patent Prosecution and Trademark Prosecution related to a Patent or Trademark that is within the MacroGenics Licensed Patents and MacroGenics Licensed Trademarks or the Green
Cross Licensed Patents that is owned solely by a Party shall be the responsibility of such Party. Such Party shall keep the JSC and the other Party informed of the status of all such Patent Prosecution and Trademark Prosecution activities.
MacroGenics shall be responsible for undertaking the Patent Prosecution with respect to Patents jointly owned by the Parties (the “Jointly Owned Patents”), and shall do as directed by the JSC. 

(ii) MacroGenics shall keep the JSC and Green Cross informed of the status of all matters affecting Patent Prosecution and
Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Jointly Owned Patents in the Territory, including providing a copy of any correspondence from any governmental authorities to the JSC and Green Cross upon
request, and consulting on the strategy and content of submissions to such governmental authorities in advance of any submissions. 
 (iii) Any dispute regarding Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, or Jointly Owned Patents, shall be resolved by the JSC.

 (iv) Without limiting the generality of the foregoing, MacroGenics shall prosecute and maintain Jointly Owned
Patents using outside counsel acceptable to Green Cross, and shall instruct such counsel to provide copies of correspondence and filings directly to Green Cross and otherwise permit Green Cross to participate with MacroGenics in any of the
activities of such counsel with respect to the Patent and Trademark Prosecution of such Jointly Owned Patents. Before taking any material step in the Patent Prosecution or Jointly Owned Patents, MacroGenics and its counsel shall allow Green Cross a
reasonable opportunity to comment on the action proposed to be taken, and agrees to incorporate in such filings all reasonable comments of Green Cross. 
 (v) Green Cross acknowledges and understands that its rights and obligations under this Section 15.2 are secondary to and shall be subject to any Third Party rights and obligations under the Upstream
Agreements. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 42 

 (c) Patent and Trademark Oppositions. The JSC will decide whether and how to
participate in Patent and Trademark oppositions and undertake activities intended to invalidate Third Party Patents. 
 15.3
Costs of Patent and Trademark Prosecution 
 (a) Costs. All out-of-pocket costs for Patent Prosecution and
Trademark Prosecution of a Party’s solely owned Patent or Trademark and for maintaining a Party’s solely owned Patent or Trademark shall be solely incurred by and the sole responsibility of that Party. All out-of-pocket costs for Patent
Prosecution of Jointly Owned Patents and for maintaining Jointly Owned Patents in the Territory shall be shared equally by the Parties. The out-of-pocket costs of MacroGenics’ participation in Patent and Trademark oppositions, interferences and
similar actions, and activities intended to invalidate Third Party Patents and Trademarks in the Territory shall be borne solely by Green Cross. 
 15.4 Patent and Trademark Prosecution Cooperation. With respect to all Patent Prosecution and Trademark Prosecution related to Patents and Trademarks included in MacroGenics Licensed Patents,
MacroGenics Licensed Trademarks or Green Cross Licensed Patents, each Party shall: 
 (a) execute all further instruments to
document their respective ownership consistent with this Agreement as reasonably requested by the other Party; 
 (b) make its
employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its
Patent Prosecution and Trademark Prosecution responsibilities; 
 (c) cooperate, if necessary and appropriate, with the other
Party in gaining Patent and Trademark term extensions; provided, however, that any dispute regarding the same shall be submitted to the JSC for resolution; and 
 (d) endeavor in good faith to coordinate its efforts under this Agreement with the other Party to minimize or avoid interference with the Patent Prosecution and Trademark Prosecution of the other
Party’s Patents and Trademarks. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 43 

 15.5 Enforcement 

(a) Notice. Each Party shall promptly provide, but in no event later than ***, the other with written notice reasonably detailing
any known or alleged infringement of any Patent or Trademark owned by the other Party and subject to a license under this Agreement. 
 (b) Enforcement of Intellectual Property Rights 
 (i) The
sole owner of a Patent, Trademark, Know-how or Confidential Information shall have the exclusive right to institute and direct legal proceedings against any Third Party believed to be infringing such Patent or
Trademark or misappropriating or otherwise violating such Know-how or Confidential Information. Green Cross shall have the initial right to institute and direct legal proceedings against any Third Party
believed to be infringing Jointly Owned Patents that claims or covers a Product sold in the Territory. If Green Cross has the right to direct legal proceedings pursuant to this Section 15.5(b)(i) and does not abate such violation of Jointly
Owned Patents, including by commencement of a lawsuit against the accused person if necessary, within *** after receiving notice of such infringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly
Owned Patents, then MacroGenics shall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation in the Territory, including commencement of a lawsuit against the accused Third Party if necessary.

 (ii) MacroGenics shall have the initial right to institute and direct legal proceedings against any Third
Party believed to be infringing Jointly Owned Patents that claims or covers a Product sold outside the Territory. If MacroGenics does not abate such violation of Jointly Owned Patents, including by commencement of a lawsuit against the accused
person if necessary, within *** after receiving notice of such infringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly Owned Patents, then Green Cross shall be entitled (but shall not be
obligated) to take all actions reasonably necessary to abate such violation in the Territory, including commencement of a lawsuit against the accused Third Party if necessary. 

(iii) All amounts recovered from enforcement of any such rights by either Party in the Territory relating to the
intellectual property licensed under this Agreement shall be first used to reimburse each Party’s costs and expenses incurred in connection with such action, and any remainder of such recovery, other than amounts recovered as lost profits,
shall be retained by the Party instituting the action, provided that any remainder retained by Green Cross shall be treated as Net Sales and shall be subject to Green Cross’ royalty payment obligations at the applicable rate specified in
Section 8.5. For amounts recovered as lost profits the amount of Net Sales represented by such lost profits and Green Cross shall be obligated to pay MacroGenics any amounts due under this Agreement if such projected Net Sales were actually
made by Green Cross. All amounts recovered from 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 44 

 
enforcement of any such rights by either Party outside the Territory relating to Jointly Owned Patents shall be first used to reimburse each Party’s costs and expenses incurred in connection
with such action, and any remainder of such recovery, shall be retained by the Party instituting the action. 
 (c)
Cooperation in Enforcement Proceedings. For any action by a Party pursuant to subsection (b) above, in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party will join such action
voluntarily and will execute all documents necessary for such Party to initiate, prosecute and maintain such action. If either Green Cross or MacroGenics initiates an enforcement action pursuant to Section 15.5(b), then the other Party shall
cooperate to the extent reasonably necessary and at the first Parties’ sole expense (except for the expenses of the non-controlling Party’s counsel, if any). Upon the reasonable request of the Party instituting any such action, such other
Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the
subject thereof. 
 (d) Status; Settlement. The Parties shall keep each other informed of the status of and of their
respective activities regarding any enforcement action pursuant to Section 15.5(b). Neither Party shall settle any litigation or legal proceeding in the Territory to enforce MacroGenics Licensed Patents or MacroGenics Licensed Trademarks
without the other Party’s written authorization. 
 15.6 Defense 

(a) Notice of Allegations. Each Party shall notify the other in writing of any allegations it receives from a Third Party that the
manufacture, production, use, development, sale or distribution of any Product or any technology or intellectual property licensed by a Party under this Agreement infringes the intellectual property rights of such Third Party. Such notice shall be
provided promptly, but in no event after more than fifteen (15) business days, following receipt of such allegations. 

(b) Notice of Suit. In the event that a Party receives notice that it or any of its Affiliates have been individually named as a
defendant in a legal proceeding by a Third Party alleging infringement of a Third Party’s Patents or other intellectual property right as a result of the manufacture, production, use, development, sale or distribution of Products or any
technology or intellectual property licensed by a Party under this Agreement, such Party shall immediately notify the other Party in writing and in no event notify such other Party later than *** after the receipt of such notice. Such written
notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably
the subject thereof. In such event, the Parties shall agree how best to mitigate or control the defense of any such legal proceeding; provided however, that if either Party or any of its Affiliates have been individually named as a defendant in a
legal proceeding relating to 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 45 

 
the alleged infringement of a Third Party’s Patents or other intellectual property right as a result of the manufacture, production, use, development, sale or distribution of Products, the
other Party shall be allowed to join in such action, at its own expense. 
 (c) Status; Settlement. The Parties shall
keep each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party in the Territory concerning a Party’s manufacture, production, use, development, sale or
distribution of Products or any technology or intellectual property licensed by a Party under this Agreement; provided, however, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section 15.6(c)
may be undertaken by a Party without the consent of the other Party which consent shall not be unreasonably withheld or delayed. 
 16.
TERMS AND TERMINATION 
 16.1 Term. Unless earlier
terminated, this Agreement shall continue in effect until the expiration of the Royalty Term as defined in Section 1.87 (“Term”), and thereafter Green Cross has no remaining payment obligations with respect to the Products
pursuant to Section 8.5 above and MacroGenics shall have no further obligations hereunder. 
 16.2 Termination for
Change in Control of Green Cross. In the event of a Change in Control involving Green Cross, Green Cross shall provide prompt written notice to MacroGenics following such Change in Control, and MacroGenics may, in its sole discretion, terminate
this Agreement by providing written notice to Green Cross within *** of MacroGenics’ receipt of such written notice of the Change in Control. 
 16.3 Termination for Change in Control of MacroGenics. In the event of a Change in Control involving MacroGenics, MacroGenics shall provide prompt written notice to Green Cross following such
Change in Control, and Green Cross may, in its sole discretion, terminate this Agreement by providing written notice to MacroGenics within *** of Green Cross’ receipt of such written notice of the Change in Control. 

16.4 Termination for Challenge to Patent Validity. MacroGenics may terminate this Agreement immediately upon written notice to
Green Cross in the event Green Cross or any of its Affiliates: 
 (a) directly or indirectly oppose, or assist any Third Party
to oppose, in any patent office proceeding, the grant of any patent or patent application within the MacroGenics Licensed Patents, or, in any patent office proceeding, dispute or directly or indirectly assist any Third Party to dispute, the validity
of any patent within the MacroGenics Licensed Patents or any of the claims thereof, including opposing any application for amendment thereto; 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 46 

 (b) directly or indirectly oppose, or assist any Third Party to oppose, in any court
proceeding, the grant of any patent or patent application within the MacroGenics Licensed Patents, or, in any court proceeding, dispute or directly or indirectly assist any Third Party to dispute, the validity of any patent within the MacroGenics
Licensed Patents or any of the claims thereof; or 
 (c) bring any claim or proceedings of whatever nature in relation to the
MacroGenics Licensed Patents against MacroGenics and/or any of MacroGenics’ Affiliates (or in respect of the foregoing their directors and officers) in respect of any activities carried out by them under any MacroGenics Licensed Patents which
may be the subject of a Valid Claim of the MacroGenics Licensed Patents. 
 16.5 Termination for Cause. This Agreement
may be terminated at any time during the Term upon written notice by either Party if the other Party is in material breach of its other obligations under this Agreement and, in each case, has not cured such breach within *** after notice
requesting cure of the breach (other than for non-payment which shall be cured within ***). 
 16.6 Effect of
Termination 
 (a) If MacroGenics terminates this Agreement pursuant to Section 16.2, 16.4, or pursuant to
Section 16.5 for cause based on material breach by Green Cross: 
 (i) Green Cross shall pay any amounts due
pursuant to Section 8 prior to the date of termination; 
 (ii) For the avoidance of doubt, the licenses and
sublicenses granted to Green Cross under Sections 10.1(a) and 10.4 shall terminate; 
 (iii) Green Cross
shall return to MacroGenics all Products (including, without limitation, all MGAH22) within its possession or control and arrange for the Green Cross Sublicensees to return to MacroGenics all Products (including, without limitation, all MGAH22)
within such Green Cross Sublicensees’ possession or control; 
 (iv) Green Cross shall cease to research,
develop, market and sell any Product that infringes a Valid Claim in a MacroGenics Licensed Patent; 
 (v) for
the Products (including, without limitation, MGAH22), Green Cross shall assign and promptly transfer to MacroGenics, at no expense to MacroGenics, all of Green Cross’ right, title and interest in and to (A) all regulatory filings (such as
INDs, CTAs and drug master files), Regulatory Approvals, and clinical trial agreements (to the extent assignable and not cancelled) for such Products(s), to the extent that MacroGenics elects to continue development of such Product(s); (B) all
data, including clinical data, materials and information of any kind 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 47 

 
or nature whatsoever, in Green Cross’ possession or in the possession of its Affiliates or its or their respective agents related to such Product(s); (C) all trademarks related to such
Products (if such termination occurs after approval of such trademark by a Regulatory Authority); and (D) all material information, and any other information reasonably requested and required by MacroGenics, relating to the manufacture of such
Products; 
 (vi) all sublicenses under the rights granted pursuant to Section 10.1(b) shall terminate; and

 (vii) MacroGenics shall revoke (and Green Cross shall allow revocation of) any powers of attorney for any
MacroGenics Licensed Patents that Green Cross holds as of the time of such termination; and 
 (b) If Green Cross terminates
this Agreement pursuant to Section 16.3: 
 (i) The provisions of Section 16.6(a) shall apply;

 (ii) Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to
***, the Products (including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of Section 6.2; and 
 (c) If Green Cross terminates this Agreement pursuant to Section 16.5 for cause based on material breach by MacroGenics: 

(i) As full satisfaction of any claims Green Cross may have based upon such material breach and termination, ***:

 (1) Such material breach by MacroGenics results in a substantial reduction in the profit Green Cross would have
received if such material breach and termination had not occurred; 
 (2) MacroGenics committed such material breach
other than as a result of a material breach committed by Green Cross; and 
 (3) Both Parties agree in writing not to
undertake arbitration in accordance with Section 17.7 to determine whether MacroGenics committed a material breach. 
 (ii) For the avoidance of doubt, the license granted under Section 10.3 shall terminate; 
 (iii) The provisions of Section 16.6(a) shall apply; 
 (iv)
Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to***, the Products (including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of
Section 6.2; and 
 (v) Green Cross shall revoke (and MacroGenics shall allow revocation of) any powers of
attorney for any Green Cross Licensed Patents that MacroGenics holds as of the time of such termination. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 48 

 (d) Return of Confidential Information. Upon expiration or termination of this
Agreement, the Parties shall comply with Section 12.1(e). 
 16.7 Survival. The following provisions shall survive
the termination or expiration of this Agreement for any reason: Sections 1, 8.9, 8.11, 9, 10.4 (with respect to the license granted to MacroGenics), 12 (to the extent provided therein), 13, 14, 15.1, 16 and 17. 

17. MISCELLANEOUS 
 17.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under
this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including, but not limited to, embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party (“Force Majeure”). The affected
Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. In the event a Party is unable to perform
its obligations under this Agreement due to Force Majeure for a period of ***, the other Party shall have the option of unilaterally terminating this Agreement upon providing *** written notice. 

17.2 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this
Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code. The
Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. The Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and may fully exercise all of
its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the “Involved Party”) under the U.S. Bankruptcy Code, the other Party
(such Party, the “Noninvolved Party”) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectual property and all embodiments of such intellectual
property, provided the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 49 

 
embodiments thereof shall be promptly delivered to the Noninvolved Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party,
unless the Involved Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request
therefor by Noninvolved Party. The foregoing is without prejudice to any rights the Noninvolved Party may have arising under the U.S. Bankruptcy Code or other applicable law. 
 17.3 Assignment. Neither Party may assign its rights and obligations under this Agreement without the prior written consent of the other Party, provided that either Party may assign its rights and
obligations under this Agreement, without such consent from the other Party, to its Affiliate or any successor in interest in connection with the sale of all or substantially all of its assets or a sale of all or substantially of the business
related to MGAH22 or a Product, or a merger, acquisition or other similar transactions. For the avoidance of doubt, the terms and conditions of this Agreement shall be binding on the permitted successors and assignees of each Party. 

17.4 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
Agreement. 
 17.5 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to MacroGenics, to:	  	 1500 East Gude Drive

Rockville, MD 20850
 Attention: Chief Executive
Officer
 Facsimile: ***

		
	 with copy to:
 (which shall not constitute notice)
	  	 Arnold & Porter, LLP
 1600
Tysons Boulevard
 Suite 900
 McLean, VA
22102
 Attention: ***

Facsimile: ***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 50 

			
	if to Green Cross, to:	  	 Green Cross Corporation
 303
Bojeong-dong, Giheung-gu
 Yongin, 446-770, Korea
 Attn: President
 Facsimile: ***

		
	 with copy to:
	  	 Green Cross Corporation
 303
Bojeong-dong, Giheung-gu
 Yongin, 446-770, Korea
 Attn: ***
 Facsimile: ***

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed to have been given upon receipt. 
 17.6 Applicable Law. All
questions of inventorship will be determined in accordance with ***. In respect to all other Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or granted
shall govern. Except as otherwise indicated, in all other respects, the right and obligations of the Parties under this Agreement shall be governed by and construed in accordance with the laws of the ***. 

17.7 Arbitration 
 (a) All disputes arising out of or in connection with the Agreement shall be finally settled under the Rules of Arbitration of the *** by three (3) arbitrators (“Arbitral
Tribunal”). 
 (b) Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the
Request for Arbitration within *** days of being requested to do so, or if the respondent should fail to appoint an arbitrator in its Answer to the Request for Arbitration within *** days of being requested to do so, the other party
shall request the *** to make such appointment. 
 (c) The arbitrators nominated by the parties shall, within ***
from the appointment of the arbitrator nominated in the Answer to the Request for Arbitration, and after consultation with the parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should such procedure
not result in an appointment within the *** time limit, either party shall be free to request the *** to appoint the third arbitrator. 
 (d) *** shall be the seat of the arbitration. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 51 

 (e) The language of the arbitration shall be English. Documents submitted in the arbitration
(the originals of which are not in English) shall be submitted together with an English translation. 
 (f) This arbitration
agreement does not preclude either party seeking conservatory or interim measures from any court of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either party’s domicile. Conservatory or
interim measures sought by either party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either party before the Arbitral Tribunal shall
not preclude any court of competent jurisdiction granting conservatory or interim measures. 
 (g) In the event that any issue
shall arise which is not clearly provided for in this arbitration agreement the matter shall be resolved in accordance with the *** Arbitration Rules. 
 17.8 Entire Agreement; Amendments. The Agreement contains the entire understanding of the Parties with respect to the Collaboration and licenses granted hereunder. All express or implied agreements
and understandings, either oral or written, with regard to the Collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Agreement may be amended, or any term hereof modified, only by a written instrument
duly executed by authorized representatives of both Parties hereto. 
 17.9 Headings. The captions to the several
Sections hereof are not a part of the Agreement, but are merely for convenience to assist in locating and reading the several Sections and Sections of this Agreement. 
 17.10 Independent Contractors. It is expressly agreed that MacroGenics and Green Cross shall be independent contractors and that the relationship between the two Parties shall not constitute a
partnership, joint venture or agency. Neither MacroGenics nor Green Cross shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the
prior written consent of the other Party. 
 17.11 Waiver. The waiver by either Party of any right hereunder, or the
failure of the other Party to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. 

17.12 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and
in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 52 

 17.13 Waiver of Rule of Construction. Each Party has had the opportunity to consult
with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

17.14 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 17.15 Further Assurances. Each Party will duly execute
and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as
the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

17.16 Construction. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural
the singular, the use of any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend
or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein means including, without limiting the generality of any description preceding such term.
References to “Section” or “Sections” are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are United States Dollars. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 53 

 The Parties have executed this Agreement as of the Effective Date. 

 

									
	Green Cross Corporation	 		 	MacroGenics, Inc.
					
	By:	 	 /s/ B. G. Rhee
	 		 	By:	 	 /s/ Scott Koenig

	Name:	 	 B. G. Rhee
	 		 	Name:	 	 Scott Koenig

	Title:	 	 President
	 		 	Title:	 	 President and CEO

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 54 

 Exhibit A 

MacroGenics Licensed Patents 
  

					
	***	  	***	  	***
	***	  	***	  	***
	***	  	***	  	***
	***	  	***	  	***
	***	  	***	  	***
	***	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 55 

 Exhibit B 

MacroGenics Licensed Trademarks 
 *** 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 56 

 Exhibit C 

Phase I Clinical Development Plan 
 ****** 
  

					
	 ***
	  	 ***
	  	 ***

	A.***	  		  	
	 1. ***
	  		  	
	 ***
	  	***	  	***
	 2. ***
	  	***	  	***
	 3. ***
	  		  	***
	 ***
	  	***	  	***
	 4. ***
	  		  	***
	 5. ***
	  		  	***
	 6. ***
	  		  	***
	 7. ***
	  		  	***
	 ***
	  		  	***
	 ***
	  	***	  	***
	 8. ***
	  		  	
	 ***
	  		  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 9. ***
	  		  	
	 ***
	  		  	***
	 ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 57 

					
	 ***
	  	 ***
	  	 ***

	 ***
	  	***	  	***
	 10. ***
	  		  	
	 ***
	  		  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 11. ***
	  		  	***
	 12. ***
	  		  	***
	 13. ***
	  		  	***
	 14. ***
	  		  	***
	 15. ***
	  		  	
	 ***
	  		  	***
	 ***
	  	***	  	***
	 B. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	***
	 4. ***
	  		  	***
	 5. ***
	  	***	  	
	 6. ***
	  		  	***
	 C. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 58 

					
	 ***
	  	 ***
	  	 ***

	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 ***
	  	***	  	
	 ***
	  	***	  	
	 8. ***
	  	***	  	
	 D. ***
	  		  	
	 1. ***
	  	***	  	***
	 2. ***
	  	***	  	***
	 3. ***
	  	***	  	***
	 4. ***
	  	***	  	***
	 5. ***
	  	***	  	
	 6. ***
	  		  	***
	 E. ***
	  		  	
	 1. ***
	  		  	***
	 2. ***
	  		  	***
	 3. ***
	  		  	***
	 4. ***
	  	***	  	***
	 5. ***
	  	***	  	***
	 6. ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 59 

					
	 ***
	  	 ***
	  	 ***

	 7. ***
	  		  	***
	 8. ***
	  		  	***
	 9. ***
	  	***	  	***
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	
	 12. ***
	  	***	  	***
	 13. ***
	  	***	  	
	 14. ***
	  		  	***
	 15. ***
	  	***	  	***
	 16. ***
	  	***	  	***
	 17. ***
	  	***	  	***
	 F. ***
	  		  	
	 1. ***
	  		  	
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 ***
	  	***	  	***
	 2. ***
	  		  	
	 ***
	  		  	***
	 ***
	  		  	***
	 3. ***
	  		  	
	 ***
	  	***	  	
	 ***
	  	***	  	

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 60 

					
	 ***
	  	 ***
	  	 ***

	 ***
	  	***	  	
	 ***
	  	***	  	
	 G. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  		  	***
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 H. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	***
	 5. ***
	  		  	***
	 6. ***
	  		  	***
	 7. ***
	  	***	  	
	 8. ***
	  		  	***
	 9. ***
	  	***	  	
	 10. ***
	  		  	***
	 11. ***
	  		  	***
	 12. ***
	  		  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 61 

					
	 ***
	  	 ***
	  	 ***

	 13. ***
	  		  	***
	 14. ***
	  		  	***
	 I. ***
	  		  	
	 1. ***
	  	***	  	***
	 2. ***
	  		  	***
	 3. ***
	  	***	  	***
	 J. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  		  	***
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 8. ***
	  	***	  	
	 9. ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	
	 12. ***
	  		  	***
	 13. ***
	  	***	  	***
	 14. ***
	  	***	  	
	 15. ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 62 

					
	 ***
	  	 ***
	  	 ***

	 16. ***
	  		  	***
	 17. ***
	  		  	***
	 K. ***
	  		  	
	 1. ***
	  		  	***
	 2. ***
	  		  	***
	 3. ***
	  		  	***
	 4. ***
	  		  	***
	 5. ***
	  		  	***
	 6. ***
	  	***	  	
	 7. ***
	  		  	***
	 ***
	  		  	***
	 8. ***
	  		  	***
	 9. ***
	  		  	***
	 10. ***
	  	***	  	***
	 11. ***
	  		  	***
	 12. ***
	  		  	***
	 L. ***
	  		  	
	 1. ***
	  	***	  	***
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	***
	 4. ***
	  		  	***
	 5. ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 63 

					
	 ***
	  	 ***
	  	 ***

	 6. ***
	  		  	***
	 M. ***
	  		  	
	 1. ***
	  		  	***
	 2. ***
	  		  	***
	 3. ***
	  	***	  	
	 N. ***
	  		  	
	 1. ***
	  		  	***
	 2. ***
	  		  	***
	 3. ***
	  		  	***
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 8. ***
	  		  	***
	 O. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 64 

					
	 ***
	  	 ***
	  	 ***

	 8.   ***
	  	***	  	
	 9.   ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	***
	 12. ***
	  	***	  	
	 13. ***
	  	***	  	
	 ***
	  	***	  	
	 ***
	  	***	  	
	 14. ***
	  	***	  	
	 15. ***
	  	***	  	
	 16. ***
	  	***	  	
	 17. ***
	  	***	  	
	 18. ***
	  	***	  	
	 19. ***
	  	***	  	
	 20. ***
	  	***	  	
	 21. ***
	  	***	  	
	 22. ***
	  	***	  	
	 23. ***
	  	***	  	***
	 24. ***
	  	***	  	
	 25. ***
	  	***	  	
	 26. ***
	  	***	  	

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 65 

					
	 ***
	  	 ***
	  	 ***

	 27. ***
	  	***	  	
	 28. ***
	  	***	  	
	 29. ***
	  	***	  	
	 30. ***
	  	***	  	
	 P. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 8. ***
	  	***	  	
	 9. ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	
	 12. ***
	  	***	  	
	 13. ***
	  	***	  	
	 Q. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 66 

					
	 ***
	  	 ***
	  	 ***

	 4. ***
	  	***	  	
	 ***
	  	***	  	
	 5. ***
	  	***	  	
	 R. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	***
	 6. ***
	  	***	  	***
	 7. ***
	  	***	  	
	 8. ***
	  	***	  	
	 9. ***
	  	***	  	
	 ***
	  	***	  	
	 ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	
	 12. ***
	  	***	  	
	 13. ***
	  	***	  	
	 14. ***
	  	***	  	
	 15. ***
	  	***	  	
	 16. ***
	  	***	  	

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 67 

					
	 ***
	  	 ***
	  	 ***

	 ***
	  	***	  	
	 17. ***
	  	***	  	
	 18. ***
	  	***	  	
	 19. ***
	  	***	  	
	 20. ***
	  	***	  	***
	 21. ***
	  	***	  	
	 22. ***
	  	***	  	
	 a. ***
	  		  	***
	 S. ***
	  		  	
	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 8. ***
	  	***	  	***
	 9. ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	
	 12. ***
	  	***	  	
	 T. ***
	  		  	

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 68 

					
	 ***
	  	 ***
	  	 ***

	 1. ***
	  	***	  	
	 2. ***
	  	***	  	
	 3. ***
	  	***	  	
	 4. ***
	  	***	  	
	 5. ***
	  	***	  	
	 6. ***
	  	***	  	
	 7. ***
	  	***	  	
	 8. ***
	  	***	  	
	 9. ***
	  	***	  	
	 10. ***
	  	***	  	
	 11. ***
	  	***	  	

 A total of twenty pages were omitted. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 69 

 Exhibit D 

Phase II Clinical Development Plan 
 ****** 
  

			
	***	  	 •   ***

		
	***	  	***
	***	  	***
	***	  	 •   ***

		
	***	  	***
	***	  	 •   ***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 70 

 Exhibit E 

Upstream Agreements 

*** 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 71 

 Exhibit F 

Joint Steering Committee 

MacroGenics: 
  

	 	1)	*** 

  

	 	2)	*** 

  

	 	3)	***  

 Green Cross: 

 

	 	1)	*** 

  

	 	2)	*** 

  

	 	3)	*** 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 72 

 Exhibit G 

SAFETY DATA EXCHANGE AGREEMENT COMPONENTS 
 *** 
 *** 
 A total of five pages were omitted. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 73 

 Exhibit H 

Product Royalty Rates 
  

			
	 ***
	 	 ***

	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 74 

			
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***
	***	 	***

 *** 

*** 
 *** 

*** 
 A total of two
pages were omitted. 

  
 *** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

  
 75EX-10.20

 Exhibit 10.20 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 Triple asterisks denote omissions. 
 EXECUTION COPY 

121752/BR/BCN 
 OPTION FOR A LICENSE AGREEMENT 
 BY AND BETWEEN 

MACROGENICS, INC. 
 AND 
 LES LABORATOIRES SERVIER 

AND 

INSTITUT DE RECHERCHES SERVIER 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1 DEFINITIONS
	  	 	1	  
		
	 ARTICLE 2 GOVERNANCE 
	  	 	15	  
			
	 2.1        
	 	Alliance Business-Development Managers.	  	 	15	  
			
	 2.2
	 	Alliance R&D Managers.	  	 	15	  
			
	 2.3
	 	Project Directors.	  	 	16	  
			
	 2.4
	 	Joint Executive Committee.	  	 	16	  
			
	 2.5
	 	Joint Steering Committee.	  	 	16	  
			
	 2.6
	 	Joint Research and Development Committee and Subcommittees.	  	 	17	  
			
	 2.7
	 	Co-Chairpersons.	  	 	18	  
			
	 2.8
	 	Committee Meetings. Frequency.	  	 	18	  
			
	 2.9
	 	Decisions.	  	 	19	  
			
	 2.10
	 	Authority.	  	 	20	  
			
	 2.11
	 	Representatives.	  	 	20	  
		
	 ARTICLE 3 RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION 
	  	 	20	  
			
	 3.1
	 	Research Overview.	  	 	20	  
			
	 3.2
	 	Conduct of the Research Programs.	  	 	20	  
			
	 3.3
	 	Evaluation of Option Trigger Data Package; Option Exercise.	  	 	21	  
		
	 ARTICLE 4 GRANT OF RIGHTS; EXCLUSIVITY 
	  	 	22	  
			
	 4.1
	 	License Grant to Servier.	  	 	22	  
			
	 4.2
	 	License Grant to MacroGenics.	  	 	23	  
			
	 4.3
	 	Sublicenses.	  	 	23	  
			
	 4.4
	 	Subcontracting.	  	 	24	  
			
	 4.5
	 	MacroGenics Third Party Agreements.	  	 	24	  

  
 *** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted 
 version of this
exhibit has been filed separately with the Commission. 

  

							
	 4.6        
	 	Rights Retained by the Parties.	  	 	24	  
			
	 4.7
	 	Section 365(n) of the Bankruptcy Code.	  	 	25	  
			
	 4.8
	 	Exclusivity.	  	 	25	  
			
	 4.9
	 	Consequences of Development and Commercialization of Competing Products.	  	 	25	  
			
	 4.10
	 	Right of First Negotiation for Independent Product.	  	 	26	  
			
	 4.11
	 	Diagnostics.	  	 	26	  
		
	 ARTICLE 5 DEVELOPMENT DURING THE LICENSE TERM
	  	 	26	  
			
	 5.1
	 	Overview.	  	 	26	  
			
	 5.2
	 	Servier Obligations.	  	 	27	  
			
	 5.3
	 	Development Activities.	  	 	27	  
			
	 5.4
	 	Updating and Amending Development Plan and Development Budget; Additional Development Activities.	  	 	28	  
			
	 5.5
	 	Development Activities.	  	 	31	  
			
	 5.6
	 	Exchange of Data.	  	 	33	  
		
	 ARTICLE 6 REGULATORY MATTERS
	  	 	34	  
			
	 6.1
	 	Servier Regulatory Responsibility.	  	 	34	  
			
	 6.2
	 	MacroGenics Regulatory Responsibility.	  	 	35	  
			
	 6.3
	 	Communications with Regulatory Authorities.	  	 	35	  
			
	 6.4
	 	Product Withdrawals and Recalls.	  	 	37	  
			
	 6.5
	 	Pharmacovigilance; Safety Data Reporting.	  	 	37	  
			
	 6.6
	 	Safety Data Reporting.	  	 	37	  
		
	 ARTICLE 7 MANUFACTURING 
	  	 	38	  
			
	 7.1
	 	Transfer of MacroGenics Manufacturing Know-How.	  	 	38	  
			
	 7.2
	 	Supply Agreements.	  	 	39	  

  
 - ii -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

							
	 ARTICLE 8 COMMERCIALIZATION
	  	 	39	  
			
	 8.1        
	 	Overview.	  	 	39	  
			
	 8.2
	 	Sales and Distribution.	  	 	40	  
			
	 8.3
	 	Ex-Territory Sales.	  	 	40	  
			
	 8.4
	 	Commercialization Plan for Licensed Territory.	  	 	40	  
			
	 8.5
	 	Trademarks.	  	 	40	  
			
	 8.6
	 	Commercial Diligence.	  	 	41	  
			
	 8.7
	 	Standards of Conduct.	  	 	41	  
		
	 ARTICLE 9 PAYMENTS
	  	 	41	  
			
	 9.1
	 	Option Grant Fee.	  	 	41	  
			
	 9.2
	 	License Grant Fees.	  	 	41	  
			
	 9.3
	 	Development and Regulatory Milestones.	  	 	41	  
			
	 9.4
	 	Sales Milestones.	  	 	44	  
			
	 9.5
	 	Royalties.	  	 	44	  
			
	 9.6
	 	Reports; Payments.	  	 	45	  
			
	 9.7
	 	Methods of Payments.	  	 	45	  
			
	 9.8
	 	Late Payments.	  	 	45	  
			
	 9.9
	 	Taxes.	  	 	45	  
			
	 9.10
	 	Books and Records; Audit Rights.	  	 	46	  
		
	 ARTICLE 10 OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS
	  	 	46	  
			
	 10.1
	 	Inventorship.	  	 	46	  
			
	 10.2
	 	Ownership.	  	 	46	  
			
	 10.3
	 	Prosecution and Maintenance of Patents.	  	 	47	  
			
	 10.4
	 	Third Party Infringement.	  	 	49	  

  
 - iii -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

							
	 10.5
	 	Patent Invalidity Claim.	  	 	51	  
			
	 10.6        
	 	Patent Term Extensions.	  	 	51	  
			
	 10.7
	 	Patent Marking.	  	 	51	  
		
	 ARTICLE 11 CONFIDENTIALITY 
	  	 	52	  
			
	 11.1
	 	Confidentiality; Exceptions.	  	 	52	  
			
	 11.2
	 	Authorized Disclosure.	  	 	52	  
			
	 11.3
	 	Press Release; Disclosure of Agreement.	  	 	53	  
			
	 11.4
	 	Existing Confidentiality Agreement.	  	 	53	  
			
	 11.5
	 	Remedies.	  	 	53	  
			
	 11.6
	 	Publications.	  	 	54	  
			
	 11.7
	 	Return of Confidential Information.	  	 	54	  
		
	 ARTICLE 12 REPRESENTATIONS AND WARRANTIES 
	  	 	55	  
			
	 12.1
	 	Representations and Warranties of Both Parties.	  	 	55	  
			
	 12.2
	 	Representations and Warranties of MacroGenics and its Affiliates.	  	 	55	  
			
	 12.3
	 	Representation and Warranty of LLS.	  	 	57	  
			
	 12.4
	 	Mutual Covenants.	  	 	57	  
			
	 12.5
	 	Disclaimer.	  	 	57	  
		
	 ARTICLE 13 INDEMNIFICATION 
	  	 	58	  
			
	 13.1
	 	Indemnification by Servier.	  	 	58	  
			
	 13.2
	 	Indemnification by MacroGenics.	  	 	58	  
			
	 13.3
	 	Procedure.	  	 	58	  
			
	 13.4
	 	Allocation.	  	 	59	  
			
	 13.5
	 	EXCLUSION OF CONSEQUENTIAL DAMAGES.	  	 	59	  

  
 - iv -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

							
	 ARTICLE 14 TERM AND TERMINATION 
	  	 	60	  
			
	 14.1        
	 	Agreement Term; Expiration.	  	 	60	  
			
	 14.2
	 	Termination for Cause.	  	 	60	  
			
	 14.3
	 	Termination for Patent Challenge.	  	 	60	  
			
	 14.4
	 	Termination for Convenience.	  	 	61	  
			
	 14.5
	 	Termination for Insolvency Event.	  	 	61	  
			
	 14.6
	 	Termination by Servier for Safety or Public Health Reasons.	  	 	61	  
			
	 14.7
	 	Effect of Expiration or Termination.	  	 	61	  
			
	 14.8
	 	Accrued Rights; Surviving Provisions of the Agreement.	  	 	63	  
		
	 ARTICLE 15 STANDSTILL 
	  	 	64	  
			
	 15.1
	 	Standstill.	  	 	64	  
		
	 ARTICLE 16 MISCELLANEOUS 
	  	 	64	  
			
	 16.1
	 	Disputes.	  	 	64	  
			
	 16.2
	 	Arbitration.	  	 	65	  
			
	 16.3
	 	Governing Law.	  	 	66	  
			
	 16.4
	 	Assignment.	  	 	66	  
			
	 16.5
	 	Force Majeure.	  	 	67	  
			
	 16.6
	 	Notices.	  	 	67	  
			
	 16.7
	 	Export Clause.	  	 	68	  
			
	 16.8
	 	Waiver.	  	 	68	  
			
	 16.9
	 	Severability.	  	 	68	  
			
	 16.10
	 	Entire Agreement.	  	 	68	  
			
	 16.11
	 	Independent Contractors.	  	 	69	  
			
	 16.12
	 	Headings; Construction; Interpretation.	  	 	69	  

  
 - v -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

							
	 16.13        
	 	Further Actions.	  	 	69	  
			
	 16.14
	 	Parties in Interest.	  	 	69	  
			
	 16.15
	 	Performance by Affiliates.	  	 	69	  
			
	 16.16
	 	Counterparts.	  	 	69	  

  
 - vi -

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 OPTION FOR A LICENSE AGREEMENT 

This Option for a License Agreement (this “Agreement”) is entered into and made effective as of the
19th day of September, 2012 (the “Effective
Date”), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 9640 Medical Center Drive Rockville, MD 20850, USA
(“MacroGenics”), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLS”) and Institut de Recherches Servier,
a company organized and existing under the laws of France, having a principal office located at 3 rue de la République - 92150 Suresnes - France (“IdRS”) and LLS and IdRS hereinafter collectively referred to as
“Servier”). MacroGenics and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties.” 
 RECITALS 
 WHEREAS, Servier possesses expertise in the Research,
Development, Manufacturing and Commercialization (each as defined below) of pharmaceutical products; 
 WHEREAS,
MacroGenics controls certain intellectual property related to DARTs generally, certain DARTS targeting CD123, certain DARTS targeting ***, and certain DARTS targeting gpA33;  

WHEREAS, Servier is interested in receiving an exclusive option to obtain a future license under which it may further research, develop
and commercialize such DARTs in the Servier Territory (as defined below), and MacroGenics is willing to grant Servier such an option to obtain a future license on the terms and conditions set forth in this Agreement; and 

WHEREAS the Parties are willing to set forth the terms and conditions of an option grant and an exclusive license to enable Servier to
research, develop and commercialize the above mentioned DARTs as further defined hereafter, upon exercise of the exclusive option by Servier. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following terms will have the
meanings set forth in this ARTICLE 1 unless context dictates otherwise: 
 1.1 *** 

  
 1 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.2 “Accounting Standards” means, with respect to a Person, generally
accepted accounting principles as practiced in the United States or, to the extent applicable, IFRS (International Financial Reporting Standards). 
 1.3 “Affiliate” means, as to a Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with said
first Person, regardless of whether such Affiliate is an Affiliate on the Effective Date or becomes an Affiliate after the Effective Date. A Person shall be deemed to “control” another Person if it (a) owns, directly or indirectly,
beneficially or legally, more than fifty percent (50%) of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or
has other comparable ownership interest with respect to any Person other than a corporation; or (b) has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the Person.

 1.4 “Agreement Term” means the period commencing on the Effective Date and ending on the expiration of this
Agreement in accordance with the provisions of Section 14.1. 
 1.5 “Annual Net Sales” means aggregate Net
Sales of Licensed Products by Servier or its Affiliates or Sublicensees in any Calendar Year, or in the first year and last year of the Royalty Term, the portion of such Calendar Year during which the Royalty Term is in effect. 

1.6 “BLA” means a Biologics License Application and any amendments or supplements thereto filed with the FDA pursuant to
21 C.F.R. Part 601 or any other application required for the purpose of marketing and selling a biological product filed with a Regulatory Authority outside the United States, including with respect to the EU a Product License Application, Marketing
Authorization Application and/or manufacturing and importation license. 
 1.7 “Business Day” means a day on
which banking institutions in Washington, DC, USA and Paris, France are open for business, excluding any Saturday or Sunday. 

1.8 “Calendar Quarter” means a period of three (3) consecutive months ending on the last day of March, June,
September, or December, respectively. 
 1.9 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31. 
 1.10 *** 

1.11 “CD123” means the Target referred to as CD123, IL3RA or interleukin 3 receptor, alpha (low affinity) that is
defined by Entrez Gene ID 3563. 
 1.12 “Commercialization” or “Commercialize” means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product (including establishing the price for such product). 

  
 2 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.13 “Commercially Reasonable Efforts” means with respect to a Party, such
efforts that are consistent with the efforts and resources normally used by *** relating to the Research, Development and Commercialization of products (a) that have scientific attributes similar to those of the relevant Program DART or
Licensed Product in oncology, (b) that are at a similar stage in their Research, Development, Commercialization or product life as the relevant Program DART or Licensed Product, and (c) that have commercial and market potential similar to
the relevant Program DART or Licensed Product, taking into account issues of intellectual property scope, subject matter and coverage, safety and efficacy, product profile, competitiveness with respect to Third Party products in the marketplace,
proprietary position and profitability (including pricing and reimbursement status achieved or likely to be achieved), and (d) solely owned by them or to which they have exclusive rights. If either Party grants a sublicense to an Affiliate or
Third Party as permitted under this Agreement, then, with respect to such sublicensee Commercially Reasonable Efforts shall mean the efforts and resources (as defined above in this Section 1.13) normally used by the Party granting the
sublicense, qualified by the items in clauses (a) – (d) inclusive. 
 1.14 “Competing Product”
means any product that *** binds a Program Target, is specifically ***, and achieves its intended ***. 
 1.15
“Complete” or “Completing” means, for a clinical trial, the date upon which all patients have completed protocol-defined drug administration and study database lock has occurred. 

1.16 “Control,” “Controls,” “Controlled” or “Controlling” means, with
respect to any item of or right under an intellectual property right, the possession (whether by ownership or license, other than pursuant to this Agreement) of the ability of a Party to grant access to, or a license or sublicense of, such items or
right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense;
provided that any intellectual property right that is licensed or acquired by a Party after the Effective Date *** and that would otherwise be considered to be under the Control of such Party shall not be deemed to be under the
Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party
in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third Party. 
 1.17 “Cover”, “Covering” or “Covered” means, with respect to a product, technology, process or method that, in the absence of ownership of or a license
granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued,
would infringe such Valid Claim if it were to issue). 

  
 3 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.18 “DART” means a dual affinity re-targeting molecule , including but not
limited to those described in Exhibit A, with one arm that binds principally to a Target expressed on an immune effector cell (e.g., a T-cell) and with the second arm that binds principally to a different Target expressed on a cancer cell.

 1.19 “Develop” or “Development” means drug development activities relating to the
development of compounds, products, or processes, and submission of information to a Regulatory Authority for the purpose of obtaining Regulatory Approval of a product. Development includes non-clinical activities, pharmacology studies, toxicology
studies, formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like), pharmacokinetic studies, clinical
studies, biomarker and companion diagnostic discovery and development, regulatory affairs activities, and all other activities relating to seeking, obtaining or maintaining any Regulatory Approvals from the FDA or any other applicable Regulatory
Authority. 
 1.20 “Development Costs” means the costs and expenses incurred by a Party or its Affiliates,
attributable to, or reasonably allocable to, the Development of a Program DART or Licensed Product and that are consistent, if applicable, with the applicable Development Budget and do not exceed the relevant amount set forth in such Development
Budget by more than *** unless approved in writing by the JRDC and such other costs as are expressly approved in writing by the JRDC as “Development costs”. “Development Costs” shall include (a) Out-of-Pocket Costs
and (b) FTE Costs of internal personnel that are attributable or reasonably allocable to the Development of such Program DART or Licensed Product determined in accordance with applicable Accounting Standards of such Party. 

1.21 “Diagnostic” means any companion diagnostic for a tumor expressing a Program Target that is (a) Developed in
combination with a Program DART and/or Licensed Product; and (b) used in combination with a Licensed Product. 
 1.22
“Dollars” or “$” means the legal tender of the United States. 
 1.23 “EMA”
means the European Medicines Agency, or any successor entity thereto. 
 1.24 “EU” means the European Union, as
its membership may be altered from time to time, and any successor thereto. 
 1.25 “Excluded Data” means any
Know-How, other than Safety Data, generated by a Party in the conduct of Development activities in accordance with a Development Collaboration Proposal where the other Party has declined to participate in such Development Collaboration Proposal and
has not paid the Buy-In Amount in accordance with Section 5.4.2(b)(iv). 
 1.26 “FDA” means the U.S. Food
and Drug Administration, or any successor entity thereto. 

  
 4 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.27 “FD&C Act” means the United States Federal Food, Drug, and
Cosmetic Act, as amended. 
 1.28 “Field” means all human fields of use (including treatment and diagnosis).

 1.29 “First Commercial Sale” means the first sale of a Licensed Product by Servier, its Affiliates or its
Sublicensees for use or consumption of such Licensed Product in a country in the Servier Territory where Regulatory Approval of such Licensed Product has been obtained or otherwise permitted for sale by the Governmental Authority of such country.
Sale of a Licensed Product by Servier to an Affiliate of Servier or a Sublicensee of Servier shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of a Licensed Product. In no event shall any sales
for premarketing, testing or sampling be deemed a First Commercial Sale. 
 1.30 “FTE” means *** of work
devoted to or in support of the Development or Manufacture of Program DARTs and Licensed Product in accordance with a Global Development Plan or as required under Section 7.2, that is carried out by one or more qualified scientific or technical
employees or contract personnel of MacroGenics or its Affiliates, or Servier or its Affiliates, as measured in accordance with the relevant Party’s normal time allocation practices. 

1.31 “FTE Cost” means, for any period, the FTE Rate multiplied by the number of FTEs in such period. 

1.32 “FTE Rate” means a rate of *** per FTE per Calendar Year (pro-rated for the period beginning on the
Effective Date and ending at the end of the first Calendar Year) for personnel engaged in Development and Manufacturing activities. The FTE Rate is “fully burdened” and will cover ***. 

1.33 “Fully Burdened Manufacturing Cost” means with respect to a Program DART or Licensed Product, the aggregate of
internal and external costs of MacroGenics and its Affiliates to Manufacture such Program DART or Licensed Product, calculated as follows: (a) to the extent that MacroGenics or its Affiliates perform all or any part of the Manufacturing of such
Program DART or Licensed Product, the direct material costs *** and FTE Costs for such Manufacturing of such Program DART or Licensed Product ***, all calculated in accordance with applicable Accounting Standards as consistently
applied by MacroGenics or its Affiliates; and (b) to the extent that Manufacturing of such Program DART or Licensed Product is performed by a Third Party, the costs paid to such Third Party for such activities *** and the reasonable direct FTE
Costs incurred by MacroGenics or any of its Affiliates in managing and overseeing the Third Party relationship, determined in accordance with applicable Accounting Standards as consistently applied by MacroGenics or its Affiliates. Fully Burdened
Manufacturing Cost shall also include ***. 
 1.34 “Generic Competition” means, with respect to a given
Calendar Quarter with respect to a Licensed Product in any country, that during such Calendar Quarter, one (1) or more Third Parties sell in such country a Generic Product, such Generic Product shall be commercially

  
 5 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
available in such country and such Generic Product shall have, in the aggregate, a *** or more market share of the aggregate of Licensed Products and Generic Products (based on data provided by
IMS Health Incorporated, Fairfield, Connecticut) as measured on a ***, or if such data is not available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based market share of Generic Products in such country.

 1.35 “Generic Product” means, with respect to a particular Licensed Product commercialized by Servier in a
particular country, any product (other than Licensed Products commercialized, directly or indirectly, by Servier, its Affiliates or Sublicensees, or by any authorized distributors of Servier, its Affiliates or Sublicensees) that either (a) is a
“follow-on biologic” (FOB) or biosimilar or equivalent version to a Licensed Product, as defined by the competent Regulatory Authority, and administered in a similar dosage form as such Licensed Product or (b) for which a Third Party
has received Regulatory Approval (based upon then-current applicable Laws governing approval of biological products) whose application for approval relies to a large extent (but not exclusively) on data generated for a Licensed Product, such as
Regulatory Approval under section 505(b)(2) of the Federal Food Drug, and Cosmetic Act. 
 1.36 “Global Clinical
Trial” means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial or a Phase 3 Clinical Trial that may be applicable to obtaining Regulatory Approval of Licensed Products in both the Servier Territory and the MacroGenics Territory or relies
on patient recruitment from both the Servier Territory and the MacroGenics Territory. 
 1.37 “Good Clinical
Practices” or “GCP” means the then-current standards, practices and procedures (a) promulgated or endorsed by the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice:
Consolidated Guidance,” including related regulatory requirements imposed by the FDA; (b) set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005//28/EC of
8 April 2005; (c) ICH Guideline for Good Clinical Practice E6; (d) equivalent Laws of an applicable Regulatory Authority; and (e) all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant
or complement any of the foregoing. 
 1.38 “Good Laboratory Practices” or “GLP” means the
then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and the equivalent regulations promulgated by the equivalent Regulatory
Authority in the jurisdiction where Development activities are performed.  
 1.39 “Good Manufacturing
Practices” or “GMP” means then-current standards for the manufacture of pharmaceutical products, pursuant to (a) the FD&C Act (21 U.S.C. 321 et seq.); (b) relevant United States regulations in Title 21 of the
United States Code of Federal Regulations (including Parts 11, 210, and 211); (c) European Community Directives 2003/94 and 91/356/EC; (d) the European Community Guide to Good Manufacturing Practice for Medicinal Intermediate Products;
(e) ICH Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; (f) equivalent Laws of an applicable Regulatory Authority at the time of Manufacture; and (g) all additional Regulatory Authority documents or
regulations that replace, amend, modify, supplant or complement any of the foregoing. 

  
 6 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.40 “Governmental Authority” means any United States federal, state or
local or any non-United States government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 1.41 “gpA33” means the Target referred to as GPA33, cell surface A33 antigen, glycoprotein A33 (transmembrane), or A33 that is identified by Entrez Gene ID 10223. 

1.42 “ICH” means the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use. 
 1.43 “IND” means an Investigational New Drug Application filed with FDA or a
similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA). 
 1.44 “Independent Product” means one or more products, other than a Competing Product, that *** binds one of the Program Targets and ***. 

1.45 “Indication” means a discrete clinically recognized form of a disease or *** any. For the avoidance of doubt, a
cancerous disease, such as any of the Cancer Types, shall each be deemed to constitute a separate clinically recognized form of a disease, provided that ***. 
 1.46 “Initial Phase 1 Clinical Trial” means ***. 
 1.47
“Insolvency Event” means, with respect to any Party, the occurrence of any of the following: (a) such Party shall commence a voluntary case concerning itself under any bankruptcy, liquidation or insolvency code; (b) an
involuntary case is commenced against such Party and the petition is not dismissed, bonded or stayed within ninety (90) days after commencement of the case; (c) a court-supervised custodian is appointed for, or takes charge of, all or
substantially all of the property of such Party to continue undischarged or unstayed for a period of ninety (90) days; (d) any order of relief or other order approving any such case or proceeding is entered; (e) such Party is
adjudicated insolvent or bankrupt; and (f) such Party makes a general assignment for the benefit of creditors. 
 1.48
“Joint IP” means all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered jointly by one or more employees, consultants or agents of MacroGenics or its Affiliates, together with
one or more employees, consultants or agents of Servier or its Affiliates in the course of the Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Product. 

  
 7 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.49 “Know-How” means all tangible and intangible (a) information,
techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and non-clinical and clinical test data and results,
and Research or Development data, reports and batch records), analytical and quality control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release, stability, storage and shelf-life
data, Manufacturing process information, results and descriptions, and software and algorithms and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material. 

1.50 “Law” or “Laws” means all laws, statutes, rules, regulations, orders, judgments, or ordinances
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 
 1.51 “Licensed Product” means any therapeutic or prophylactic product that comprises or incorporates a Program DART as an active pharmaceutical ingredient alone or in combination with one
or more other active agents. 
 1.52 “Licensed Program” means a Program for which (a) Servier exercised
its Option in accordance with Section 3.3.3 and (b) MacroGenics has received the applicable License Grant Fee. 
 1.53
“License Term” means, with respect to a Licensed Program, each period commencing upon the License Grant Date for such Licensed Program and ending on the date of expiration or termination of this Agreement with respect to such
Licensed Program in accordance with the provisions of ARTICLE 14. 
 1.54 *** 

1.55 “MacroGenics Indemnitees” means MacroGenics, its Affiliates and the directors, officers and employees of
MacroGenics and its Affiliates. 
 1.56 “MacroGenics IP” means the MacroGenics Know-How and the MacroGenics
Patents. 
 1.57 “MacroGenics Know-How” means Know-How that is (a) Controlled by MacroGenics or its
Affiliates on the Effective Date or thereafter during the Agreement Term; (b)(i) an improvement, modification, enhancement or novel use of a Program DART or Licensed Product or Diagnostic, or any improvement, modification or enhancement in the
Manufacturing process or formulation of a Program DART or Licensed Product or Diagnostic by or on behalf of MacroGenics or its Affiliates; or (ii) disclosed by or on behalf of MacroGenics or its Affiliates to Servier or its Affiliates pursuant
to this Agreement; and (c) necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product or Diagnostic in the Field in the Servier Territory. MacroGenics Know-How excludes MacroGenics’ interest
in the Joint IP. 

  
 8 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.58 “MacroGenics Patents” means Patents Controlled by MacroGenics or its
Affiliates on the Effective Date or thereafter during the Agreement Term that claim or are directed to MacroGenics Know-How. The MacroGenics Patents existing as of the Effective Date are set forth on Exhibit B. MacroGenics Patents excludes
MacroGenics’ interest in the Joint IP. 
 1.59 “MacroGenics Territory” means the United States, Canada,
Mexico, India, Japan, Korea and any Terminated Territory. 
 1.60 “MacroGenics Third Party Agreements” means
(a) the agreement set forth on Exhibit C(1), and (b) any other agreement ( including those listed in Exhibit C( 2) and C(3)) pursuant to which MacroGenics licenses or acquires Patents or Know-How that relates to the Program DARTs or
Licensed Products in the Field in the Servier Territory after the Effective Date pursuant to an agreement with a Third Party, the terms and conditions of which have been approved (not to be unreasonably withheld) by Servier before its execution by
MacroGenics and which Servier and MacroGenics agree shall be deemed a MacroGenics Third Party Agreement, in which case Exhibit C shall be amended accordingly. For purposes of clarity, in the event that Servier does not approve the terms and
conditions of any such proposed agreement with a Third Party, nothing herein shall be deemed to preclude MacroGenics from entering into such agreement with a Third Party; provided that such agreement with a Third Party shall not be deemed a
MacroGenics Third Party Agreement hereunder. 
 1.61 “Manufacture” or “Manufacturing” means
all activities related to the manufacturing of a DART or product, including *** related to all of the foregoing. 
 1.62
“Manufacturing Process Development Costs” means the costs and expenses incurred by a Party or its Affiliates attributable to, or reasonably allocable to, the development of a Manufacturing process for Program DARTs or Licensed
Products (including ***). “Manufacturing Process Development Costs” shall include (a) Out-of-Pocket Costs and (b) FTE Costs of internal personnel that are attributable or reasonably allocable to the development of a
Manufacturing process for Program DARTs or Licensed Products determined in accordance with applicable Accounting Standards of such Party. 
 1.63 “Net Sales” means, in the case of sales by or for the benefit of Servier, its Affiliates, and its Sublicensees (the “Seller”) to independent, unrelated persons
(“Buyers”) in bona fide arm’s length transactions (except as provided below with respect to clinical trial samples), the gross amount billed or invoiced by Seller with respect to the Licensed Product during the Royalty Term,
less the following deductions, in each case to the extent actually allowed and taken by such Buyers and not otherwise recovered by or reimbursed to Seller in connection with such Licensed Product (“Permitted Deductions”):

 (a) *** 
 (b) *** 
 (c) *** 

  
 9 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (d) *** 
 (e) *** 
 (f) *** 

(g) *** 
 (h)
*** 
 “Net Sales” shall not include any consideration received with respect to a sale, use or other disposition of any Licensed
Product in a country as part of a clinical trial necessary to obtain Regulatory Approval in such country. All of the foregoing elements of Net Sales calculations shall be determined in accordance with IFRS or successor standards and guidelines
thereto. In the case of transfers of Licensed Product between any of Servier, its Sublicensees, and Affiliates of any of the foregoing, for subsequent sale, rental, lease or other transfer of such Licensed Products to Third Parties, Net Sales shall
be the gross invoice or contract price charged to the Third Party customer for that Licensed Product, less the deductions set forth in clauses *** above. 
 1.64 “Option Trigger Data Package” means a written report (including an electronic report) containing specified information and data for the indicated Research Program as follows, such
list may be modified by the Parties subject to the Parties mutual written agreement: 
 (a) with respect to the CD123 Program:
each of the following ***; and 
 (b) with respect to each of the A33 Program ***. 

1.65 “Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses paid or payable by
either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Product. 
 1.66 “Patent” means (a) all patents and patent applications in any country or supranational jurisdiction, and (b) any substitutions, divisionals, continuations,
continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications. 

1.67 “Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust,
association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. 

1.68 “Phase 1 Clinical Trial” means a human clinical trial that is intended to initially evaluate the safety and/or
pharmacological effect of a product or that would otherwise satisfy the requirements of 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country other than the United States. 

  
 10 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.69 “Phase 2 Clinical Trial” means a human clinical trial for which the
primary endpoints include a determination of dose ranges or an indication of efficacy of a product in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country other than the United States.

 1.70 “Phase 3 Clinical Trial” means a human clinical trial that is prospectively designed to demonstrate
statistically whether a product is safe and effective for use in humans in the indication being investigated in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as
described in 21 C.F.R. §312.21(c), or an equivalent clinical trial in a country other than the United States. 
 1.71
“PMDA” means the Japanese Pharmaceuticals and Medical Devices Agency or any successor agency thereto. 
 1.72
“Program” means a scientific and/or Development program undertaken by MacroGenics to generate and Develop DARTs that bind to a Program Target. 
 1.73 “Program DART” means any naked DART (i.e. without any drug or radioactive material attached to them) for which one arm principally binds to a Program Target, including the DARTs
listed in Exhibit A, ***. 
 1.74 “Program Target” means one or more of the following Targets: (i) CD123,
(ii) *** or (iii) gpA33 
 1.75 “Qualified Transaction” means a transaction MacroGenics
desires to enter into with one or more Third Party(ies) with respect to one or more Independent Products, which transaction (a) ***; and (b) ***. 
 1.76 “Regulatory Approval” means the approval, license or authorization of the applicable Regulatory Authority necessary for Development and/or Commercialization of a Program DART and/or
a Licensed Product for a particular Indication. 
 1.77 “Regulatory Authority” means the FDA in the United
States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for allowing development of Program DARTs and/or granting Regulatory Approval for a Licensed Product in such country, including
the EMA, and any successor(s) thereto. 
 1.78 “Regulatory-Based Exclusivity Period” means, with respect to a
Licensed Product, that period of time during which Servier or any of its Affiliates or Sublicensees has been granted the exclusive legal right by a Regulatory Authority either to market and sell a Licensed Product in a country in the Servier
Territory or the exclusive right to the use of or reference to clinical data in relation to a Licensed Product. 
 1.79
“Regulatory Documentation” means, with respect to the Program DARTs or Licensed Products, all INDs, BLAs, and other regulatory applications submitted to any Regulatory 

  
 11 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Authority, copies of Regulatory Approvals, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. §314.420 and any non-United States
equivalents), and any other reports, records, regulatory correspondence, meeting minutes, telephone logs, and other materials relating to Regulatory Approval of the Program DARTs or Licensed Products (including any underlying safety and
effectiveness data whether or not submitted to any Regulatory Authority), or required to manufacture, distribute or sell Licensed Products including any information that relates to pharmacology, toxicology, chemistry, manufacturing and controls
data, batch records, safety and efficacy, and any safety database required to be maintained for Regulatory Authorities. 
 1.80
“Research” means the discovery, identification, research, characterization, modification, derivatization and optimization of pharmaceutical compounds. 
 1.81 “Research Plan” means a research plan developed by the Parties that sets forth the activities to be undertaken during the Option Period for a specific Program, which research plan
may be amended from time to time by the JRDC. 
 1.82 “Research Term” means for each Program the period
commencing with the Effective Date ***. 
 1.83 “Right of Reference or Use” means a “Right of
Reference or Use” as that term is defined in 21 C.F.R. §314.3(b), and any non-United States equivalents. 
 1.84
“Safety Data” means adverse event information and other information (if any) required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws. 

1.85 “Servier Collaboration IP” means the Servier Collaboration Know-How and the Servier Collaboration Patents.

 1.86 “Servier Collaboration Know-How” means Know-How that is (a) Controlled by Servier or its
Affiliates on the Effective Date or thereafter during the Agreement Term; (b) (i) an improvement, modification, enhancement or novel use of a Program DART or Licensed Product or Diagnostic, or any improvement, modification or enhancement
in the Manufacturing process or formulation of a Program DART or Licensed Product or Diagnostic by or on behalf of Servier or its Affiliates; or (ii) disclosed by or on behalf of Servier or its Affiliates to MacroGenics or its Affiliates
pursuant to this Agreement; and (c) necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product or Diagnostic in the Field. Servier Collaboration Know-How excludes Servier’s interest in the
Joint IP. 
 1.87 “Servier Collaboration Patent(s)” means Patents Controlled by Servier and its Affiliates on
the Effective Date or thereafter during the Agreement Term claiming or directed to Servier Collaboration Know-How. 

  
 12 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.88 “Servier Indemnitees” means Servier, its Affiliates and the directors,
officers and employees of Servier and its Affiliates. 
 1.89 “Servier Territory” means the entire world
excluding the MacroGenics Territory. 
 1.90 “SFDA” means the Chinese State Food and Drug Administration or any
successor agency thereto. 
 1.91 “Significant Patent” means any *** 

1.92 “Sublicensee” means a Third Party to whom a Party, as permitted under this Agreement, grants a license or
sublicense, as the case may be, under the MacroGenics IP or Servier IP to Research, Develop, Manufacture, Commercialize or use Program DARTs and/or Licensed Products in the Field or otherwise grants rights to distribute, promote or sell Licensed
Products in the Field. For clarification purpose, a Party’s subcontractor shall not be deemed a Sublicensee, but shall be subject to the provisions of Section 4.4. 
 1.93 “Target” means (a) *** 
 1.94 “Terminated
Licensed Program” means with respect to a termination of this Agreement pursuant to ARTICLE 14, as applicable, (i) the Licensed Programs subject to such termination; and (ii) with respect to termination of this Agreement in its
entirety, all Licensed Programs. 
 1.95 “Terminated Option” means with respect to a termination of this
Agreement pursuant to ARTICLE 14, as applicable, (a) the Options subject to such termination; and (b) with respect to termination of this Agreement in its entirety, all Options. 

1.96 “Terminated Territory” means with respect to a termination of this Agreement pursuant to ARTICLE 14, as applicable,
(a) the country(ies) subject to such termination; and (b) with respect to termination of this Agreement in its entirety, the Servier Territory. 
 1.97 “Third Party” means any Person other than MacroGenics or Servier that is not an Affiliate of MacroGenics or of Servier. 

1.98 “United States” or “U.S.” means the United States of America and all of its territories and
possessions. 
 1.99 “Valid Claim” means (a) a claim of an issued patent that has not expired or been
abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time
period) or (b) ***. 

  
 13 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 1.100 Additional Definitions. Each of the following definitions is set forth in the
section of this Agreement indicated below: 
  

			
	 Definition:
	  	Section:
	 Alliance Business-Development Manager
	  	2.1
	 Alliance R&D Manager
	  	2.2
	 Arbitration Request
	  	16.2.1
	 Audited Party
	  	9.10
	 Auditing Party
	  	9.10
	 Bankruptcy Code
	  	4.7
	 Breaching Party
	  	14.2
	 Buy-In Amount
	  	5.4.2(b)(iv)
	 Buy-In Party
	  	5.4.2(b)(ii)
	 Clinical Supply Agreement
	  	7.2.1
	 Co-Chairperson
	  	2.7
	 Commercial Supply Agreement
	  	7.2.2
	 Commercialization Plan
	  	8.4
	 Commercializing Party
	  	8.1
	 Confidential Information
	  	11.1
	 De Minimis Overage Amount
	  	5.5.2(a)
	 Development Budget
	  	5.3.1
	 Development Collaboration Proposal
	  	5.4.2(b)
	 Disclosing Party
	  	11.1
	 Excess Overage Amount
	  	5.5.2(a)
	 Effective Date
	  	Preamble
	 Existing Confidentiality Agreement
	  	11.4
	 Global Development Plan
	  	5.3.1
	 ***
	  	16.2.3
	 IdRS
	  	Preamble
	 ***
	  	9.3.1
	 Indemnified Party
	  	13.3
	 Indemnifying Party
	  	13.3
	 Initial Development Budget
	  	5.5.2
	 Initiating Party
	  	10.4.3
	 Inspected Party
	  	6.3.2
	 JEC
	  	2.4.1
	 Joint Patents
	  	10.3.3(a)
	 JRDC
	  	2.6.1
	 JSC
	  	2.5.1
	 License Grant Date
	  	3.3.3(a)
	 License Grant Fee
	  	9.2
	 LLS
	  	Preamble
	 Losses
	  	13.1
	 M&A Event
	  	16.4
	 MacroGenics
	  	Preamble

  
 14 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

			
	 Definition:
	  	Section:
	 MacroGenics Product Patents
	  	10.3.1(a)
	 Non-Arbitrable Dispute
	  	16.1.2
	 Non-Breaching Party
	  	14.2
	 Option
	  	3.3.3(a)
	 Option Grant Fee
	  	9.1
	 Option Period
	  	3.3.3(a)
	 Party or Parties
	  	Preamble
	 Project Director
	  	2.3
	 Proposed Development

Plan Amendment
	  	5.4.2(a)
	 Receiving Party
	  	11.1
	 Reconciliation Payment
	  	5.5.2(c)
	 Research Program
	  	3.1
	 Responsible Party
	  	10.3.3(b)
	 Royalty Term
	  	9.5.2
	 SDEA Agreement
	  	6.5.1
	 Servier
	  	Preamble
	 Servier Product Patents
	  	10.3.2(a)
	 Supplemental Data
	  	3.2.1

 ARTICLE 2 
 GOVERNANCE 
 2.1 Alliance Business-Development Managers. Within
thirty (30) days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its business development alliance manager for each Program under this Agreement
(“Alliance Business-Development Manager”). The Alliance Business-Development Managers shall be there to coordinate any business related activities under this Agreement. Each Alliance Business-Development Manager shall attend all JSC
meetings and may bring any matter in relation to business regarding such Program to the attention of any committee if such Alliance Business-Development Manager reasonably believes that such matter warrants such attention. Each Party may replace an
Alliance Business-Development Manager which it appointed upon written notice to the other Party. 
 2.2 Alliance R&D
Managers. Within thirty (30) days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its alliance research and development manager for each Program under this
Agreement (“Alliance R&D Manager”). With regard to Research and Development activities, the Alliance R&D Managers shall serve as the primary contact points for their designated Programs between the Parties and shall be
primarily responsible for facilitating the flow of information, interaction and 

  
 15 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
collaboration between the Parties and shall be responsible for ensuring that the governance procedures and rules set forth herein are complied with. Each Alliance R&D Manager shall attend the
meetings of the JRDC and the JSC and may bring any matter in relation to such Program to the Research and Development management to the attention of any committee, if such Alliance R&D Manager reasonably believes that such matter warrants such
attention. Each Party may replace an Alliance R&D Manager it appointed upon written notice to the other Party. 
 2.3
Project Directors. Within thirty (30) days following the Effective Date each Party shall appoint (and notify the other Party of the identity of a representative to act as its project director for the Programs (“Project
Director”). The Project Director shall be responsible for the follow-up of the respective Research and Development activities under this Agreement for his/her designated Program on a regular basis. The Project Director shall attend the
meetings of the JRDC, and may bring any matter in relation to the project management to the attention of the JSC, if such Project Director reasonably believes that such matter warrants such attention. Each Party may replace its Project Director upon
written notice to the other Party. 
 2.4 Joint Executive Committee. 

2.4.1 Composition. Promptly after the Effective Date, the Parties shall establish a joint executive committee (the
“JEC”). The JEC shall be comprised of up to three (3) senior executives from each Party. Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JEC meetings by its
representatives. 
 2.4.2 Function and Powers of the JEC. The JEC shall manage the overall collaboration between the
Parties, resource allocation and major changes to the collaboration requiring amendments to this Agreement and shall resolve disagreements that may arise at the JSC. 
 2.5 Joint Steering Committee. 
 2.5.1 Composition. Promptly after
the Effective Date, the Parties shall establish a joint steering committee (a “JSC”). The JSC shall be comprised of three (3) named representatives of Servier and three (3) named representatives of MacroGenics (or such
other number as the Parties may agree) as well as each Party’s Alliance Business-Development Manager and Alliance R&D Manager. As soon as practicable after the Effective Date (but in no event more than thirty (30) days after the
Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other
Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JSC meetings by its
representatives. The JSC shall be co-chaired by a representative from each Party. 

  
 16 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 2.5.2 Function and Powers of the JSC. The JSC’s responsibilities shall be
limited to matters regarding the Programs: (a) coordinating the activities of the Parties, including facilitating communications between the Parties with respect to the Development, Manufacture and Commercialization of Program DARTS and
Licensed Products; (b) providing a forum for discussion of the Development, Manufacture, and Commercialization of Licensed Products; (c) reviewing and approving each Research Plan and Global Development Plan and associated Development
Budget and any annual or interim updates and proposed amendments thereto; (d) reviewing and discussing Servier’s Commercialization Plan and related activities with respect to Licensed Products throughout the Servier Territory and (if
applicable) the MacroGenics Territory, including pre-launch and go-to-market strategies; (e) directing and overseeing the JRDC and any operating subcommittee established by the JSC, on all significant issues that fall within the purview of such
committees; (f) attempting to resolve issues presented to it by, and disputes within, the other committees, including the JRDC and any of its subcommittees, in accordance with Section 2.9; and (g) considering and acting upon such
other matters as specified in this Agreement. 
 2.5.3 Subcommittees. The JSC may establish and disband such
subcommittees as deemed necessary by the JSC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its
representatives on written notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality
set forth in ARTICLE 11. Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC for its designated Program. 

2.6 Joint Research and Development Committee and Subcommittees.  

2.6.1 Composition. Promptly after the Effective Date, the Parties shall establish a joint research and development committee (the
“JRDC”). The JRDC shall be comprised of three (3) named representatives of Servier and three (3) named representatives of MacroGenics (or such other number as the Parties may agree) as well as each Party’s Project
Director. As soon as practicable after the Effective Date (but in no event more than thirty (30) days after the Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JRDC. Each Party
may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing
familiarity with the Research and Development activities hereunder. Either Party may, from time to time, invite additional representatives or consultants to attend JRDC meetings, subject to such representative’s and consultant’s written
agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JRDC meetings by its representatives. The JRDC shall be co-chaired by a
representative from each Party. 

  
 17 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 2.6.2 Function and Powers of the JRDC. The JRDC’s responsibilities shall be
limited to matters regarding the Programs and Licensed Programs and shall include the following activities for each Program or Licensed Program, as applicable: (a) during the Research Term, proposing the Research Plan for such Program,
proposing any changes or amendments to the Research Plan for approval by the JSC; (b) during the Research Term, reviewing and monitoring progress for all activities performed under the Research Plan and provide regular updates on the status of
the Option Trigger Data Package; (c) during the License Term, proposing the initial Global Development Plan, coordinating the activities of the Parties under and overseeing the implementation of the Global Development Plan; (d) during the
License Term, preparing annual and interim updates to the Global Development Plans; (e) during the Agreement Term, serving as a forum for and facilitating communications between the Parties with respect to the Research and Development of
Licensed Products, including any joint Development activities to be pursued by the Parties during the License Term; (f) during the License Term, monitoring and coordinating all regulatory actions, communications and submissions for Licensed
Products; (g) informal resolution of disagreements that may arise in the relation to the Parties activities under the Research Program and the Global Development Plan; and (h) considering and acting upon such other matters as specified in
this Agreement. 
 2.7 Co-Chairpersons. Each Party shall designate one of its members of the JSC and JRDC, respectively,
as a co-chairperson (each, a “Co-Chairperson”) of such committee. The Co-Chairpersons shall have the following roles and responsibilities: (a) to call meetings of the relevant committee, send notice of each such meeting and
designate the time, date and place of each such meeting; (b) to convene or poll the members of the relevant committee by other permitted means; (c) to establish a reasonably detailed agenda, including identification of relevant supporting
information and materials to be discussed during such meeting, for each meeting of the relevant committee, subject to the right of any member of such committee to add additional agenda items at any meeting; and (d) to promptly draft and
finalize minutes of each meeting of such committee, for review and approval by members of such committee at the following meeting. Each Co-Chairperson shall sign and date the final minutes. 

2.8 Committee Meetings. Frequency. The JRDC and each of the subcommittees shall each hold at least one (1) meeting per
Calendar Quarter at such times during such Calendar Quarter as the co-chairpersons elect to do so and the JSC and JEC shall hold at least one (1) meeting per Calendar Year as the co-chairpersons elect to do so. 

2.8.1 Quorum; Location. Except where a Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or
fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittee, respectively, shall be effective only if at least one (1) representative of each Party is present or participating. The
JEC, JSC, JRDC and subcommittee may meet either (a) in person at either Party’s facilities or at such locations as the Parties may otherwise agree or (b) by audio or video 

  
 18 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
teleconference; provided that no less than one (1) meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittee may also
be held with the consent of each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in
connection with participating in all such meetings. 
 2.8.2 Cooperation. Each Party shall provide the JSC and JRDC such
information as required under each Research Plan or Global Development Plan, as applicable, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under, as applicable,
each such Research Plan or Global Development Plan. 
 2.9 Decisions. 

2.9.1 Initial Dispute Resolution Procedures. Subject to the provisions of this Section 2.9, actions to be taken by the JEC,
JSC, JRDC and subcommittees shall be taken only following a *** ***. If the JRDC or any subcommittee *** on a matter before it for decision for a period in excess of ***, the matter shall be referred to the JSC. If the
JSC fails to reach unanimous agreement on a matter before it for decision for a period in excess of ***, the matter shall be referred to the JEC. 
 2.9.2 Conduct of Development during the Option Period. Notwithstanding any other provision in this Agreement, unless otherwise agreed upon to the contrary by the Parties, ***. MacroGenics shall
reasonably consult with Servier regarding the conduct of preclinical and clinical studies and shall reasonably consider any input provided by Servier with respect thereto. For clarification purposes MacroGenics shall not have the ability to alter
the the specified information and data required for the Option Trigger Data Package set forth in Section 1.63. 
 2.9.3
Final Decision-Making. If the JEC fails to reach *** on a matter before it for decision for a period in excess of ***, during the License Term for a Licensed Program, *** *** any matter involving the Development or
Commercialization of Program DARTs and Licensed Products in the Field in the Servier Territory for such Licensed Program and the JEC representatives appointed by MacroGenics shall have the deciding vote on any matter involving the Development or
Commercialization of Program DARTs and Licensed Products in the Field in the MacroGenics Territory for such Licensed Program. 

2.9.4 Exceptions. Notwithstanding the foregoing, neither Party shall exercise its right to finally resolve a dispute pursuant to
Section 2.9.3: 
 (a) in a manner that excuses such Party from any of its obligations specifically enumerated under this
Agreement; 
 (b) in a manner that negates any consent rights or other rights specifically allocated to the other Party under
this Agreement; 

  
 19 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (c) during the License Term, to increase Development Costs for the other Party for any
Global Clinical Trial for a given Calendar Year by more than *** above the Initial Development Budget for such Global Clinical Trial; 
 (d) to resolve any dispute regarding whether a Party may conduct Development or Commercialization activities in the other Party’s territory; 

(e) to resolve any dispute regarding whether a milestone event set forth in Section 9.3 has been achieved; or 

(f) in a manner that would require the other Party to perform any act that it reasonably believes to be inconsistent with any Law or any
approval, order, policy or guidelines of a Regulatory Authority. 
 2.10 Authority. The JEC, JSC, JRDC and any
subcommittee shall have only the powers assigned expressly to it in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall
retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JEC, JSC, JRDC or subcommittee unless such delegation or vesting of rights is expressly provided
for in this Agreement or the Parties expressly so agree in writing. 
 2.11 Representatives. For purposes of clarity, a
Party may appoint the same person to simultaneously serve as the Alliance Business Development Manager, Alliance R&D Manager, and/or Project Director for a Program or multiple Programs for such Party and/or serve on multiple committees
established pursuant to this ARTICLE 2. 
 ARTICLE 3 

RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION 
 3.1 Research Overview. Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Servier shall conduct the research activities indicated in each Research Plan during
each Research Term for each Program (each a “Research Program”). The primary objective of each Research Program is to generate, create and/or obtain the data and documentation necessary to complete the Option Trigger Data Package
for such Program. Neither Party warrants that any Research Program shall achieve any of the research objectives contemplated in its Research Plan. At the end of the applicable Research Term, each Party’s obligation to conduct such Research
Program shall cease unless the Parties mutually agree to extend its Research Term. 
 3.2 Conduct of the Research
Programs. 
 3.2.1 Research Plan. *** after the Effective Date, the JRDC will prepare a Research Plan for each
Program to be submitted for approval by JSC. The Parties may mutually agree to specify in a Research Plan activities to be conducted by Servier to generate additional 

  
 20 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
pre-clinical and clinical data to be shared by both Parties (the “Supplemental Data”). Servier shall disclose to MacroGenics all Supplemental Data for a Research Program within
*** after the completion of such activities and MacroGenics shall have the right to use such Supplemental Data in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products. For the *** and the gpA33 DART
Program, ***. Neither the availability and finalization of such Supplemental Data nor any modification to the Initial Phase 1 Clinical Trial that the Parties may agree upon shall in any way delay the timing of the delivery of the Option
Trigger Data Package to Servier in accordance with Section 3.3.2. To the extent that any provision of a Research Plan conflicts or is inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control.

 3.2.2 Diligence. MacroGenics and Servier shall use Commercially Reasonable Efforts to conduct each Research Program in
a good scientific manner and in accordance with the applicable Research Plan. 
 3.2.3 Expenses. Except as otherwise set
forth elsewhere in this Agreement, each Party shall bear its own costs and expenses of conducting the activities allocated to such Party under each Research Plan, including the costs of clinical supply of Program DARTs and Licensed Products. 

 3.2.4 Reports. MacroGenics and Servier shall provide written progress reports on the status of its Research and
Development activities under each Research Plan, including summaries of data generated in the applicable Research Program, at least *** in advance of each JRDC meeting. 
 3.3 Evaluation of Option Trigger Data Package; Option Exercise.  
 3.3.1
Limited Evaluation License; Supply. MacroGenics hereby grants Servier an exclusive, royalty and other fee-free license, with the right to sublicense only to Servier’s Affiliates, under MacroGenics IP, to (a) conduct the activities,
if any, allocated to Servier under each Research Plan and (b) use the Option Trigger Data Package for each Research Program solely for purposes of evaluating Program DARTs to determine whether to exercise its Option for the Program that is
subject to such Option. 
 3.3.2 Delivery of Option Trigger Data Package. MacroGenics shall provide Servier with each
Option Trigger Data Package ***. 
 3.3.3 Option Exercise. 

(a) For each Program, Servier shall have an exclusive option to obtain an exclusive license under MacroGenics IP to Research, Develop and
Commercialize Program DARTs and Licensed Products from such Program in the Field in the Servier Territory (each an “Option”). Servier may exercise each such Option by providing MacroGenics written notice within *** after the
receipt of the Option Trigger Data Package for the corresponding Program (each an “Option Period”). In the event Servier elects to exercise an Option, it shall, no later than 

  
 21 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
the end of the last day of the Option Period for such Option, deliver to MacroGenics (i) written notice specifying that Servier has elected to exercise the Option, and (ii) payment of
the corresponding License Grant Fee. Provided Servier has properly exercised the Option in accordance with the preceding sentence, the later of the date of the written notice and receipt by MacroGenics of the License Grant Fee shall be the
“License Grant Date” of the resulting Licensed Program. The Research Term and Option Period will be deemed to have ended for such Program, and the License Term of such Licensed Program will be deemed to have commenced, on such
License Grant Date. 
 (b) Upon the exercise by Servier of an Option in accordance with this Section 3.3, the provisions
set forth in Sections 4.1, 4.2 and 4.3 of this Agreement shall constitute the terms and conditions of the license and sublicense rights granted by MacroGenics to Servier with respect to Licensed Products and the MacroGenics IP from the Licensed
Program that was licensed under such Option in the Field in the Servier Territory, and by Servier to MacroGenics with respect to Servier IP and Licensed Products from such Licensed Program in the Field in the MacroGenics Territory. During each
period commencing on the Effective Date and ending on the expiration of an Option Exercise Period, MacroGenics will not grant a license or other rights to any Third Party or take any other action that would prevent MacroGenics from being able to
grant to Servier the license set forth in Section 4.1 for the Program that is subject to such Option. In the event Servier does not exercise the Option for a Program during the applicable Option Exercise Period, with regard to such Program
Servier (i) Servier’s Option shall expire and all right and interest with respect to the Program DARTs, Licensed Products and MacroGenics IP for such Program shall revert to MacroGenics; (ii) Servier shall have no right to or interest
in such Program DARTs and Licensed Products; (iii) the license granted to Servier under Section 3.3.1 shall terminate; (iv) the licenses and other rights granted under ARTICLE 4 shall have no force or effect; (v) Servier shall
and hereby does assign and transfer to MacroGenics all right, title and interest in and to the Supplemental Data; (vi) *** 

ARTICLE 4 

GRANT OF RIGHTS; EXCLUSIVITY 
 4.1 License Grant to Servier. Subject to the terms of this Agreement, upon MacroGenics’ receipt of a License Grant Fee with respect to a Licensed Program, MacroGenics shall and hereby does
grant Servier (a) an exclusive, royalty-bearing, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics IP
and MacroGenics’ and its Affiliates’ interests in Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs and Licensed Products from such Licensed Program in and for the Servier Territory in the Field; (b) an
exclusive, royalty-bearing, non-transferable (except in accordance 

  
 22 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics IP and MacroGenics’ and its Affiliates’ interests in Joint IP, to
Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from such Licensed Program in the Field in and for the Servier Territory; and (c) a non-exclusive, royalty-bearing, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under MacroGenics IP and MacroGenics’ and its Affiliates’ interests in
Joint IP and Servier Collaboration IP, to Research, Develop and Manufacture Program DARTs and Licensed Products from such Licensed Program in the MacroGenics Territory for the sole purpose of using, offering for sale and selling such Licensed
Products in, and importing such Program DARTs and such Licensed Products into, the Servier Territory in the Field; provided however, that Servier shall not, directly or indirectly, conduct clinical trials or other clinical studies,
including any investigator initiated studies, in the MacroGenics Territory using Program DARTs or Licensed Products without the prior approval of the JRDC. 
 4.2 License Grant to MacroGenics. Subject to the terms of this Agreement, upon MacroGenics’ receipt of a License Grant Fee with respect to a Licensed Program, Servier hereby grants
MacroGenics: (a) an exclusive, royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under Servier Collaboration
IP and Servier’s and its Affiliates’ interest in Joint IP, to Research, Develop, Manufacture and Commercialize Program DARTs and Licensed Products from such Licensed Program in the Field in and for the MacroGenics Territory; (b) an
exclusive, royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under Servier Collaboration IP and Servier’s
and its Affiliates’ interest in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from such Licensed Program in the Field in and for the MacroGenics Territory; and
(c) a non-exclusive, royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense (subject to Section 4.3), under Servier Collaboration IP and
Servier’s and its Affiliates’ interest in Joint IP, to Research, Develop and Manufacture Program DARTs and Licensed Products under the corresponding Licensed Program in the Servier Territory for the sole purpose of using, offering for sale
and selling Licensed Products in, and importing Program DARTs and Licensed Products from the corresponding Licensed Program into, the MacroGenics Territory in the Field; provided however, that MacroGenics shall not, directly or
indirectly, conduct clinical trials or other clinical studies, including any investigator initiated studies, in the Servier Territory using Program DARTs or Licensed Products without the prior approval of the JRDC. 

4.3 Sublicenses. Each Party shall have the right to grant sublicenses within the scope of the licenses under Section 4.1 or
4.2, as applicable, solely to its Affiliates and to Third Parties that are conducting Research, Development, Manufacture and/or Commercialization activities with such Party or its Affiliates with respect to Program DARTs and Licensed Products;
provided that any sublicense granted to Third Party collaborators under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement, including
the confidentiality provisions of ARTICLE 11. If either Party grants a sublicense to a Third Party as permitted by this Section 4.3, then such Party shall provide the other Party prompt written notice thereof and shall provide the other Party
with an executed copy of any such sublicense (redacted as necessary to protect confidential or commercially sensitive information). Except as otherwise agreed by the Parties in writing, each Party shall be jointly and severally responsible with its
sublicensees to the other Party for failure by its sublicensees to comply with this Agreement. 

  
 23 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 4.4 Subcontracting. Subject to the terms of this Agreement, each Party shall have the
right to engage Affiliates, licensees, Sublicensees or Third Party subcontractors to perform activities ascribed to such Party, under this Agreement. Any Affiliate, licensee or subcontractor to be engaged by a Party to perform a Party’s
obligations under this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity; provided that any Party engaging an Affiliate, licensee
or subcontractor hereunder shall remain principally responsible and obligated for such activities. In addition, each Party engaging a licensee, Sublicensee or subcontractor shall obtain Control of any and all Know-How, Patents or other intellectual
property rights created, discovered, invented, conceived or reduced to practice by such licensee, Sublicensee or subcontractor with respect to any Program DART or Licensed Product so that the other Party is not impeded from carrying out its rights
and responsibilities under this Agreement by such Know-How, Patents or other intellectual property rights. To the extent a Party cannot obtain assignment of, or an exclusive license to, all Know-How, Patents and other intellectual property rights
created, discovered, invented, conceived or reduced to practice by any licensee, Sublicensee or subcontractor engaged by such Party with respect to any Program DART or Licensed Product or in the performance of activities under this Agreement at the
time such Party initially enters into such arrangement with such licensee, Sublicensee or subcontractor, such Party shall bring such matter to the JSC for the prior approval of such arrangement and for the express approval by the JRDC of the
licensing terms and conditions with respect to such arrangement. 
 4.5 MacroGenics Third Party Agreements. Servier
acknowledges and agrees that the rights, licenses and sublicenses granted by MacroGenics to Servier under this Agreement may be or are subject to the terms of the MacroGenics Third Party Agreements. Servier covenants to comply with, and to cause its
Affiliates and Sublicensees to comply with, the MacroGenics Third Party Agreements, and to take any action or provide any information reasonably requested by MacroGenics, to prevent any potential breach of any terms of such MacroGenics Third Party
Agreements. To the extent there is a conflict between the terms of any MacroGenics Third Party Agreement and the rights granted to Servier hereunder, the terms of such MacroGenics Third Party Agreement shall control solely with respect to the
Patents and Know-How owned or controlled by such Third Party licensor. MacroGenics shall not terminate or consent to the termination of the MacroGenics Third Party Agreement without Servier’s prior reasonable consent if such termination would
materially adversely affect Servier’s license granted hereunder; however, for clarity, MacroGenics may (a) terminate any MacroGenics Third Party Agreement by acquiring all of the relevant intellectual property licensed thereunder, in which
case Servier agrees to consent to such termination of such MacroGenics Third Party Agreement; and (b) terminate its obligation to make royalty and milestone payments by making a lump-sum payment. 

4.6 Rights Retained by the Parties. Any rights of MacroGenics or Servier, as the case may be, not expressly granted to the other
Party pursuant to this Agreement shall be retained by such Party. Notwithstanding the exclusive licenses granted to Servier pursuant to Section 4.1, 

  
 24 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
MacroGenics retains the right to practice under the MacroGenics IP and Joint IP to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and any supply
agreement entered into in accordance with ARTICLE 7, including for the purpose of performing its activities in connection with clinical trials for Licensed Products and any related manufacture of Program DARTs and Licensed Products. 

4.7 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement
are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual property” as
defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under
this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for “intellectual property.”
The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to
a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in such Party’s possession, will be promptly delivered to it upon such
Party’s written request thereof. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 

4.8 Exclusivity. For the period commencing with the Effective Date and ending on the *** of the Effective Date (subject to
earlier termination pursuant to Article 14), other than with respect to the Development and Commercialization activities pursuant to this Agreement, neither Party nor its Affiliates shall, directly or indirectly, (a) initiate or conduct
clinical development for a Competing Product in each other’s respective territory; or (b) Commercialize a Competing Product in the other Party’s territory. During such ***, a Third Party that acquires all of the outstanding
shares of a Party and has a Competing Product in Development at the time of such acquisition shall have the right to (i) continue any ongoing Clinical Trials it is conducting with such Competing Product; and (ii) initiate Clinical Trials
in an Indication for which such Third Party previously conducted a Clinical Trial with the Competing Product provided that under such scenario the provisions of section 4.9. below shall apply. 

4.9 Consequences of Development and Commercialization of Competing Products. Subject to Section 4.8, in the event MacroGenics or
Servier, directly or indirectly conducts clinical Development for or Commercializes a Competing Product in the other Party’s territory, the other Party shall have the right, within *** after becoming aware of such Development or
Commercialization activities with respect to a Competing Product, to provide written notice to the Party Developing or Commercializing the Competing Product, of its election to have the following apply to the Licensed Products that bind to the same
Program Target as such Competing Product: 
 4.9.1 The Parties’ reporting and information sharing obligations *** with
respect to such Licensed Product except with respect to ***. The responsibilities of the JRDC with respect to such Licensed Product shall be limited to the ongoing exchange of information and cooperation necessary after the termination of
information sharing obligations pursuant to this Section. For purposes of clarity, nothing in this Section 4.9 shall require either Party to disclose to the other Party any information regarding its Development or Commercialization plans for such
Licensed Product which it deems to be ***. 
 4.9.2 Each Party shall continue to have the right to possess, retain and use all
clinical and non-clinical data and related Regulatory Documentation Controlled by either Party and provided to it prior to the termination of such information sharing obligations in order to Develop and Commercialize Licensed Products in the Field
in such Party’s territory in accordance with the terms of this Agreement. 
 4.9.3 If MacroGenics directly or indirectly
Commercializes a Competing Product in *** for the same *** as is being Commercialized by Servier, its Affiliates or Sublicensees for a Licensed Product, Servier shall *** that would otherwise be due to MacroGenics resulting from the Development and
Commercialization of such Licensed Product for the same Cancer Type as such Competing Product, in such country. 
 4.9.4 If
Servier directly or indirectly Commercializes a Competing Product in *** for the same *** as is being Commercialized by MacroGenics, its Affiliates or Sublicensees for a Licensed Product, the royalty and milestone payment obligations under Sections
9.3, 9.4 and 9.5 shall be *** resulting from the Development and Commercialization of such Licensed Product for the same Cancer Type as such Competing Product, in such country. 

  
 25 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 4.10 Right of First Negotiation for Independent Product. If at any time during the
Agreement Term MacroGenics or its Affiliates desires to enter into a Qualified Transaction, MacroGenics shall notify Servier of such intent and propose to Servier to enter into negotiations with respect to the subject matter of such Qualified
Transaction, identifying the applicable Independent Product(s) that is(are) proposed to be the subject of such Qualified Transaction. Servier shall have *** from receipt of such written notice to notify MacroGenics in writing as to whether
Servier desires to negotiate for such rights, and if Servier so notifies MacroGenics that it does desire to negotiate for such rights, Servier and MacroGenics shall have *** from the date of such notification to negotiate and enter into a
definitive agreement for such rights; provided that, if either Servier does not provide such written notice within such *** period or Servier and MacroGenics do not enter into a definitive agreement within such *** period, MacroGenics
shall be free to enter into negotiations and agreements with Third Parties relating to such Qualified Transaction, provided however that if, within *** after such negotiations with Servier terminate, MacroGenics should *** of such terms, and
Servier shall have a period of *** following receipt of the same to notify MacroGenics as to whether Servier would be prepared to accept such terms (subject to execution of a mutually acceptable license agreement) in which case the Parties
will use commercially reasonable efforts to conclude such license agreement within *** after Servier notifies MacroGenics of the same. If the Parties cannot conclude such license agreement or such ***, the Parties agree that,
MacroGenics shall be free to enter into negotiations and agreements with Third Party(ies) relating to such Qualified Transaction during the remainder of the Agreement Term without further obligation to Servier. 

4.11 Diagnostics. The Parties acknowledge and agree that each Party shall have the right to use Diagnostics in combination with
Competing Products Researched, Developed or Commercialized by such Party. 
 ARTICLE 5 

DEVELOPMENT DURING THE LICENSE TERM 
 5.1 Overview. During each License Term, (a) Servier will, subject to the terms of this Agreement, be responsible for the Development of Licensed Products from the corresponding Licensed
Program in the Field for the Servier Territory, and (b) MacroGenics will remain responsible for Development of Licensed Products from the same Licensed Program in the Field in the MacroGenics Territory. While the Parties may choose, at their
sole discretion, to work together on particular projects, except as otherwise provided in this Agreement, the Parties will operate independently in their activities for their respective Development of Licensed Products, but will provide access to
certain information to the JRDC and to each other as expressly described in this Agreement. 

  
 26 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 5.2 Servier Obligations. Servier shall use Commercially Reasonable Efforts to Develop
Licensed Products from each Licensed Program in the Servier Territory. Servier shall be deemed to not have used Commercially Reasonable Efforts to Develop Licensed Products from a Licensed Program in the Servier Territory, and MacroGenics shall have
the right to terminate this Agreement in accordance with Section 14.2, if at any point in time prior to the First Commercial Sale of a Licensed Product under such Licensed Program, Servier fails to undertake Development activities, with the
intention of rapidly advancing a Licensed Product under such Licensed Program toward registration (and not for the sole purpose of preserving rights hereunder) during at least the preceding ***. 

5.3 Development Activities.  
 5.3.1 Global Development Plan. During the License Term for each Licensed Program, the Development of Licensed Products under this Agreement under such Licensed Program shall be conducted pursuant
to a reasonably comprehensive written research and development plan (each, a “Global Development Plan”), which shall include a detailed budget for all Development Costs and Manufacturing Process Development Costs (each, a
“Development Budget”), and which shall include the resource allocations for the Parties based upon the general principle that the allocation shall endeavor to take advantage of the respective resources, capabilities and expertise of
MacroGenics and Servier, respectively. Within *** after the License Grant Date, the JRDC shall prepare an initial draft of the Global Development Plan for approval by the JSC for such Licensed Program. Each Global Development Plan also shall
set forth the specific activities (including non-clinical and clinical studies to be conducted by each Party) and the estimated timeline for Development of Licensed Products licensed under such Licensed Program in order to obtain the data that the
Parties intend will be useful, by both Parties, to obtain Regulatory Approvals of the Licensed Products in both the United States, and the EU. Servier shall be the sponsor of all clinical studies conducted in the Servier Territory and shall be
solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the Servier Territory, and MacroGenics shall be the sponsor of all clinical studies conducted in the MacroGenics Territory and shall be
solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the MacroGenics Territory. The JRDC shall discuss which Party(ies) shall be the sponsor of all clinical studies conducted in countries of
both the MacroGenics Territory and the Servier Territory under such Licensed Program. 
 5.3.2 Details in Global Development
Plan. Without limiting Section 5.3.1, each Global Development Plan shall set forth, among other things, the following activities to be undertaken jointly or coordinated by Servier and MacroGenics: 

(a) any non-clinical studies, toxicology studies, pharmaco-economic studies, process development studies and other clinical studies,
whether pre- or post-approval and whether sponsored or merely supported by Servier or MacroGenics, in each case, together with all protocols, endpoints and investigators conducting such studies, with respect to Licensed Products in the Servier
Territory and MacroGenics Territory; 

  
 27 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (b) regulatory plans and other elements of obtaining and maintaining Regulatory Approvals in
the Field in each country in the Servier Territory and MacroGenics Territory; 
 (c) the timeline for completing such
Development activities; and 
 (d) the plans and timeline for preparing the necessary Regulatory Documentation and for obtaining
Regulatory Approval in the Field in the Servier Territory and MacroGenics Territory. 
 5.4 Updating and Amending Development
Plan and Development Budget; Additional Development Activities.  
 5.4.1 Development Plan Reviews and Updates. On or
before January 1st of each Calendar Year during the License Term, the JRDC shall review, update and approve each Global Development Plan (including the Development Budget contained therein) which shall cover the Development activities and
Manufacturing process development activities to be conducted with respect to the Development of Licensed Products subject to such Global Development Plan for use in the Field during the upcoming Calendar Year, and the JRDC shall, on at least a
quarterly basis, review and update, as appropriate, each then-current Global Development Plan (including the Development Budget) to reflect any changes, reprioritizations of, or additions to the Global Development Plan. 

5.4.2 Amendments to Development Plan; New Development Collaboration Proposals.  

(a) Amendments to Development Plan. From time to time during the License Term, either Party may submit to the JRDC any proposed
amendment of any Global Development Plan to amend the then-currently approved Development activities (such proposed amendment, a “Proposed Development Plan Amendment”) for the JRDC’s review and approval by the JSC. Any Proposed
Development Plan Amendment shall contain, at a minimum, information supporting the rationale for the Proposed Development Plan Amendment related to Licensed Products from a scientific, regulatory and commercial standpoint, as well as an estimated
developmental critical path, and an estimate of the cost of such Development. The JRDC shall consider any submitted Proposed Development Plan Amendment during its next scheduled meeting. Once approved by the JSC (or otherwise resolved pursuant to
Section 2.9), each amended Global Development Plan (including the Development Budget contained therein) shall become effective and supersede the previous Global Development Plan and Development Budget as of the date of such approval or at such
other time as decided by the JSC. 
 (b) New Development Collaboration Proposals. If either Party proposes to conduct new
Development activities in connection with the Development of a Licensed Product not included in the then approved Global Development Plan of the Licensed Program for such Licensed Product, including any proposal to collaborate to *** (such
proposal, a “Development Collaboration Proposal”), such Party shall submit the Development Collaboration Proposal to the 

  
 28 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
other Party through the JRDC. Every Development Collaboration Proposal shall include a proposal to collaborate with the other Party for such Development activities so that, subject to the terms
of this Agreement, with respect to the Development activities underlying the Development Collaboration Proposal, Servier shall be able to Develop Licensed Products for Commercialization in the Field in the Servier Territory and MacroGenics shall be
able to Develop Licensed Products for Commercialization in the Field in the MacroGenics Territory. 
 (i) In the event the
other Party approves a Development Collaboration Proposal and the Parties agree to collaborate to conduct the Development activities underlying the Development Collaboration Proposal with respect to Licensed Products, (A) the Global Development
Plan shall be amended to include such Development Collaboration Proposal and (B) each Party shall use Commercially Reasonable Efforts to perform the activities allocated to it under the approved Development Collaboration Proposal, and the
Parties shall share in the payment of Development Costs incurred in connection with such activities in accordance with Section 5.5.1(a). 
 (ii) In the event the other Party declines to participate in and share the funding of such activity (the “Buy-In Party”), the submitting Party may proceed with the activities described in
such Development Collaboration Proposal at its sole expense unless the other Party reasonably objects to the conduct of such activity as reasonably likely to result in a safety or public health issue that will have a material adverse effect in the
Development or Commercialization of Program DARTs and Licensed Product in its territory. Any disputes regarding whether an activity is reasonably likely to result in a safety or public health issue that will have a material adverse impact on the
Development and/or Commercialization of Program DARTs and Licensed Products in a Party’s territory shall be referred to the JRDC for a determination and resolved in accordance with Section 2.9; provided that neither Party shall have the
right to exercise its final decision making authority pursuant to Section 2.9.3 with respect to such issue. 
 (iii) Once
during each Calendar Quarter following the commencement of, and until the completion of, the activities described in the Development Collaboration Proposal, the Buy-In Party may request that the Party conducting such Development activity provide a
summary of the current status of such Development activity, the Development Costs incurred to date, any significant milestones achieved and any topline initial results of such Development activity. 

(iv) The Buy-In Party may obtain access to and use of the Excluded Data in accordance with the procedure described in this paragraph;
provided that the Buy-In Party shall be provided access to Safety Data, at no cost, in accordance with the SDEA Agreement. At any time following the commencement of the activities described in the Development Collaboration Proposal, the Buy-In Party
shall provide the other Party with written notice of its election to buy-in to such Development, and promptly thereafter the other Party shall provide the Buy-In Party with an invoice for *** of the cumulative Development Costs as well as the
costs of clinical supply of the Program DART and/or Licensed Product used in connection with such 

  
 29 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Development incurred by a Party in the generation of such data as of the date of the Buy-In Party’s written request (the “Buy-in Amount”), which invoice the Buy-In Party
shall pay within *** after receipt. Each Party shall thereafter share, in accordance with the allocation of costs set forth in Section 5.5.1(a), in the Development Costs incurred after the date of the Buy-In Party’s written request
in connection with such Development activities under such Development Collaboration Proposal and Global Development Plan shall be amended to include such Development activities. 

5.4.3 Unilateral Development Costs and Manufacturing Process Development Costs.  

(a) Servier Territory Exclusive Development Activities. Except as provided in Section 5.5 and for Development activities
conducted by a Party at its own expense pursuant to Section 5.4.2(b)(ii), Servier shall be responsible for *** of all Development Costs (whether incurred by Servier or MacroGenics (if the activities and their cost are agreed to in
advance in writing by Servier) or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory Approval for
Licensed Products in the Field in any country or other regulatory jurisdiction in the Servier Territory. On a Licensed Program-by-Licensed Program basis, Servier shall disclose to MacroGenics a summary of efficacy results and detailed safety
information Controlled by Servier and generated in the course of such Development activities for each Licensed Program within *** after the completion of such activities, subject to the pharmacovigilence provision under Section 6.5.
MacroGenics may obtain access to and use Servier’s data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive development activities if MacroGenics provides Servier
with written notice of its election to buy-in such Development, and promptly thereafter Servier shall provide MacroGenics with an invoice for *** of the cumulative Development Costs as well as the costs *** in connection with such
Development incurred by Servier in the generation of such data as of the date of MacroGenics written request, which invoice MacroGenics shall pay within *** after receipt. 
 (b) MacroGenics Territory Exclusive Development Activities. Except as provided in Section 5.5 and for Development activities conducted by a Party at its own expense pursuant to
Section 5.4.2(b)(ii), MacroGenics shall be responsible for *** of all Development Costs (whether incurred by Servier (if the activities and their costs are agreed to in advance in writing by MacroGenics) or MacroGenics or their
respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products in the Field in any
country or other regulatory jurisdiction in the MacroGenics Territory. On a Licensed Program-by-Licensed Program basis, MacroGenics shall disclose to Servier a summary of efficacy results and detailed safety information Controlled by Servier and
generated in the course of such Development activities for each Licensed Program within *** after the completion of such activities, subject to the pharmacovigilence provision under Section 6.5. Servier may obtain access to and use
MacroGenics’ data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive Development activities if Servier 

  
 30 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
provides MacroGenics with written notice of its election to buy-in such Development, and promptly thereafter MacroGenics shall provide Servier with an invoice for *** of the cumulative
Development Costs as well as the costs *** in connection with such Development incurred by MacroGenics in the generation of such data as of the date of Servier written request, which invoice Servier shall pay within *** after receipt. 

(c) Servier Phase 2 Clinical Trial Funding. For each Global Development Plan, Servier shall reimburse MacroGenics for up to the
first *** of Development Costs incurred by MacroGenics in conducting or participating in Phase 2 Clinical Trials for Licensed Products included in such Global Development Plan. 

(d) Manufacturing Process Development Costs. Servier and MacroGenics shall each be responsible for *** of each
Manufacturing Process Development Cost provided the activity which resulted in such cost was conducted under a Global Development Plan. 
 5.5 Development Activities.  
 5.5.1 Except for Development activities
conducted by a Party at its own expense pursuant to Section 5.4.2(b)(ii), with respect to any Development activities conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products both in the Servier
Territory and in the MacroGenics Territory (including Development activities with respect to which a Party has paid the Buy-in Amount in accordance with Section 5.4.2(b)(iv)) pursuant to the Development Plan: 

(a) subject to Section 5.5.2, Servier shall be responsible for *** and MacroGenics shall be responsible for *** of all
Development Costs as well as the costs of clinical supply of the Program DART and/or Licensed Product used in connection with such Development (in each case, whether incurred by Servier or MacroGenics or their respective Affiliates). For purposes of
clarity, MacroGenics may seek reimbursement from Servier under Section 5.4.3(c) to apply to Development Costs for which MacroGenics is responsible under this Section 5.5.1(a) to the extent such Development Costs are for Phase 2 Clinical
Trials; 
 (b) On a Licensed Program by Licensed Program basis each Party shall disclose to the other Party all clinical data
and related Regulatory Documentation Controlled by such Party and generated in the course of such Manufacturing process development activities and Development activities for each Licensed Program within ***; 

(c) each Party shall have the right to use all clinical data and related Regulatory Documentation Controlled by either Party and
generated in the course of such Manufacturing process development activities and Development activities in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products in the Field in such Party’s territory, in
accordance with the terms of this Agreement; and 
 (d) each Party hereby grants to the other Party a Right of Reference or Use
to any and all such Regulatory Documentation with respect to Licensed Products in the Field in the other Party’s territory, and agrees to sign, and cause its Affiliates to sign, any instruments reasonably requested by such other Party in order
to effect such grant. 

  
 31 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 5.5.2 Development Costs Budget and Timeline Overruns.  

(a) Budget Overruns. With respect to any Development Costs which, pursuant to this Agreement and/or a Global Development Plan or
an approved Development Collaboration Proposal, are meant to be allocated between the Parties (rather than one Party being solely responsible for such Development Costs), each Party shall promptly inform the other Party upon determining that it is
likely to exceed the budget amounts set forth in the annual Development Budget for the activities such Party is responsible for under the applicable Global Development Plan. To the extent that a Party (or its Affiliates or Sublicensees) incurs
Development Costs for the activities such Party is responsible for under a Global Development Plan for a particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the initial
Development Budget for that Global Development Plan that includes such activity (the “Initial Development Budget”) by *** or less (a “De Minimis Overage Amount”), then such De Minimis Overage Amount shall
automatically be included in such Development Budget for such year. However, to the extent that a Party (or its Affiliates or Sublicensees) incurs Development Costs for the activities such Party is responsible for under a Development Plan for a
particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the Initial Development Budget by more than ***, the “Excess Overage Amount”), the Party that has
so exceeded its budget shall provide to the JRDC a full explanation for so exceeding its budget and such Excess Overage Amount shall only be included in such Development Budget to the extent that the JRDC agrees to allow some or all of the Excess
Overage Amount to be included in such Development Budget as it considers equitable under the circumstances. To the extent that the JRDC does not agree to treat the Excess Overage Amount as Development Costs, the Party that has exceeded its budget
shall be solely responsible for the Excess Overage Amount. 
 (b) Timeline Overruns. Each Party shall promptly inform the
other Party upon determining that it is likely to miss a Development date set forth in a Global Development Plan. To the extent that a Party (or its Affiliates) misses such a date by *** or more, the Party that has experienced such
Development timeline failure shall provide to the JRDC a full explanation for such Development timeline failure. Such notification shall not serve to excuse a Party from its diligence or other obligations under this Agreement. 

(c) Reconciliation. Within *** following the end of each Calendar Quarter beginning with the License Grant Date, each Party
shall prepare and deliver to the other Party on a Licensed Program by Licensed Program basis a quarterly report detailing its Development Costs and Manufacturing Process Development Costs incurred during such period, with each Party reporting on all
Development Costs incurred with respect to Development Collaboration Proposals. Each Party shall submit any additional information reasonably requested by the other Party related to the Development Costs and Manufacturing Process Development Costs
included in its report within *** of its receipt of such request. Within *** after the receipt of the 

  
 32 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
report delivered by Servier pursuant to this Section 5.5.2(c), MacroGenics shall prepare and deliver to Servier a composite report that (i) summarizes the Development Costs and
Manufacturing Process Development Costs incurred by each Party for such Calendar Quarter; (ii) applies the percentage of such costs for which each Party is responsible for the total Development Costs and Manufacturing Process Development Costs
attributable to the Development and Manufacturing activities for such Calendar Quarter pursuant to Sections 5.4.3 and 5.5.1; and (iii) computes the amount due to MacroGenics or Servier, as applicable, for such Calendar Quarter in order for the
Parties to share the total Development Costs and Manufacturing Process Development Costs for such quarter based on the Development Plan and the principles set forth in Sections 5.4.3 and 5.5.1 (each, a “Reconciliation Payment”). The
Party to whom a Reconciliation Payment is due shall issue an invoice to the other Party for the Reconciliation Payment, and such other Party shall pay all undisputed amounts within *** after its receipt of the invoice. Each Party shall have
the right to audit the records of the other Party with respect to any Development Costs and Manufacturing Process Development Costs included in such reports, in accordance with Section 9.10. 

5.6 Exchange of Data. During the License Term, the following shall apply: 

5.6.1 Initial Exchange of Data. Promptly after each License Grant Date, MacroGenics shall transfer to Servier the MacroGenics
Know-How related to Program DARTs and Licensed Products (other than the MacroGenics Know-How related directly and solely to Manufacturing) that was licensed to Servier on such License Grant Date. Such transfer shall occur in a manner and following a
reasonable schedule to be established by the JSC. MacroGenics shall provide Servier with copies of relevant material, information, reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory
Authorities for the purpose of obtaining Regulatory Approval. 
 5.6.2 Ongoing Exchange of Data. During each License
Term, except as provided in Section 5.4.2(b)(iv) with respect to Excluded Data, each Party shall provide to the other Party (a) all Know-How Controlled by such Party that is specified in the applicable Global Development Plan to the extent
necessary or useful for the Development or Commercialization of Program DARTs or Licensed Products under such Global Development Plan in the other Party’s territory, and (b) any Know-How Controlled by such Party that is not specified in
such Global Development Plan that such Party reasonably believes to be necessary or useful for the Development or Commercialization of Program DARTs or Licensed Products that were licensed under the Licensed Program for such Global Development Plan
in the other Party’s territory, in a timely fashion and as promptly as possible for use by such other Party in accordance with this Section 5.6.2. Servier shall only use and disclose to Third Parties such MacroGenics Know-How as may be
necessary or useful for Development and Commercialization of Program DARTs and/or Licensed Products in the Servier Territory; or as may otherwise be agreed by MacroGenics and Servier. Servier may not use any MacroGenics Know-How (or permit any Third
Party to use any MacroGenics Know-How) outside the Servier Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed by MacroGenics and Servier (including as provided in Sections 4.1 and 4.2). MacroGenics
shall not use any Servier Know-How (or permit 

  
 33 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
any Third Party to use any Servier Know-How) outside the MacroGenics Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed by MacroGenics and
Servier. 
 5.6.3 Use. All preclinical, non-clinical, analytical, manufacturing, and clinical data and associated reports
disclosed by one Party to the other under this Agreement may be used by the receiving Party subject to the terms of this Agreement solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in its respective territory.
Each Party shall have the right to share any and all such data and other regulatory materials received from the other Party with its Affiliates and any Third Party sublicensees or licensees in its respective territory solely for the purpose of
Developing, Manufacturing and Commercializing Licensed Products in its respective territory. Access to and use of such data and regulatory materials are given by each Party to the other Party without cost (except as otherwise provided herein) on an
“as is” basis without any warranty of any kind. Each receiving Party accepts all risk and liability in relation to the use of the data and regulatory materials received from the other Party and shall indemnify and hold harmless the Party
providing such data and regulatory materials from any Third Party’s claim(s) based upon such data and regulatory materials as provided in ARTICLE 13. 
 5.6.4 Reports. In addition to information and reports required elsewhere in this Agreement, each Party shall provide the other Party and the JRDC with a written annual report summarizing the major
activities performed by it under each Global Development Plan during the previous year, conduct of non-clinical activities and clinical trials, information regarding the status of Regulatory Approvals. The other Party shall have the opportunity to
reasonably seek further explanation or clarification of matters covered in such reports and to provide observations and suggestions to the disclosing Party regarding the subject matter thereof, and the disclosing Party shall provide such explanation
or clarification and shall consider such observations and suggestions in good faith. Furthermore, if after receiving such a report the receiving Party wishes to meet with the disclosing Party to discuss such report, the disclosing Party shall meet
with the receiving Party at a site reasonably requested by the receiving Party within *** after the disclosing Party’s requests such meeting. 
 ARTICLE 6  
 REGULATORY MATTERS 

The provisions of this ARTICLE 6 shall apply during the License Term. 

6.1 Servier Regulatory Responsibility.  
 6.1.1 During the License Term, Servier shall own and be responsible for preparing, filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for the Development
(unless otherwise agreed by the JRDC on the basis of Section 4.2), Manufacture or Commercialization of the Program DARTs or Licensed Products in the Field in the Servier Territory and Servier shall otherwise be responsible for and have sole
authority as to all interactions with Regulatory Authorities in the Servier Territory. Servier shall comply with all applicable Laws in the Servier Territory, including local regulations and ICH guidelines. 

  
 34 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 6.1.2 Servier hereby grants to MacroGenics a Right of Reference or Use to any Regulatory
Documentation in the Servier Territory Controlled by Servier for use by MacroGenics in the MacroGenics Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by
MacroGenics in order to further effect such grant. Servier shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. Servier shall also permit MacroGenics, upon reasonable notice, during regular business hours, to
audit any such Regulatory Documentation; provided that, MacroGenics shall limit such audits by MacroGenics to a moderate frequency reasonably necessary in order for MacroGenics to perform the Development and Commercialization of the
Program DARTs and Licensed Product. 
 6.2 MacroGenics Regulatory Responsibility.  

6.2.1 MacroGenics shall own and be responsible for preparing, filing and maintaining all Regulatory Documentation and Regulatory
Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of Section 4.1), or Commercialization of Program DARTs or Licensed Products in the Field in the MacroGenics Territory and MacroGenics shall
otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the MacroGenics Territory. MacroGenics shall comply with all applicable Laws in the MacroGenics Territory, including local regulations and ICH
guidelines. 
 6.2.2 MacroGenics hereby grants to Servier a Right of Reference or Use to any Regulatory Documentation in the
MacroGenics Territory Controlled by MacroGenics for use by Servier in the Servier Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by Servier in order to
further effect such grant. MacroGenics shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. MacroGenics shall also permit Servier, upon reasonable notice, during regular business hours, to audit any such
Regulatory Documentation; provided that, Servier shall limit such audits by Servier to a moderate frequency reasonably necessary in order for Servier to perform the Development and Commercialization of the Program DARTs and Licensed
Product. 
 6.3 Communications with Regulatory Authorities.  

6.3.1 For purposes of this Article 6.3, “material” shall mean any ***. Servier shall be responsible for all submissions
to, and communications and interactions with, Regulatory Authorities in the Servier Territory with respect to Program DARTs and Licensed Products (unless otherwise agreed by the JRDC on the basis of Section 4.2), and MacroGenics shall be
responsible for submissions to, and communications and interactions with, Regulatory Authorities in the MacroGenics Territory with respect to Program DARTs and Licensed Products (unless otherwise agreed by the JRDC on the basis of Section 4.1).
In connection therewith: 
 (a) On a Licensed Program by Licensed Program basis Servier shall keep MacroGenics reasonably
informed regarding Servier’s (or its Affiliate’s or Sublicensee’s) 

  
 35 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
regulatory strategy, planned regulatory submissions and material communications with the Regulatory Authorities in the Servier Territory with respect to the Program DARTs and Licensed Products
for each Licensed Program, including any material changes to such strategy, submissions or communications. Servier shall provide MacroGenics with copies of material regulatory submissions to, and material communications with the *** relating to the
Program DARTs and Licensed Products. To the extent permitted by Regulatory Authorities, MacroGenics shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or their agents, as well as
participate in internal meetings or discussions of Servier occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to Servier’s materials prepared for such meetings. MacroGenics shall also
have the right to review and comment upon any correspondence with the *** or their agents related to such meetings. Servier shall provide MacroGenics regularly prepared minutes of material meetings with the *** regarding Program DARTs and Licensed
Products in the Field in the Servier Territory and available material teleconference reports with the *** pertaining to Program DARTs and Licensed Products in the Field in the Servier Territory. 

(b) On a Licensed Program by Licensed Program basis MacroGenics shall keep Servier reasonably informed regarding MacroGenics’ (or
its Affiliate’s or Sublicensee’s) regulatory strategy, planned regulatory submissions and material communications with the *** with respect to the Program DARTs and Licensed Products for each Licensed Program, including any material
changes to such strategy, submissions or communications. MacroGenics shall provide Servier with copies of material regulatory submissions to, and material communications with the *** relating to the Program DARTs and Licensed Products. To the extent
permitted by Regulatory Authorities, Servier shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or its agents, as well as participate in internal meetings or discussions of MacroGenics
occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to MacroGenics’ materials prepared for such meetings. Servier shall also have the right to review and comment upon any
correspondence with the *** or its agents related to such meetings. MacroGenics shall provide Servier regularly prepared minutes of material meetings with the *** regarding Licensed Products in the Field in the MacroGenics Territory and available
material teleconference reports with the *** pertaining to Licensed Products in the Field in the MacroGenics Territory. 
 6.3.2
If either Party or its Affiliates or subcontractors (each, an “Inspected Party”) are to be inspected by a Government Authority regarding the development, manufacture, registration or commercialization of a Licensed Product, the
Inspected Party shall promptly notify the other Party of the inspection in writing as soon as reasonably practicable, and in advance, if any such inspection is a scheduled inspection. The Inspected Party shall, where practicable, permit
representatives of the other Party to participate as observers with respect to such inspection, and shall provide the other Party with a written report of any such inspection, noting with specificity any records or documents reviewed by the
regulatory inspector, and including copies of any FDA 483s (or their non-U.S. equivalent) or written communications provided by or to any Government Authority relating to such inspection. The Inspected Party will use Commercially Reasonable Efforts
to provide an opportunity for the other Party to assist in responding to any issues or 

  
 36 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
concerns relating to such inspections, and shall provide copies of all communications to and from any Government Authority relating thereto to the other Party. The Parties shall cooperate in good
faith and otherwise mutually support any regulatory inspections of facilities, clinical sites, contract manufacturers or the like with respect to Licensed Products, including by using Commercially Reasonable Efforts to make available such
facilities, documents, information and/or personnel as are reasonably necessary or useful for such regulatory inspections by a Government Authority. 
 6.4 Product Withdrawals and Recalls. If any Regulatory Authority (a) threatens, initiates or advises any action to remove any Licensed Product from the market in any country of the world, or
(b) requires or advises either Party or such Party’s Affiliates or sublicensees to distribute a “Dear Doctor” letter or its equivalent regarding use of any Licensed Product in any country of the world, then Servier (if such
action is in the Servier Territory) or MacroGenics (if such action is in the MacroGenics Territory), as applicable, shall notify the other Party of such event within *** (or sooner if required by applicable Law) after such Party becomes aware
of the action, threat, advice or requirement (as applicable). The JRDC will discuss and attempt to agree upon whether to recall or withdraw such Licensed Product; provided, however, that if the Parties fail to agree within an appropriate time period
or if the matter involves a safety issue that, in order to protect patient safety, does not allow for sufficient time for a discussion at the JRDC level, Servier shall decide whether to recall or withdraw such Licensed Product in the Servier
Territory and shall undertake any such recall or withdrawal in the Servier Territory at its own cost and expense, and MacroGenics shall decide whether to recall or withdraw such Licensed Product in the MacroGenics Territory and shall undertake any
such recall or withdrawal in the MacroGenics Territory at its own cost and expense. 
 6.5 Pharmacovigilance; Safety Data
Reporting.  
 6.5.1 Pharmacovigilance. *** after each License Grant Date the Parties shall negotiate in good
faith, with respect to Licensed Products under the applicable Licensed Program, a safety data exchange agreement, governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experience, Licensed
Product quality and Licensed Product complaints, sufficient to permit each Party to comply with its legal obligations (the “SDEA Agreement”). The SDEA Agreement will be promptly updated if required by changes in legal requirements.

 6.6 Safety Data Reporting.  
 (a) Each Party shall keep the other Party informed about any adverse drug reactions such Party becomes aware or is informed about regarding the use of a Licensed Product. As between the Parties, Servier
shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in countries in the Servier Territory, and MacroGenics shall be responsible for reporting all adverse drug reactions/experiences to
the appropriate regulatory authorities in the MacroGenics Territory, in accordance with the appropriate laws and regulations of the relevant countries and authorities. Servier shall ensure that its Affiliates and Sublicensees comply with such
reporting obligations in the Servier Territory and 

  
 37 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
MacroGenics shall ensure that its Affiliates and sublicensees (other than Servier and its Sublicensees) comply with such reporting obligations in the MacroGenics Territory. These reporting
obligations shall apply to other adverse events as described in the SDEA Agreement, including adverse events occurring from product overdose or from product withdrawal, as well as any toxicity, sensitivity, failure of expected pharmacological
action, or laboratory abnormality which is, or is thought by the reporter, to be serious or associated with relevant clinical signs or symptoms. 
 (b) For each Research Program and Global Development Plan each Party will designate a pharmacovigilance liaison to be responsible for communicating with the other Party regarding the reporting of adverse
drug reactions/experiences. Each Party (the “Notifying Party”) shall notify the other Party in writing of all information coming to the Notifying Party’s attention, regardless of the origin of such information, and including
such information coming to its attention through clinical and non-clinical sources (including journal publications and other media), regarding adverse drug experiences associated with a Licensed Product, whether in the Servier Territory or in the
MacroGenics Territory. 
 ARTICLE 7 
 MANUFACTURING 
 The provisions of this ARTICLE 7 shall apply during the
License Term for each Licensed Program. 
 7.1 Transfer of MacroGenics Manufacturing Know-How.  

7.1.1 For each Licensed Program, at Servier’s request and sole expense, and on a schedule and a product comparability plan agreed
upon by the Parties, MacroGenics shall disclose (and provide copies, as applicable) to either Servier or the Third Party manufacturer that is mutually acceptable to both Parties, all MacroGenics Know-How necessary or useful to enable Servier or such
Third Party manufacturer (as appropriate) *** for such Licensed Program to Manufacture Licensed Product based on a manufacturing process ***. For clarity, nothing in this Section 7.1 with respect to MacroGenics’ obligation to
transfer MacroGenics Know-How to Servier shall limit MacroGenics’ right to use any such MacroGenics Know-How to fulfill MacroGenics’ obligations to Manufacture and supply Licensed Product to Servier under this Agreement or the Supply
Agreement. In addition, MacroGenics shall, at Servier’s sole expense, make available to Servier, on a reasonable consultation basis, advice of its technical personnel as may reasonably be requested by Servier in connection with such transfer of
MacroGenics Know-How. MacroGenics shall thereafter during the Agreement Term, continue to promptly and regularly disclose any material new MacroGenics Know-How related to Manufacturing Program DARTs and Licensed Products to Servier or to the Third
Party manufacturer mentioned above at Servier’s cost. 
 7.1.2 Servier and/or its Third Party manufacturer shall use the
MacroGenics Know-How transferred under Section 7.1.1 solely for the purpose of Manufacturing Program DARTs and finished Licensed Products in accordance with the terms and conditions of this Agreement, and for no other purpose. 

  
 38 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 7.1.3 Servier acknowledges and agrees that MacroGenics may condition any of its agreement to
transfer any MacroGenics Know-How to a Third Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and MacroGenics that contains terms substantially equivalent to those of ARTICLE 11. 

7.2 Supply Agreements.  
 7.2.1 Clinical Supply Agreement. For each Program, the Parties shall enter into good faith negotiations regarding the terms of a clinical supply agreement, pursuant to which MacroGenics shall
provide clinical supply of Program DARTs and/or Licensed Products from such Program for (a) Phase 1 Clinical Trials and the first two (2) Phase 2 Clinical Trials of Licensed Products to be conducted by Servier and its Affiliates and
Sublicensees and (b) at MacroGenics’ option, Clinical Trials of Licensed Products conducted by Servier and its Affiliates and Sublicensees *** of Licensed Products to be conducted by Servier and its Affiliates and Sublicensees (the
“Clinical Supply Agreement”). The cost for such supply of Program DARTs and/or Licensed Products for Clinical Trials shall be equal to MacroGenics’ Fully Burdened Manufacturing Cost; ***. The Fully Burdened Manufacturing
Cost for supply of Program DARTs and/or Licensed Products for clinical trials used by Servier in connection with the Development of a Program DARTs and/or Licensed Products outside a Global Development Plan shall be invoiced by MacroGenics on a
quarterly basis. 
 7.2.2 Commercial Supply Agreement. Following each License Grant Date, if requested by Servier, the
Parties shall enter into good faith negotiations regarding the terms of a quality and supply agreement, pursuant to which MacroGenics shall provide commercial supply of Program DARTs and/or Licensed Products licensed under such Licensed Program to
Servier and its Affiliates and Sublicensees (the “Commercial Supply Agreement”). 
 ARTICLE 8 

COMMERCIALIZATION 
 The provisions of this ARTICLE 8 shall apply during the License Term. 
 8.1
Overview. Servier shall have sole control and responsibility for the Commercialization of Licensed Products in the Servier Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the
Servier Territory. MacroGenics shall have sole control and responsibility for the Commercialization of Licensed Products in the MacroGenics Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in
the MacroGenics Territory. The Party with responsibility for Commercialization in a territory and field shall be referred to as the “Commercializing Party” for such territory. 

  
 39 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.2 Sales and Distribution. It is understood that as between the Parties, the
Commercializing Party shall be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and receivables for Licensed Products in the applicable territory and indication. 

8.3 Ex-Territory Sales. Subject to applicable Law, neither Party shall engage in any advertising or promotional activities
relating to Licensed Product directed primarily to customers or other buyers or users of Licensed Product located outside its territory or accept orders for Licensed Products from or sell Licensed Products into such other Party’s territory for
its own account or for the Commercializing Party’s account, and if such other Party receives any order for Licensed Products in the Commercializing Party’s territory, it shall refer such orders to the Commercializing Party for acceptance
or rejection. 
 8.4 Commercialization Plan for Licensed Territory. Servier shall pursue
Commercialization of Licensed Products in the Servier Territory, in accordance with Commercially Reasonable Efforts. Servier shall deliver an initial Commercialization plan to MacroGenics no later than *** prior to the anticipated date of the
first filing of the first BLA for a Licensed Product in the Servier Territory (the “Commercialization Plan”). After the establishment of the initial Commercialization Plan, Servier shall prepare updates and amendments to such
Commercialization Plan at least annually and deliver such updated Commercialization Plan to MacroGenics no later than March 31st of each Calendar Year. 
 8.5 Trademarks. 
 8.5.1 Generally. Servier and its Affiliates shall
select their own trademarks under which they will market Licensed Products (provided that no such trademark shall contain the word “MacroGenics”) and shall own such trademarks. MacroGenics and its Affiliates shall select
their own trademarks under which they will market Licensed Products (provided that no such trademark shall contain the word “Servier” or “Les Laboratoires Servier”) and shall own such trademarks. 

8.5.2 Acknowledgement. Servier shall use, in connection with all packaging, literature, labels and other printed matters, to the
extent required by Law, and where reasonably practicable in light of space limitations, an expression to the effect that the Licensed Products were developed under license from MacroGenics, together with the MacroGenics logo. The provisions of this
Section 8.5.2 shall not apply to primary packaging of the Licensed Products. Primary packaging shall mean packaging that is in direct contact with the Licensed Products or the Licensed Products themselves, including vials, blister packs,
tablets and capsules.  
 8.5.3 Housemarks. Neither Party shall, and shall ensure that its Affiliates and
sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto. 

  
 40 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 8.6 Commercial Diligence. During each License Term, Servier shall use Commercially
Reasonable Efforts to Commercialize Licensed Products that were licensed under the applicable Licensed Program throughout the Servier Territory. 
 8.7 Standards of Conduct. Each Party shall in all respects comply with all applicable Laws and applicable guidelines concerning the advertising, sales and marketing of prescription drug products in
Commercializing Products under this Agreement, including any applicable local anti-bribery laws. 
 ARTICLE 9  

PAYMENTS 

9.1 Option Grant Fee. In consideration for the Options as granted by MacroGenics to Servier hereunder and to review the Option
Trigger Data Packages, Servier shall pay MacroGenics a non-refundable, non-creditable payment of Twenty Million Dollars ($20,000,000) (the “Option Grant Fee”) within *** after the Effective Date and the date of receipt of the
corresponding invoice. 
 9.2 License Grant Fees. Upon exercise of an Option and *** after the date of receipt of the
corresponding invoice, Servier shall pay MacroGenics a *** payment (the “License Grant Fee”) of 
 (a) Fifteen
Million Dollars ($15,000,000) for exercise of the Option for the CD123 Program; 
 (b) *** for exercise of the Option for the
A33 Program; and 
 (c) *** for exercise of the Option for the *** Program. 

9.3 Development and Regulatory Milestones.  
 9.3.1 IND Approval/Acceptance Milestones. For each Program or Licensed Program, Servier shall pay to MacroGenics the non-refundable, non-creditable amount of Five Million Dollars ($5,000,000) upon
approval or acceptance of the first IND filed with the FDA (or corresponding Regulatory Authority in the EU) for such Program or Licensed Program (each an “IND Approval Milestone”), within *** following receipt of the
corresponding invoice. 

  
 41 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 9.3.2 License Term Development and Regulatory Milestones. During the License Term for
each Licensed Program, for each milestone set forth in this Section 9.3.2 achieved in such Licensed Program, Servier shall pay, depending on the Licensed Program, the corresponding *** amount indicated for that milestone for the first instance
of its achievement: 
  

					
	 Milestone Event
	  	Payment
For each of the ***
Licensed Program and gpA33
Licensed Program	 	Payment
For the CD123
Licensed Program
			
	 (i)       ***
	  	***	 	***
			
	 (ii)      ***
	  	***	 	***
			
	 (iii)     ***
	  	***	 	***
			
	 (iv)     ***
	  	***	 	***
			
	 (v)      ***
	  	***	 	***
			
	 (vi)     ***
	  	***	 	***
			
	 (vii)    ***
	  	***	 	***
			
	 (viii)  ***
	  	***	 	***
			
	 (ix)     ***
	  	***	 	***

 In no event shall the total of the amounts paid under this Section 9.3.2 for the *** Licensed
Program and gpA33 Licensed Program exceed ***, or exceed *** for the CD 123 Licensed Program, and exceed *** in the aggregate for all of the Licensed Programs. 
 9.3.3 Milestone Payments. Servier shall make the milestone payments required by Section 9.4.1 and 9.3.2 in accordance with Section 9.3.6. If an event described in a clause in
Section 9.3.2 occurs before or concurrently with another event described in a preceding clause in Section 9.3.2, Servier shall also pay the milestone payment described in such earlier clause when the milestone payment described in such
later clause is paid. 
 9.3.4 Follow-On Products.  

(a) Subject to the terms of this Agreement, *** 
 (b) If prior to the time at which a milestone payment pursuant to Section 9.3.4(a) is to be made with respect to a subsequent Licensed Product, the first Licensed Product has been substituted by a
subsequent Licensed Product in the same Licensed Program or development of the first Licensed Product in the same Licensed Program has been discontinued, then the achievement by such subsequent Licensed Product of a milestone event to the extent the
corresponding milestone payment under Section 9.3.2 has not been made with respect to such 

  
 42 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
substituted or discontinued first Licensed Product, shall be deemed to be achievement of the corresponding milestone event under Section 9.3.2 by the first Licensed Product entitling
MacroGenics to the corresponding milestone payment under Section 9.3.2. 
 9.3.5 Reductions in Milestones Payable for
Phase 3 Clinical Trials for the *** DART Program or gpA33 DART Program. In the event that the conduct by Servier of a Phase 1 Clinical Trial or Phase 2 Clinical Trial for Licensed Product in accordance with the applicable Research Plan
results in Servier, its Affiliates or Sublicensees conducting a Phase 3 Clinical Trial for such Licensed Product under the Global Development Plan in the same Indication as that studied in such Phase 1 Clinical Trial or Phase 2 Clinical Trial,
***. Prior to the initiation of any such Phase 3 Clinical Trial, Servier shall provide MacroGenics ***. MacroGenics shall have the right to have an independent public accountant reasonably acceptable to Servier audit
Servier’s books and records solely for purposes of verifying such Development Costs, upon reasonable advance notice and during Servier’s business hours, subject to the confidentiality provisions of ARTICLE 11. 

9.3.6 CD123 Licensed Program Deferred Milestone Payments. In the event that upon the achievement of a milestone event set forth in
Section 9.3.2(e) or (i) with respect to a Licensed Product from the CD123 Licensed Program the MacroGenics Patents do not include an issued patent in a final and non-appealable status before the European Patent Office, which MacroGenics
Patent claims the composition of matter of the Licensed Product for which such milestone event(s) were achieved, then one hundred percent (100%) of the milestone payment(s) set forth in Section 9.3.2(e) or (i), as applicable, shall not be
due until the issuance in a final and non-appealable status before the European Patent Office of a patent included in the MacroGenics Patents which specifically claims the composition of matter of such Licensed Product from the CD123 Licensed
Program. For purposes of clarity, following the issuance in the EU of a patent included in the MacroGenics Patents which claims the composition of matter of a Licensed Product from the CD123 Licensed Program as provided herein above, this
Section 9.3.6 shall cease to apply and Servier shall have no right to defer, in part or in whole, any milestone payment as provided in this Section 9.3.6. For further clarity, it is agreed by the Parties that as of the Effective Date none
of the MacroGenics Patents listed in Exhibit B Cover the composition of matter of a Licensed Product from the CD123 Program in the EU.
 9.3.7 Notification; Payment. Servier shall promptly notify MacroGenics in writing of the first achievement of each of the milestones under this Section 9.3 (other than milestones under
Section 9.3.1) and the corresponding milestone payment shall be due within *** after receipt of the corresponding invoice from MacroGenics. 

  
 43 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 9.4 Sales Milestones.  

9.4.1 Sales Milestone Payments. For each Licensed Program, Servier shall make the *** payments to MacroGenics set forth below upon
the earliest achievement of each of the corresponding milestone events by the first Licensed Product to achieve such milestone in such Licensed Program: 
  

			
	 Milestone Event
	  	Payment
		
	 (i)       ***
	  	***
		
	 (ii)      ***
	  	***
		
	 (iii)     ***
	  	***
		
	 (iv)     ***
	  	***

 9.4.2 Payment of Milestones. Servier shall make the milestone payments required by
Section 9.4.1 in accordance with Section 9.6. If an event described in a clause in Section 9.4.1 occurs before or concurrently with another event described in a preceding clause in Section 9.4.1, Servier shall also pay the
milestone payment described in such earlier clause when the milestone payment described in such later clause is paid. By way of example, if, during March 2015, ***, Servier shall pay MacroGenics the milestone payments set forth in both Sections
9.4.1(a) and (b). 
 9.5 Royalties.  
 9.5.1 Servier shall pay MacroGenics royalties on Net Sales of Licensed Products at the following rates with respect to all such Net Sales of such applicable Licensed Products achieved during the
applicable Calendar Year: 
  

			
	 Annual Net Sales Threshold
	  	Royalty Rate
		
	 (i)       ***
	  	***
		
	 (ii)      ***
	  	***
		
	 (iii)     ***
	  	***
		
	 (iv)     ***
	  	***

 9.5.2 Royalty Term. Servier’s royalty obligations to MacroGenics under this Section 9.5
shall expire on a country-by-country and Licensed Product-by-Licensed Product basis on the later of: (a) the expiration of the last Valid Claim (i) within the MacroGenics Patents and/or Joint Patents licensed to Servier under this Agreement and
Covering the composition of matter or therapeutic use of such Licensed Product in such country or (ii) within the Significant Patents licensed to Servier under this Agreement; (b) the twelfth (12th) anniversary of the date of the First Commercial
Sale by Servier or any of its Affiliates or Sublicensees of such Licensed Product in such country; and (c) the expiration of the last-to-expire applicable Regulatory-Based Exclusivity Period for such Licensed Product in such country (the
“Royalty Term”). 
 9.5.3 Third Party Royalty Offset. If, after the License Grant Date, Servier or its
sublicensee or designee: (ai) is required, as agreed by the Parties in good faith, ***, to obtain a license from any Third Party under Patents controlled by such Third Party in order to make, have made, use, sell, offer for sale or import a Program
DART and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license *** or (b) is required by any court of 

  
 44 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
competent jurisdiction, due to infringement of patent rights controlled by such Third Party in any country(ies) in the Servier Territory, *** then Servier may deduct from the milestones and/or
royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such country in a Calendar Quarter *** of the amount paid by Servier to such Third Party with respect to such Licensed Product for
such country during such Calendar Quarter; *** 
 9.5.4 Generic Competition. If at any time following the First
Commercial Sale, Generic Competition exists in any country of the Servier Territory, Servier shall deduct *** from the royalties that would otherwise be due to MacroGenics on Net Sales (based on the effective, weighted-average royalty rate)
resulting from the sales of such Licensed Product in such country during the applicable Calendar Quarter in which such Generic Competition exists. 
 9.6 Reports; Payments. Within *** after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section 9.4 or 9.5, Servier shall submit to
MacroGenics a report identifying for each Licensed Product, the Net Sales for such Licensed Product for each country in the Servier Territory for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken
from gross sales), and the royalties and the sales milestones payable to MacroGenics. Within *** of the delivery of each such report, Servier shall pay to MacroGenics all royalties and sales milestones payable by it under Sections 9.4 and 9.5.

 9.7 Methods of Payments.  
 9.7.1 All payments due under this Agreement shall be paid in Dollars *** by wire transfer to a bank in the United States designated in writing by MacroGenics. 

9.7.2 For the purposes of determining the amount of any sales milestone payment under Section 9.4 or royalties due for the relevant
Calendar Quarter under Section 9.5, the amount of Net Sales in any non-Euro currency shall be converted into Euro using the average of daily closing rates of exchange published by European Central Bank for the monthly period in which Net Sales
are accounted. 
 9.8 Late Payments. Any amount owed by Servier to MacroGenics under this Agreement that is not paid on
or before the date such payment is due shall bear interest at a rate per annum equal to the lesser of (a) ***, or (b) the highest rate permitted by applicable Law, calculated on the number of days such payments are paid after such
payments are due and compounded monthly. *** 
 9.9 Taxes. All payments due and payable under this
Agreement will be made without any deduction or withholding for on account of any tax by application of the Tax Treaty in force between France and The United States since August 31st 1994 and in accordance with its amendment signed January 13th 2009 which came into force retroactively January 1st 2009, unless such deduction or withholding tax is required by
applicable laws. If the paying Party is so required to deduct or withhold, such Party shall (a) promptly notify the other Party of such requirement, (b) 

  
 45 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
pay to the relevant authorities the full amount required to be deducted or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice
that such amount has been assessed against the other Party, and (c) promptly forward to the other Party an official receipt (or certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such
authorities. 
 9.10 Books and Records; Audit Rights. Each Party (the “Audited Party”) shall keep (and,
in the case of Servier, shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the “Auditing Party”)
to determine the payments due and costs incurred under this Agreement. Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected
by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than ***
prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a *** period preceding the date of the request for review. The
report of such accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Development Costs and the
amount of any Net Sales, milestone or royalty discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such
inspection lead to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party shall pay the amount of the discrepancy within *** after its receipt from the accounting firm of the certificate showing the amount of the
discrepancy. The Auditing Party shall pay the full cost of the review unless the underpayment of milestones, royalties and/or Development Costs, is greater than *** of the amount due for the applicable period, in which case the Audited Party shall
pay the reasonable costs charged by such accounting firm for such review. 
 ARTICLE 10  

OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS 
 10.1 Inventorship. Inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities pursuant to this Agreement shall be determined in
accordance with patent laws where the invention was invented. 
 10.2 Ownership. Subject to the licenses and rights
granted to Servier under this Agreement, MacroGenics shall own the entire right, title and interest in and to all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or
consultants of MacroGenics or acquired solely by MacroGenics in the course of Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Products. Subject to the licenses and rights granted to MacroGenics under this
Agreement, Servier shall own the entire right, title and interest in and to all inventions and discoveries (and Patents 

  
 46 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
claiming patentable inventions therein) first made or discovered solely by employees or consultants of Servier or acquired solely by Servier in the course of Research, Development, Manufacture or
Commercialization of Program DARTs and/or Licensed Product. The Parties shall jointly own any Joint IP. 
 10.3 Prosecution
and Maintenance of Patents. 
 10.3.1 MacroGenics Patents.  

(a) MacroGenics shall have the sole right to, at MacroGenics’ discretion, file, prosecute, and maintain (including the defense of
any interference or opposition proceedings), all MacroGenics Patents. *** MacroGenics shall provide to Servier copies of all prosecution filings related to MacroGenics Patents comprising claims Covering Program DARTs and/or Licensed Products
(“MacroGenics Product Patents”) sent to or received from patent offices in the Servier Territory, unless otherwise directed by Servier, and, shall provide Servier with a draft of any filing within thirty (30) days in advance of
submission, provide Servier an opportunity to provide comments on and make request of MacroGenics concerning such filings and shall consider in good faith any comments regarding such draft filings that Servier may timely provide. If Servier no
longer desires to retain its license under any MacroGenics Patent in the Servier Territory, and desires to ***, it shall have the right to *** upon *** written notice. Following such *** period, the Patent(s) referenced in such notice
shall no longer be deemed a MacroGenics Patent(s) and Servier shall have no rights hereunder with respect to such Patent. 
 (b)
Subject to the requirements and limitations of the MacroGenics Third Party Agreements, with respect to the filing, prosecution and maintenance of the MacroGenics IP, including any rights of, and time-frames for, such Third Party licensors to comment
on and review any filings and correspondence related thereto, in the event MacroGenics decides not to file a patent application on MacroGenics Know-How specific to Program DARTs and/or Licensed Product in a country of the Servier Territory, or
decides to abandon prosecution of any claim of a MacroGenics Product Patent in a country of the Servier Territory or decides to not otherwise maintain or extend any MacroGenics Product Patent in a country of the Servier Territory, MacroGenics shall
give Servier written notice sufficiently in advance thereof. Unless MacroGenics’ discontinuation of filing, prosecution or maintenance of such MacroGenics Product Patent is in order to effect a settlement or to avoid an interference, opposition
or other proceeding in which the validity of such MacroGenics Product Patent may be determined or because another MacroGenics Product Patent of similar claim scope is being prosecuted or has been issued, Servier shall have the first right to file,
prosecute, maintain and extend, as the case may be, such MacroGenics Product Patent, in Servier’s name, in such country. 

10.3.2 Servier Collaboration Patents.  
 (a) Servier shall have the sole right to, at Servier’s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Servier Collaboration
Patents. MacroGenics shall reimburse Servier for the Out-of-Pocket Costs incurred in the filing, prosecution and maintenance of the Servier Collaboration Patents in the MacroGenics 

  
 47 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Territory. Servier shall provide to MacroGenics copies of all prosecution filings related to Servier Collaboration Patents comprising claims Covering Program DARTs and/or Licensed Products
(“Servier Product Patents”) sent to or received from patent offices in the MacroGenics Territory, unless otherwise directed by MacroGenics, and, with respect to patent applications having information not previously filed that is
intended to be submitted to patent offices in the MacroGenics Territory, shall provide MacroGenics with a draft of each such filing *** in advance of submission, provide MacroGenics an opportunity to provide comments on and make request of
Servier concerning such filings and shall consider in good faith any comments regarding such draft application that MacroGenics may timely provide. In addition, Servier shall provide to MacroGenics such other information related to prosecution of
the Servier Collaboration Patents in the MacroGenics Territory as MacroGenics may from time to time reasonably request to allow MacroGenics to track prosecution and maintenance of such Patents. If MacroGenics no longer desires to retain its license
under any Servier Collaboration Patent in the MacroGenics Territory, and desires to cease payment of the costs of prosecution and maintenance thereof, it shall have the right to terminate such license to such Patent, and terminate reimbursement to
Servier of such costs, upon *** written notice. 
 (b) In the event Servier decides not to file a patent application on Servier
Collaboration Know-How specific to Program DARTs and/or Licensed Product, or decides to abandon prosecution of any claim of a Servier Product Patent or decides to not otherwise maintain or extend any Servier Product Patent, Servier shall give
MacroGenics written notice sufficiently in advance thereof. Unless Servier’s discontinuation of filing, prosecution or maintenance of such Servier Product Patent is in order to effect a settlement or to avoid an interference, opposition or
other proceeding in which the validity of such Servier Product Patent may be determined or because another Servier Product Patent of similar claim scope is being prosecuted or has been issued, MacroGenics shall have the first right to file,
prosecute and maintain or extend at its costs, as the case may be, such Servier Product Patent, in MacroGenics’ name, in such country. 
 10.3.3 Joint IP.  
 (a) MacroGenics shall have the first right, at
MacroGenics’ discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patents claiming patentable inventions included in the Joint IP (“Joint Patents”) in the
MacroGenics Territory, in the names of both MacroGenics and Servier. Servier shall have the first right, at Servier’s discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Joint
Patents in the Servier Territory, in the names of both MacroGenics and Servier. 
 (b) With respect to Joint Patents, if the
Party with the responsibility for filing, prosecuting and maintaining such Patents in accordance with clause (a) above (the “Responsible Party”) elects not to seek or continue to seek or maintain patent protection on any Joint
Patent in its territory, the other Party shall have the right to seek, prosecute and maintain patent protection on such Joint Patent in the other Party’s name and the Responsible Party shall assign its entire right, title and interest in such
Joint Patent to the other Party. The Responsible Party shall use 

  
 48 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Commercially Reasonable Efforts to make available to the other Party its authorized attorneys, agents or representatives, and to assist the other Party in obtaining and maintaining such patent
protection. The Responsible Party shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

(c) The Parties shall establish procedures to coordinate the filing and prosecution of Joint Patents. With respect to Joint Patents, the
Responsible Party shall provide the other Party, within *** after submitting or receiving such filings or correspondence, with copies of all filings and correspondence submitted to and received from patent offices and, with respect to
substantive filings and correspondence to be submitted to patent offices, shall use reasonable efforts to provide the other Party with drafts of such filings and correspondence reasonably in advance of submission and shall consider in good faith any
comments regarding such filings and correspondence that the other Party may timely provide. 
 (d) Each Party shall be
responsible for the costs and expenses it occurs in connection with the filing, prosecution and maintenance of Joint Patents. 

10.4 Third Party Infringement.  
 10.4.1 Notice. Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the MacroGenics Patents, Servier Patents or Joint Patents,
(ii) unauthorized use or misappropriation of any of the MacroGenics Know-How, Servier Know-How or Joint Know-How of which such Party becomes aware, or (iii) notification under the Biologics Price Competition and Innovation Act of 2009, as
amended, or similar law, from a biosimilar applicant arising from the filing of an application for the Regulatory Approval of a Generic Product intending to show that the Generic Product is biosimilar to any Licensed Product that is a reference
product for which a claim of infringement of any of the MacroGenics Patents, Joint Patents or Servier Patents by the manufacture or sale of the Generic Product could reasonably be asserted, and shall provide the other Party with all available
evidence regarding such known or suspected infringement or unauthorized use. 
 10.4.2 Enforcement Rights. Subject to the
requirements and limitations of the MacroGenics Third Party Agreements with respect to the enforcement of Patents, including any rights of, and timeframes for, such Third Party licensors to comment on and review any filings or materials related
thereto, the Parties agree: 
 (a) Servier shall have the first right, but not the obligation, to initiate a lawsuit or take
other reasonable action to enforce the Joint Patents and MacroGenics Product Patents in the Field in the Servier Territory to the extent such infringement or misappropriation involves the Development, Manufacture, use or Commercialization of a
product or product candidate that is or may be competitive with the Program DARTs or Licensed Products being Developed or Commercialized hereunder. Notwithstanding the foregoing sentence, Servier shall not initiate any such lawsuit or other
enforcement action asserting any such Joint Patents or MacroGenics Product Patents without first consulting with MacroGenics and giving good faith consideration to any 

  
 49 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
reasonable objection from MacroGenics regarding Servier’s proposed course of action. MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier;
provided that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. In connection with any such proceeding, Servier
shall not enter into any settlement admitting the invalidity of, or otherwise impairing MacroGenics’ rights in, MacroGenics IP or Joint IP without the prior written consent of MacroGenics. Any recoveries resulting from such an action brought by
Servier in accordance with this clause (a) shall be applied as follows: 
 (i) First, to reimburse each Party for all
Out-of-Pocket Costs in connection with such proceeding (on a pro rata basis, based on each Party’s respective litigation costs, to the extent the recovery was less than all such litigation costs); and 

(ii) Second, *** 
 (b) MacroGenics shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the Joint Patents in the Field in the MacroGenics Territory.
Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or other enforcement action asserting any such Joint Patents without first consulting with Servier and giving good faith consideration to any reasonable
objection from Servier regarding MacroGenics’ proposed course of action. Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; provided that MacroGenics shall promptly reimburse all
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. In connection with any such proceeding, MacroGenics shall not enter into any settlement admitting the
invalidity of, or otherwise impairing the Parties’ rights in Joint IP without the prior written consent of Servier. Any recoveries resulting from such an action brought by MacroGenics in accordance with this clause (b) shall be applied as
follows: 
 (i) First, to reimburse each Party for all Out-of-Pocket Costs in connection with such proceeding (on a pro rata
basis, based on each Party’s respective litigation costs, to the extent the recovery was less than all such litigation costs); and 
 (ii) Second, *** 
 (c) If Servier does not initiate a lawsuit or take other
reasonable action pursuant to Section 10.4.2(a) with respect to any Joint Patents or Servier Product Patents (i) if there is no time limit for the filing of such action, within *** following the notice of alleged infringement or
following a biosimilar applicant’s failure to act or (ii) if there is a time limit for the filing of such action (including those set forth in applicable Laws) within at least *** before the time limit, then MacroGenics shall have
the right (in cases where MacroGenics has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing *** notice to Servier and giving good faith consideration to Servier’s reason(s) for not
initiating a lawsuit or taking other action. For this purpose, Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; provided that MacroGenics shall promptly reimburse all

  
 50 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. Any recoveries resulting from such an action brought by
MacroGenics in accordance with this clause (c) will *** after payment of each Party’s costs and expenses. 
 (d) If
MacroGenics does not initiate a lawsuit or take other reasonable action pursuant to Section 10.4.2(b) with respect to any Joint Patents (i) if there is no time limit for the filing of such action, within *** following the notice of
alleged infringement or following a biosimilar applicant’s failure to act or (ii) if there is a time limit for the filing of such action (including those set forth in applicable Laws) within at least *** before the time limit, then
Servier shall have the right (in cases where Servier has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing *** notice to MacroGenics and giving good faith consideration to MacroGenics’
reason(s) for not initiating a lawsuit or taking other action. For this purpose, MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier; provided that Servier shall promptly reimburse all
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. Any recoveries resulting from such an action brought by Servier in accordance with this clause
(d) will be *** after payment of each Party’s costs and expenses. 
 10.4.3 Conduct of Certain Actions; Costs.
The Party initiating legal action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section 10.3.2 or 10.3.3 (the “Initiating Party”). Unless otherwise expressly provided, the
Initiating Party shall bear its own out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action
(in cases where such other Party has standing) by its own counsel at its own expense. 
 10.5 Patent Invalidity Claim.
Each Party shall promptly notify the other in the event of any legal or administrative action by any Third Party against a Joint Patent, MacroGenics Patent or Servier Patent of which it becomes aware, including any nullity, revocation, reexamination
or compulsory license proceeding. Servier shall have the first right, but not the obligation, at its expense, to defend against any such action relating to the Servier Patents. MacroGenics shall have the first right, but not the obligation, at its
expense, to defend against any such action relating to the MacroGenics Patents or the Joint Patents. If MacroGenics does not defend against any such action involving a MacroGenics Product Patent or a Joint Patent, then Servier shall have the right,
but not the obligation, to defend such action at Servier’s expense. 
 10.6 Patent Term Extensions. The Parties
shall cooperate with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country, where applicable to Joint Patents, MacroGenics Patents and Servier Patents. 

10.7 Patent Marking. Servier shall comply with the patent marking statutes in each country in which a Licensed Product is sold by
Servier, its Affiliates and/or its Sublicensees. 

  
 51 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 ARTICLE 11 
 CONFIDENTIALITY 
 11.1 Confidentiality; Exceptions. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise disclose or use for any
purpose other than as provided for in this Agreement any Know-How in any form (written, oral, photographic, electronic, magnetic, or otherwise) that is disclosed to it by the other Party (the “Disclosing Party”) or otherwise
received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement (collectively, “Confidential Information”), except to the extent that it can be established by the
Receiving Party that such Confidential Information: 
 11.1.1 was in the lawful knowledge and possession of the Receiving Party
prior to the time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual
use by the Receiving Party; 
 11.1.2 was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the Receiving Party; 
 11.1.3 became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; or 

11.1.4 was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to
the Disclosing Party not to disclose such information to others. 
 11.2 Authorized Disclosure. Except as expressly
provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: 
 11.2.1 under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its obligations or exercise of rights granted or reserved in this Agreement;

 11.2.2 to the extent such disclosure is reasonably necessary in filing or prosecuting patent and copyright applications,
prosecuting or defending litigation, complying with applicable governmental regulations (including the rules and regulations of any stock exchange or NASDAQ), conducting non-clinical activities and clinical activities, preparing and submitting
filings to Regulatory Authorities or is otherwise required by Law; provided, however, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party’s Confidential Information (other than a
disclosure to a Regulatory Authority in a filing required by Law) it will give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall furnish only that portion of the Disclosing Party’s Confidential
Information that the Receiving Party is legally required to furnish; 

  
 52 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 11.2.3 in communications with existing or prospective acquirers, investors, consultants,
advisors, licensees or collaborators or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or 

11.2.4 to the extent mutually agreed to in writing by the Parties. 

11.3 Press Release; Disclosure of Agreement.  
 11.3.1 On or promptly after the Effective Date, the Parties shall jointly issue a public announcement of the execution of this Agreement in a form to be mutually agreed to by the Parties (such agreement
not to be unreasonably withheld, conditioned or delayed). Neither Party shall issue any subsequent press release or make other disclosures regarding this Agreement or the Parties’ activities hereunder, or any results or data arising hereunder,
except (a) with the other Party’s prior written consent; (b) in accordance with Section 11.6; or (c) for any disclosure that is reasonably necessary to comply with applicable securities exchange listing requirements or other
applicable Laws. Notwithstanding the foregoing, to the extent information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the consent of the other Party.
Each Party shall be permitted to disclose the terms of this Agreement, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to any actual or potential acquirers, merger partners, licensees,
sublicensees, investors and professional advisors on a need to know basis. 
 11.3.2 Each Party shall, if practicable, give the
other Party a reasonable opportunity to review those portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the United
States) describing the terms of this Agreement (including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the
provisions of this Agreement for which confidential treatment should be sought. 
 11.4 Existing Confidentiality
Agreement. For the avoidance of doubt, any information disclosed by MacroGenics to Servier prior to the Effective Date pursuant to the Non-Disclosure Disclosure Agreement between MacroGenics and Servier dated *** (the “Existing
Confidentiality Agreement”) shall be treated as Confidential Information for all purposes under this Agreement. 
 11.5
Remedies. In the event a Party breaches the confidentiality obligations set forth in this ARTICLE 11, the other Party shall be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary
injunction, without the posting of any bond or other security, enjoining or restraining the breaching Party from any violation or threatened violation of this ARTICLE 11. 

  
 53 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 11.6 Publications. Neither Party nor its Affiliates shall publish or publicly
disclose the results of any of the Research or Development activities conducted by either Party under this Agreement without the prior written consent of the other Party, except as expressly permitted in this Section 11.6 or otherwise in this
Agreement. The Parties recognize that it may be useful or required to publish or publicly disclose the results of Research and Development work on Program DARTs and Licensed Products, and each Party (and its Affiliates) shall be free to publish or
publicly disclose such results, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section 11.6. The Party that desires to publish results hereunder shall provide
the other Party with a copy of such proposed abstract, manuscript, or presentation no less than *** prior to its intended submission for publication. The reviewing Party shall respond in writing promptly and in no event later than thirty
*** after receipt of the proposed material, with one or more of the following: (a) comments on the proposed material, which the publishing Party shall consider in good faith, (b) a specific statement of concern, based upon the need
to seek patent protection, or (c) an identification of the reviewing Party’s Confidential Information that is contained in the material reviewed. In the event of concern over patent protection, the publishing Party agrees not to submit
such publication or to make such presentation that contains such information until the reviewing Party is given a reasonable period of time, and in no event less than ***, to seek patent protection for any material in such publication or
presentation which it believes is patentable. Any Confidential Information of the reviewing Party shall, if requested by the reviewing Party, be removed by the other Party. 
 11.7 Return of Confidential Information. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing Party all Confidential Information received by the
Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: (a) any notes, reports or other documents prepared by the Receiving Party which contain Confidential
Information of the Disclosing Party; and (b) any Confidential Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. Alternatively,
upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof) and any notes, reports or other
documents prepared by the Receiving Party which contain Confidential Information of the Disclosing Party. Nothing in this Section 11.7 shall require the alteration, modification, deletion or destruction of archival tapes or other electronic
back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11 with respect to any Confidential Information
contained in such archival tapes or other electronic back-up media. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such
destruction. Notwithstanding the foregoing, (i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s Confidential Information solely for the purpose of determining the Receiving Party’s continuing
obligations under this ARTICLE 11 and (ii) the Receiving Party may retain the Disclosing Party’s Confidential Information and its own notes, reports and other documents (A) to the extent reasonably required (i) to comply with
applicable Law and regulatory requirements; (ii) to exercise the rights and 

  
 54 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; and (iii) to perform the obligations of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (B) to the extent it is impracticable to do so without incurring disproportionate cost. Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information, the Receiving Party
shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11. 
 ARTICLE
12 
 REPRESENTATIONS AND WARRANTIES 
 12.1 Representations and Warranties of Both Parties. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: 

12.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 12.1.2 such Party
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; 
 12.1.3 this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;

 12.1.4 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any
provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party; and

 12.1.5 no government authorization, consent, approval, license, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement, or
for the performance by it of its obligations under this Agreement, except as necessary to conduct clinical trials or to seek or obtain Regulatory Approvals. 
 12.2 Representations and Warranties of MacroGenics and its Affiliates. MacroGenics and its Affiliates hereby represent and warrant to Servier that: 

12.2.1 As of the Effective Date, MacroGenics is the owner of, or has Control via a license to, the MacroGenics Patents listed on
Exhibit B; 
 12.2.2 There are not as of the Effective Date, nor have there been over the *** period immediately
preceding the Effective Date, any claims, lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, complaints or investigations by any 

  
 55 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Government Authority (except in the ordinary administrative course of the granting of patents and proceedings relating thereto) or by any Third Party relating to the MacroGenics Patents or
MacroGenics Know-How; 
 12.2.3 As of the Effective Date, to MacroGenics’ and its Affiliates knowledge, the exercise by
Servier of the rights and licenses granted to Servier by MacroGenics under this Agreement shall not infringe any rights owned or controlled by any Third Party in the Servier Territory; 

12.2.4 As to the Effective Date, to MacroGenics’ and its Affiliates knowledge *** it has not (i) employed and has not used a
contractor or consultant that has employed, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA), or, (ii) employed any individual who or entity that is the subject of an FDA debarment investigation or
proceeding (or similar proceeding of EMA), in the conduct of any pre-clinical activities or clinical studies of Program DARTs; 

12.2.5 As to the Effective Date, MacroGenics has the right to grant all rights and licenses it purports to grant to Servier with respect
to the MacroGenics IP under this Agreement and it has not granted any license, right or interest in, to or under MacroGenics IP to any Third Party that is inconsistent with the licenses and rights granted to Servier under Section 4.1;

 12.2.6 As of the Effective Date, to MacroGenics and its Affiliates’ knowledge the MacroGenics IP are all of the Patents
and Know-How Controlled by MacroGenics or its Affiliates which are reasonably necessary for the Development, Manufacture, Commercialization of the Program DART and/or Licensed Products in the Field in the Servier Territory; 

12.2.7 To MacroGenics knowledge, the Research and Development of the Program DART and the Licensed Product prior to the Effective Date by
or on behalf of MacroGenics has been carried out without infringing any Patent owned or controlled by a Third Party; 
 12.2.8
As of the Effective Date, to MacroGenics’ knowledge, there are no activities by Third Party that would constitute infringement or misappropriation of the MacroGenics IP; 
 12.2.9 As of the Effective Date, to MacroGenics’ knowledge, there is no reason for MacroGenics or a court of competent jurisdiction to reasonably conclude that the MacroGenics Patents are invalid or
unenforceable. To MacroGenics’ knowledge, the claims included in any issued MacroGenics Patent are valid and in full force and effect. All fees required to be paid to the governmental authorities prior to the Effective Date to prosecute or
maintain the MacroGenics Patent in the Servier Territory have been filed and have been paid; 
 12.2.10 MacroGenics has
maintained prior to the Effective Date and, unless agreed to otherwise by Servier and except as provided in this Agreement, during the Agreement Term will maintain and keep in full force and effect all agreements and filings (including Patent
filings) necessary to perform its obligations hereunder. 

  
 56 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 12.3 Representation and Warranty of LLS. LLS hereby represents and warrants to
MacroGenics that IdRS is an Affiliate of LLS. 
 12.4 Mutual Covenants. Each Party hereby covenants to the other Party
that: 
 12.4.1 Such Party shall comply with all applicable Laws in connection with this Agreement and the transactions
contemplated hereby. 
 12.4.2 All employees of such Party or its Affiliates working under this Agreement will be under the
obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 
 12.4.3 To its knowledge *** such Party will not (a) employ or use any contractor or consultant that employs, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA) or,
(b) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in each of clauses (a) and (b) in the conduct of its activities under this Agreement;

 12.4.4 Such Party shall perform its activities pursuant to this Agreement in compliance in all material respects with GLP,
GCP and cGMP (including those specified by the ICH), in each case as applicable; and 
 12.4.5 Neither Party shall, during the
Agreement Term grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted or to be granted to the other Party hereunder
pursuant to the provisions of ARTICLE 4. 
 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement,
NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing except as otherwise expressly set forth in this Agreement, each Party disclaims any warranties with regards to: (a) the success of any study or test
commenced under this Agreement, (b) the safety or usefulness for any purpose of the technology or materials, including any compounds, it provides or discovers under this Agreement; or (c) the validity, enforceability, or non-infringement
of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

  
 57 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 ARTICLE 13 
 INDEMNIFICATION 
 13.1 Indemnification by Servier. Servier shall
defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all losses, damages, fees, expenses, settlement amounts or costs (including reasonable attorneys’ fees and witness fees) (“Losses”)
relating to or in connection with a Third Party claim in the Servier Territory arising out of (a) any actual death, personal bodily injury or damage to real or tangible personal property proven to result, directly or indirectly, from the
possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched, Developed, Manufactured or Commercialized in the Servier Territory by or on behalf of Servier or its Affiliates or Sublicensees, including any
product liability claims; (b) any breach by Servier of its representations, warranties or covenants made under this Agreement; or (c) any negligent act or omission or willful misconduct of Servier or its Affiliates or Sublicensees or any
of their employees, contractors or agents, in performing Servier’s obligations or exercising Servier’s rights under this Agreement; provided, however, that the foregoing indemnity shall not apply to the extent that any such
Losses (i) are attributable to the gross negligence or willful misconduct of the MacroGenics Indemnitees, or (ii) are otherwise subject to an obligation by MacroGenics to indemnify the Servier Indemnitees under Section 13.2. For
purposes of clarity, notwithstanding anything to the contrary in this Agreement, Servier shall not be liable for any Losses resulting from any claim in the MacroGenics Territory that results from any acts or omissions of MacroGenics, its Affiliates
or Sublicensees, even if Servier had knowledge of, reviewed, commented on, or approved such acts or omissions of MacroGenics’ or its Affiliates’ or Sublicensees’ plans with respect thereto. 

13.2 Indemnification by MacroGenics. MacroGenics shall defend, indemnify and hold harmless the Servier Indemnitees from and
against any and all Losses relating to or in connection with a Third Party claim in the MacroGenics Territory arising out of (a) any actual death, personal bodily injury or damage to real or tangible personal property proven to result, directly
or indirectly, from the possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched, Developed, Manufactured or Commercialized in the MacroGenics Territory by or on behalf of MacroGenics or its Affiliates or
Sublicensees, including any product liability claims; (b) any breach by MacroGenics of its representations, warranties or covenants made under this Agreement; or (c) any negligent act or omission or willful misconduct of MacroGenics or its
Affiliates or Sublicenses or any of their employees, contractors or agents, in performing MacroGenics’ obligations or exercising MacroGenics’ rights under this Agreement; provided, however, that the foregoing indemnity shall
not apply to the extent that any such Losses are attributable to (i) the gross negligence or willful misconduct of the Servier Indemnitees, or (ii) are otherwise subject to an obligation by Servier to indemnify the MacroGenics Indemnitees
under Section 13.1. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, MacroGenics shall not be liable for any Losses resulting from any claim in the Servier Territory that results from any acts or omissions of
Servier, its Affiliates or Sublicensees, even if MacroGenics had knowledge of, reviewed, commented on, or approved such acts or omissions of Servier’s or its Affiliates’ or Sublicensees’ plans with respect thereto. 

13.3 Procedure. In the event of a claim by a Third Party against any Person entitled to indemnification under this Agreement, the
Party claiming indemnification (in such capacity, the “Indemnified Party”) shall promptly notify the other Party (in such capacity, the “Indemnifying  

  
 58 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
Party”) in writing of the claim (it being understood that the failure by the Indemnified Party to give prompt notice of a Third Party claim as provided in this Section 13.3 shall
not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give prompt notice). Within *** after
delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, undertake and solely manage and control, at its sole expense and with counsel reasonably satisfactory to the Indemnified Party, the
defense of the claim. If the Indemnifying Party does not undertake such defense, the Indemnified Party shall control such defense. The Party not controlling such defense shall cooperate with the other Party and may, at its option and expense,
participate in such defense with counsel of its choice; provided, that, if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and
the Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnified Party’s counsels may fully
participate in such defense and the Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the indemnified Persons solely in connection therewith. The Party controlling such defense shall keep the other Party
advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. Except if the Indemnifying Party did not undertake defense of the claim or if
the Indemnifying Party and the Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim and the Indemnified Party
engages separate counsel, as provided above, the Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnified Party shall not
settle any such action, suit, proceeding or claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not settle, without the prior written
consent of the Indemnified Party, any such action, suit, proceeding or claim, or consent to any judgment in respect thereof, that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto,
that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party. 
 13.4
Allocation. In the event a claim is based partially on an indemnified claim and partially on a non-indemnified claim or based partially on a claim indemnified by one Party and partially on a claim indemnified by the other Party, any payments
in connection with such claims are to be apportioned between the Parties in accordance with the degree of cause attributable to each Party. 
 13.5 EXCLUSION OF CONSEQUENTIAL DAMAGES. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 11 OR THIRD PARTY CLAIMS THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 13, NEITHER MACROGENICS NOR
SERVIER, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE

  
 59 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER SUCH PARTY OR ANY REPRESENTATIVE OF SUCH PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE
POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. 
 ARTICLE 14 

TERM AND TERMINATION 
 14.1 Agreement Term; Expiration. This Agreement shall become effective as of the Effective Date, and, in the event Servier does not exercise a Option by the end of the Option Periods, shall expire
in its entirety at the end of the last Option Period to expire, unless earlier terminated in accordance with this ARTICLE 14. In the event Servier exercises an Option in accordance with Section 3.3, this Agreement shall continue in full force
with respect to the Licensed Program that was licensed under such Option until the last to expire Royalty Term for a Licensed Product from such Licensed Program in the Servier Territory. After the last to expire Royalty Term for a Licensed Product
in a country in the Servier Territory, Servier shall be granted a fully paid-up non-exclusive license to use MacroGenics Know-How to Manufacture and Commercialize such Licensed Product in the Field in such country in the Servier Territory.

 14.2 Termination for Cause. Either Party (the “Non-Breaching Party”) may, without prejudice to any
other remedies available to it under applicable Law or in equity, terminate this Agreement in its entirety or with respect to an Option or Licensed Program if the other Party (the “Breaching Party”) shall have materially breached or
defaulted in the performance of its obligations hereunder with respect to the Program which is subject to such Option and/or such Licensed Program, and such default shall have continued for *** after written notice thereof was provided to the
Breaching Party by the Non-Breaching Party, such notice describing the alleged breach. Any such termination of this Agreement under this Section 14.2 shall become effective at the end of such *** cure period, unless the Breaching Party
has cured such breach or default prior to the expiration of such cure period provided however that if the Breaching Party notifies the Non-Breaching Party within such *** period that the Breaching Party disagrees in good faith with such
asserted basis for termination, this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 16.2 and the arbitration award rendered in accordance with Section 16.2 specify that the
Non-Breaching Party shall have the right to terminate this Agreement based on such asserted Breach. The right of either Party to terminate this Agreement as provided in this Section 14.2 shall not be affected in any way by such Party’s
waiver or failure to take action with respect to any previous default. 
 14.3 Termination for Patent Challenge. If
either Party or any of its Affiliates or Sublicensees: (a) commences or otherwise voluntarily determines to participate in any action or proceeding (including any patent opposition or re-examination proceeding), challenging or denying the
validity of any of the other Party’s Patents or Joint Patents licensed hereunder or any claim thereof, or (b) actively assists any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or
re-examination proceeding) challenging or denying the validity of any of such Patents or any claim thereof, the non-challenging Party shall 

  
 60 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
have the right to terminate this Agreement with respect to the Option or Licensed Program to which such Patents are subject upon *** written notice to the other Party. Any such termination shall
only become effective if the challenging Party or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. 
 14.4 Termination for Convenience.  
 14.4.1 During the Research
Term. At any time following ***, Servier shall have the right to terminate this Agreement in its entirety or with respect to an Option upon not less than *** prior written notice thereof to MacroGenics. 

14.4.2 During a License Term. At any time during a License Term, Servier shall have the right to terminate this Agreement in its
entirety or to terminate the Licensed Program subject to such License Term or to terminate this Agreement or such Licensed Program on a country-by-country basis upon not less than *** prior written notice thereof to MacroGenics. 

14.5 Termination for Insolvency Event. Either Party may terminate this Agreement upon written notice to the other Party if the
other Party suffers an Insolvency Event. 
 14.6 Termination by Servier for Safety or Public Health Reasons. If Servier
reasonably determines that a safety or public health issue has arisen which (a) is demonstrated by clinically relevant events which are documented and (b) relates to a Program DART or a Licensed Product, such that the medical risk/benefit
of such Program DART of Licensed Product is sufficiently unfavorable as to be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize such Program DART or Licensed Product, Servier shall
immediately notify MacroGenics, and Servier shall be permitted to terminate this Agreement with respect to the Option or Licensed Program to which such Program DART or Licensed Product is subject upon written notice to MacroGenics, but in any event
within *** of Servier’s determination of such issue. 
 14.7 Effect of Expiration or Termination.  

14.7.1 Upon termination of this Agreement by MacroGenics in whole or with respect to one or more Terminated Options, Terminated Licensed
Programs and/or Terminated Territories pursuant to Section 14.2, 14.3, or 14.5 or by Servier in whole or with respect to one or more Terminated Options, Terminated Licensed Programs or Terminated Territories pursuant to Section 14.4 or
14.6: 
 (a) all rights, licenses and options granted by MacroGenics to Servier with respect to each Terminated Option,
Terminated Licensed Program and/or Terminated Territory hereunder shall terminate and Servier shall not have any rights to use or exercise any rights under the MacroGenics IP with respect to any such Terminated Option, Terminated Licensed Program
and Terminated Territory; 

  
 61 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 (b) if such termination occurs during a Research Term, (i) Servier shall Complete any
ongoing Clinical Studies in the Servier Territory for Licensed Product that is subject to the Terminated Option where such completion is required by any applicable Law, requested by any Regulatory Authority or would be dictated by any applicable
Institutional Review Board with oversight of such Clinical Study in the Servier Territory; and (ii) Servier shall promptly transfer and assign to MacroGenics all Supplemental Data and *** and 

(c) if such termination occurs during a License Term: 
 (i) Servier shall provide to MacroGenics a fair and accurate detailed written description of the status of the Development and Commercialization of the Program DARTs and Licensed Products subject to such
Terminated Licensed Program and/or in the Terminated Territory through the effective date of termination within *** of such termination; 
 (ii) the licenses granted to MacroGenics pursuant to Section 4.2 with respect to such Terminated Licensed Program shall remain in effect and shall become irrevocable; 

(iii) Servier hereby grants to MacroGenics, effective upon the request of MacroGenics, ***. 

(iv) In the event that MacroGenics requests a license under clause (iii) above and Servier has previously Completed a Phase 3
Clinical Trial for a Licensed Product subject to the Terminated Licensed Program or such Terminated Territory before the effective date of termination, ***; 
 (v) Servier shall promptly transfer and assign to MacroGenics all Regulatory Documentation and other technical and other information or materials in Servier’s or its Affiliates’ possession or
control which are necessary or useful for the Research, Development or Commercialization of the Program DARTs or Licensed Products in each Terminated Licensed Program and Terminated Territory or, if Licensed Program remains or country remains in the
Servier Territory, anywhere in the world; provided, that Servier may retain a single copy of such items for its records; 
 (vi) Promptly upon request by MacroGenics, but in no event commencing later than *** after the effective date of termination or continuing for more than *** (except to the extent that
requirements of a Regulatory Authority necessitate a longer period), Servier shall provide such assistance to MacroGenics as may be reasonably necessary or useful for MacroGenics to commence or continue Developing, Manufacturing or Commercializing
Licensed Products under or in the Terminated Licensed Program or Terminated Territory, to the extent Servier is then performing or having performed such activities, including transferring or amending as appropriate, upon request of MacroGenics, any
agreements or arrangements with Third Party vendors to Develop, Manufacture or Commercialize Licensed Products under or in such Terminated Licensed Program or Terminated Territory. To the extent that any such contract between Servier and a Third
Party is not assignable to MacroGenics, Servier shall reasonably cooperate with MacroGenics to arrange to continue to provide such services for a reasonable time 

  
 62 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
after termination, not exceeding ***. Within *** after MacroGenics’ receipt of a proper invoice therefor, MacroGenics shall reimburse Servier for Servier’s and its Affiliates’
reasonable Out-of-Pocket Costs incurred in connection with any technology transfer conducted pursuant to this clause (vi); and 

(vii) in the event this Agreement is terminated pursuant to Section 14.6, Servier shall reasonably cooperate with MacroGenics to
either (A) wind down any ongoing Global Clinical Trial conducted under a Global Development Plan previously approved by Servier or (B) which is conducted by Servier in the Servier Territory for the Licensed Product, and/or diligently
perform any follow-up of a clinical trial initiated in Servier Territory requested by any Regulatory Authority or dictated by any applicable Institutional Review Board. *** the activities mentioned in (A) above and *** shall entirely
fund the activities mentioned in (B) above. Servier and Servier’s Affiliates shall provide MacroGenics written notice of the quantity of Licensed Product that Servier has in inventory for sale under or in each Terminated Licensed Program
or Terminated Territory and permit MacroGenics, at MacroGenics’ option, to purchase all or any part of Servier’s worldwide unsold inventory of such Licensed Product ***. 

14.7.2 Upon termination of this Agreement by Servier pursuant to Section 14.2 or 14.3: 

(a) all rights, licenses and options granted to Servier, its Affiliates or Sublicensees pursuant to this Agreement shall remain in
effect; 
 (b) all payment obligations under ARTICLE 8 shall remain in effect; and 

(c) all licenses granted by Servier, its Affiliates or Sublicensees pursuant to this Agreement, if this Agreement was terminated in its
entirety, or with respect to a Terminated Licensed Program, including pursuant to section 4.2, shall terminate. 
 14.8
Accrued Rights; Surviving Provisions of the Agreement.  
 14.8.1 Accrued Rights. Termination or expiration of any
aspect of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration including the payment obligations under ARTICLE 9 hereof, and any and all
damages or remedies arising from any breach hereunder. Such termination or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. 

14.8.2 Surviving Provisions of the Agreement. The provisions of Sections 3.3.3(c), 6.1.2, 9.6-9.9 (with regard to accrued but
unpaid amounts), 9.10, 10.3.3, 12.5, 14.7 and 14.8 and ARTICLE 13 and ARTICLE 16, and any applicable definitions in ARTICLE 1, shall survive any partial or entire termination of this Agreement or partial or entire expiration of this Agreement for
any reason, in accordance with their respective terms and conditions, and for the duration stated, and where no duration is stated, shall survive indefinitely. ARTICLE 11 shall survive for a period of *** after the effective date of the
entire termination or expiration of this Agreement. 

  
 63 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 ARTICLE 15 
 STANDSTILL 
 15.1 Standstill. Servier agrees that neither it nor any
Affiliate, acting alone or as part of any group, shall directly or indirectly, for a period commencing on the Effective Date and ending *** after the Effective Date, without the prior written approval of MacroGenics’ Board of Directors:***

 15.1.1 acquire or agree, offer, seek or propose to acquire, or cause to be acquired, ownership (including, but not limited
to, beneficial ownership as defined in Rule 13d 3 under the Securities and Exchange Act of 1934) of any of the assets or businesses of MacroGenics or of any securities of MacroGenics, or any rights or options to acquire any such ownership (including
from a third party); 
 15.1.2 make, or in any way ***, in any “solicitation” of “proxies” (as such terms
are used in the proxy rules of the Securities and Exchange Commission) to vote, or seek to advise or influence any person with respect to the voting of any voting securities of MacroGenics; 

15.1.3 form, join or in any way participate in, a “group” (within the meaning of Section 13(d)(3) of the Securities Exchange
Act of 1934) with respect to any voting securities of MacroGenics; 
 15.1.4 otherwise act, whether alone or in concert with
others, to seek to propose to MacroGenics any merger, business combination, restructuring, recapitalization or similar transaction to or with MacroGenics or otherwise act, whether alone or in concert with others, to seek to control, *** of
MacroGenics who is not nominated by the then incumbent directors, 
 15.1.5 solicit, negotiate with, or provide any information
to, any person with respect to a merger, exchange offer or liquidation of MacroGenics or any other acquisition of MacroGenics, any acquisition or voting securities of or all or any portion of the assets of MacroGenics or any other similar
transaction; 
 15.1.6 announce an intention to, *** with any third party with respect to, any of the foregoing; or 

15.1.7 disclose any *** with the foregoing, or advise, assist or encourage any other persons in connection with any of the foregoing.

 In addition, Servier hereby agrees that during the term of this Agreement, it shall not request MacroGenics, directly or
indirectly, to amend or waive any provision of this ARTICLE 15, (including this sentence.) ***. 
 ARTICLE 16 

MISCELLANEOUS 
 16.1 Disputes.  
 16.1.1 In the event any dispute arises out of or in
relation to or in connection with this Agreement, including failure to perform under or breach of, this Agreement or any issue relating to the interpretation or application of this Agreement, the Parties shall use good faith efforts to resolve such
dispute within *** *** after a Party notifies the other Party of such dispute, whether through the JEC, JSC, JRDC or any subcommittee, as applicable, if the dispute is within the responsibilities of such a committee, or otherwise. If the
Parties are unable to resolve such dispute, at the JSC, JRDC or subcommittee level or otherwise, within such *** *** period, either Party may, by written notice to the other Party refer such dispute to the JEC for resolution, and the JEC
shall attempt in good faith to resolve such dispute within *** days after such notice. 
 16.1.2 Any dispute with respect
to which a Party has final decision-making authority pursuant to Section 2.9.3 or any dispute between the Parties concerning the validity, scope, enforceability, inventorship, or ownership of intellectual property rights (each, a
“Non-Arbitrable Dispute”), shall not be subject to resolution by binding arbitration under 16.2. 

  
 64 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 16.2 Arbitration. If the JEC is unable to resolve a given dispute referred to it
pursuant to Section 2.9.3 or 16.1 within *** *** following such referral of such dispute to the JEC, except for any Non-Arbitrable Disputes, either Party may have the given dispute settled by binding arbitration in the manner described
below: 
 16.2.1 Arbitration Request. If a Party intends to begin an arbitration to resolve a dispute arising under this
Agreement, such Party shall provide written notice (the “Arbitration Request”) to the other Party of such intention and the issues for resolution. 
 16.2.2 Additional Issues. Within *** *** after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution. 

16.2.3 Arbitration Rules; Location. Except as expressly provided herein, the sole mechanism for resolution of any claim, dispute
or controversy arising out of or in connection with or relating to this Agreement or the breach or alleged breach thereof shall be arbitration by the *** then in effect except as provided herein. Neither Party shall be required to give
general discovery of documents, but may be required to produce documents or testimony which are considered relevant by the arbitrators to the dispute. The production of electronic documents shall be limited to those located in sources that are used
in the ordinary course of business. Neither Party shall be ordered to restore backup tapes; erased, damaged or fragmented data, or data normally deleted in the ordinary course of business. When the cost and burden of discovery are disproportionate
to the likely importance of the requested materials, the arbitrator may deny the requests or require that the requesting party advance the reasonable cost of production to the other Party. The Parties can further agree to limit the extent of
discovery in any arbitration undertaken pursuant to this Agreement. The arbitration shall take place in *** 
 16.2.4
Privileges. If a Party is entitled to attorney-client or attorney work product privileges from disclosure established under public policy provisions, such privileges shall apply and may be invoked by the other Party. 

16.2.5 English Language. All proceedings shall be held in English and a transcribed record prepared in English. Documents
submitted in the arbitration (the originals of which are not in English) shall be submitted together with a reasonably complete and accurate English translation. 
 16.2.6 Selection of Arbitrators. The Parties shall each choose one arbitrator within *** after receipt of notice of the intent to arbitrate and the said two arbitrators shall select by
mutual agreement a third arbitrator within *** after they have been selected as arbitrators. If no arbitrator is appointed within the times herein provided or any extension of time that is mutually agreed on, *** shall make such
appointment (i.e. shall appoint three arbitrators) within *** after such failure. Additionally, if the two arbitrators selected by the Parties fail to appoint a third arbitrator within the time provided, *** shall appoint the third
arbitrator. 
 16.2.7 Experience. If the issues in dispute involve scientific or technical matters, any arbitrators
chosen hereunder shall have educational training or experience sufficient to demonstrate a reasonable level of knowledge in the pharmaceutical and biotechnology fields. 

  
 65 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 16.2.8 Powers of Arbitrators. The arbitrators shall be limited in the scope of their
authority to resolving only the specific matter which the Parties have referred to arbitration for resolution and shall not have authority to render any decision or award on any other issues. Without limiting the foregoing, the arbitrators:

 (a) shall not have any power or authority to add to, alter, amend or modify the terms of this Agreement but shall specify
rules sufficient to allow reasonable discovery by the Parties; 
 (b) shall establish and enforce appropriate rules to ensure
that the proceedings, including the decision, be kept confidential and that all Confidential Information of the Parties be kept confidential and be used for no purpose other than the arbitration; and 

(c) shall issue all preliminary awards and the final award in writing. 

16.2.9 Injunctive Relief. Nothing in this Agreement shall be deemed as preventing either Party from seeking injunctive relief (or
any other provisional remedy such as temporary restraining order, preliminary injunction or other interim equitable relief) from the arbitrators or from any court having jurisdiction over the Parties (and prior to or during any arbitration if
necessary to protect the interests of such Party in avoiding irreparable harm or to preserve the status quo pending the arbitration proceeding) and the subject matter of the dispute as necessary to protect either Party’s name, proprietary
information, Know-How or any other proprietary right or otherwise to avoid irreparable harm. 
 16.2.10 Costs; Exclusion from
Award. The award rendered by the arbitrators ***. 
 16.2.11 Survivability. Any duty to arbitrate under this
Agreement shall remain in effect and be enforceable after termination of this Agreement. 
 16.3 Governing Law. This
Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the *** without reference to conflicts of laws principles. *** 

16.4 Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any
Party without the consent of the other Party; provided, however, that any Party may, without such consent, assign this Agreement, in whole or in part: (a) to any of its respective Affiliates; provided that the assigning
Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b) to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this
Agreement relates (an “M&A Event”); provided that such successor agrees in writing to be bound by the terms of this Agreement as if it were the assigning party. Any assignment not in accordance with this Section 16.4
shall be void. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with an M&A Event, such assignment shall not provide the non-assigning Party with
rights or access to any 

  
 66 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 
intellectual property or technology of the acquirer of the assigning Party. *** 
 16.5 Force Majeure. No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in
fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement,
force majeure is defined as causes beyond the control of the Party, including acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; external labor disturbances; epidemic;
and failure of public utilities or common carriers. In such event MacroGenics or Servier, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party
giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up to a maximum of ***, after which time MacroGenics and Servier
shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by this Agreement. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure. If a force
majeure event prevents a Party from performing any of its Development obligations for a Global Clinical Trial or Manufacturing obligations hereunder that would delay the Development or Manufacture of Licensed Product in the non-affected Party’s
Territory, then, if the Parties can not agree on how to best proceed following such discussions, then, notwithstanding the exclusive license grants hereunder, the Party not affected by the force majeure event shall be permitted to either perform
directly or engage a Third Party clinical research organization or contract manufacturing organization to perform such Development and/or Manufacturing obligations for the duration of such force majeure event. 

16.6 Notices. Any notice or request required or permitted to be given under or in connection with this Agreement shall be deemed
to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or reputable international business courier (signature required), prepaid, to the
Party for which such notice is intended, at the address set forth for such Party below: 
 If to MacroGenics, 

addressed to: 

MacroGenics, Inc. 

9640 Medical Center Drive 
 Rockville, MD 20850 
 Attention: Chief Executive Officer 

Facsimile: *** 

  
 67 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 If to Servier, 
 addressed to: 
 Les Laboratoires Servier 

50 rue Carnot 

92284 Suresnes Cedex 
 France 
 Attention: *** 

Facsimile: *** 

or to such other address for such Party as it shall have specified by like notice to the other Parties, provided that notices of a
change of address shall be effective only upon receipt thereof. The effective date of any notice shall be the actual date of receipt by the Party receiving the same. 
 16.7 Export Clause. Each Party agrees that, as of the Effective Date, it will not export or re-export restricted commodities or the technical data of the other Party in any form without the
appropriate United States and non-United States government licenses. 
 16.8 Waiver. Neither Party may waive or release
any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.

 16.9 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the
Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and
shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any
other jurisdiction. 
 16.10 Entire Agreement. This Agreement, together with the Schedules and Exhibits hereto, set forth
all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties as to the subject matter of this Agreement and supersedes and terminates all prior agreements and understanding between the
Parties with respect to the subject matter hereof. In particular, and without limitation, this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this
Agreement and exchanged between the Parties prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties as to the subject matter of
this Agreement other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers
of the Parties. 

  
 68 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 16.11 Independent Contractors. Nothing herein shall be construed to create any
relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other
Party. Neither Party shall have the authority to bind or obligate the other Party and neither Party shall represent that it has such authority. 
 16.12 Headings; Construction; Interpretation. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this
Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion,
whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with
the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the
executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph,
clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires, (a) any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to any Law refers to such Law as from time
to time enacted, repealed or amended, (c) the words “herein,” “hereof” and “hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, (d) the
words “include,” “includes,” “including,” “exclude,” “excludes,” and “excluding,” shall be deemed to be followed by the phrase “but not limited to,” “without limitation”
or words of similar import. 
 16.13 Further Actions. Each Party shall execute, acknowledge and deliver such further
instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 
 16.14 Parties in Interest. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit of and be enforceable by the Parties hereto and their respective
successors, heirs, administrators and permitted assigns. 
 16.15 Performance by Affiliates. To the extent that this
Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

16.16 Counterparts. This Agreement may be signed in counterparts, each and every one of which shall be deemed an original,
notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile signatures and signatures transmitted via portable document
format (PDF) shall be treated as original signatures. 

  
 69 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 [Signature page to follow] 

  
 70 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement to be
executed by their duly authorized representatives as of the Effective Date. 
  

			
	MACROGENICS, INC.
		
	By:	 	/s/ Scott Koenig
	 Name:
 Title:
	 	 Scott Koenig

CEO

	
	LES LABORATOIRES SERVIER
		
	By:	 	  

	 Name: ***

Title: ***

		
	 By:
	 	  

	 Name: *** 
 Title: ***

	
	INSTITUT DE RECHERCHES SERVIER
		
	By:	 	  

	 Name: *** 
 Title: ***

  
 71 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 Exhibit A 
 DART Platform 
 *** 

A total of two pages were omitted. 
  

  
 1 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 Exhibit B 
 MacroGenics Patents 
  

					
	 Title
	  	 Pending Application

Number
	  	 Foreign Rights

			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***
			
	 ***
	  	***	  	***

 A total of five pages were omitted. 

 

  
 1 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 Exhibit C 
 MacroGenics Third Party Agreements 
  

	1.	*** 

  

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]